<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en" article-type="review-article">
<?release-delay 0|0?>
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">OL</journal-id>
<journal-title-group>
<journal-title>Oncology Letters</journal-title>
</journal-title-group>
<issn pub-type="ppub">1792-1074</issn>
<issn pub-type="epub">1792-1082</issn>
<publisher>
<publisher-name>D.A. Spandidos</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3892/ol.2026.15702</article-id>
<article-id pub-id-type="publisher-id">OL-32-2-15702</article-id>
<article-categories>
<subj-group>
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Advantages and research progress of three-dimensional culture systems for lung cancer drug screening (Review)</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author"><name><surname>Tian</surname><given-names>Yihe</given-names></name>
<xref rid="af1-ol-32-2-15702" ref-type="aff">1</xref>
<xref rid="af2-ol-32-2-15702" ref-type="aff">2</xref>
<xref rid="fn1-ol-32-2-15702" ref-type="author-notes">&#x002A;</xref></contrib>
<contrib contrib-type="author"><name><surname>Liu</surname><given-names>Hai</given-names></name>
<xref rid="af1-ol-32-2-15702" ref-type="aff">1</xref>
<xref rid="af3-ol-32-2-15702" ref-type="aff">3</xref>
<xref rid="fn1-ol-32-2-15702" ref-type="author-notes">&#x002A;</xref></contrib>
<contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Minhong</given-names></name>
<xref rid="af1-ol-32-2-15702" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author"><name><surname>Cui</surname><given-names>Aiping</given-names></name>
<xref rid="af1-ol-32-2-15702" ref-type="aff">1</xref>
<xref rid="af2-ol-32-2-15702" ref-type="aff">2</xref></contrib>
<contrib contrib-type="author"><name><surname>Chen</surname><given-names>Hao</given-names></name>
<xref rid="af1-ol-32-2-15702" ref-type="aff">1</xref>
<xref rid="af4-ol-32-2-15702" ref-type="aff">4</xref></contrib>
<contrib contrib-type="author"><name><surname>Shi</surname><given-names>Lei</given-names></name>
<xref rid="af1-ol-32-2-15702" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author"><name><surname>Zhu</surname><given-names>Junyao</given-names></name>
<xref rid="af1-ol-32-2-15702" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author"><name><surname>Li</surname><given-names>Mingchun</given-names></name>
<xref rid="af5-ol-32-2-15702" ref-type="aff">5</xref></contrib>
<contrib contrib-type="author"><name><surname>Wang</surname><given-names>Biao</given-names></name>
<xref rid="af1-ol-32-2-15702" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author"><name><surname>Huang</surname><given-names>Hao</given-names></name>
<xref rid="af3-ol-32-2-15702" ref-type="aff">3</xref>
<xref rid="af4-ol-32-2-15702" ref-type="aff">4</xref></contrib>
<contrib contrib-type="author"><name><surname>Yang</surname><given-names>Jianqiong</given-names></name>
<xref rid="af1-ol-32-2-15702" ref-type="aff">1</xref>
<xref rid="af6-ol-32-2-15702" ref-type="aff">6</xref>
<xref rid="af7-ol-32-2-15702" ref-type="aff">7</xref>
<xref rid="c1-ol-32-2-15702" ref-type="corresp"/></contrib>
</contrib-group>
<aff id="af1-ol-32-2-15702"><label>1</label>The Clinical Medicine Research Center of The First Clinical Medical College, Gannan Medical University, Ganzhou, Jiangxi 341000, P.R. China</aff>
<aff id="af2-ol-32-2-15702"><label>2</label>School of Rehabilitation Medicine, Gannan Medical University, Ganzhou, Jiangxi 341000, P.R. China</aff>
<aff id="af3-ol-32-2-15702"><label>3</label>Jiangxi Province Key Laboratory of Pharmacology of Traditional Chinese Medicine, Gannan Medical University, Ganzhou, Jiangxi 341000, P.R. China</aff>
<aff id="af4-ol-32-2-15702"><label>4</label>College of Pharmacy, Gannan Medical University, Ganzhou, Jiangxi 341000, P.R. China</aff>
<aff id="af5-ol-32-2-15702"><label>5</label>Department of Oncology, First Clinical Medical College, Gannan Medical University, Ganzhou, Jiangxi 341000, P.R. China</aff>
<aff id="af6-ol-32-2-15702"><label>6</label>Ganzhou Key Laboratory of Antitumor Effects of Natural Products, Gannan Medical University, Ganzhou, Jiangxi 341000, P.R. China</aff>
<aff id="af7-ol-32-2-15702"><label>7</label>Ganzhou Key Laboratory of Osteoporosis Research, Gannan Medical University, Ganzhou, Jiangxi 341000, P.R. China</aff>
<author-notes>
<corresp id="c1-ol-32-2-15702"><italic>Correspondence to</italic>: Professor Jianqiong Yang, The Clinical Medicine Research Center of The First Clinical Medical College, Gannan Medical University, 23 Qingnian Road, Zhanggong, Ganzhou, Jiangxi 341000, P.R. China, E-mail: <email>yangjianqiong2010@163.com</email></corresp>
<fn id="fn1-ol-32-2-15702"><label>&#x002A;</label><p>Contributed equally</p></fn></author-notes>
<pub-date pub-type="collection"><month>08</month><year>2026</year></pub-date>
<pub-date pub-type="epub"><day>12</day><month>06</month><year>2026</year></pub-date>
<volume>32</volume>
<issue>2</issue>
<elocation-id>347</elocation-id>
<history>
<date date-type="received"><day>10</day><month>12</month><year>2025</year></date>
<date date-type="accepted"><day>01</day><month>05</month><year>2026</year></date>
</history>
<permissions>
<copyright-statement>Copyright: &#x00A9; Tian et al.</copyright-statement>
<copyright-year>2026</copyright-year>
<license license-type="open-access">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivs License</ext-link>, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.</license-p></license>
</permissions>
<abstract>
<p>Conventional two-dimensional cell cultures predominantly grow as monolayers, lacking the complex spatial architecture of in vivo tumors. However, three-dimensional (3D) tumor culture systems can overcome these limitations by reconstituting cell-cell and cell-matrix interactions, thereby recapitulating the essential hallmarks of solid tumors, including spatial gradients of oxygen, growth factors and metabolites. 3D tumor models are essential preclinical tools in lung cancer research, providing valuable resources for studying cancer biology and developing novel anticancer drugs. The present review examines different 3D culture methods, highlighting the benefits and applications of multicellular tumor spheroids and organoid models in the screening process for anti-lung cancer drugs. The present review aims to provide a novel perspective on tumor biology and in vitro drug screening, and a theoretical basis for developing and applying 3D culture models.</p>
</abstract>
<kwd-group>
<kwd>3D culture</kwd>
<kwd>lung cancer</kwd>
<kwd>MCTS</kwd>
<kwd>LCO</kwd>
<kwd>drug screening</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source>The National Natural Science Foundation of China</funding-source>
<award-id>82260985</award-id>
</award-group>
<award-group>
<funding-source>The Natural Science Foundation of Jiangxi Province</funding-source>
<award-id>20242BAB25572</award-id>
</award-group>
<award-group>
<funding-source>The Science and Technology Project of Ganzhou</funding-source>
<award-id>2022DSYS9969</award-id>
</award-group>
<award-group>
<funding-source>The Science and Technology Research Project of Education Department of Jiangxi Province</funding-source>
<award-id>GJJ2201459</award-id>
<award-id>GJJ2201415</award-id>
</award-group>
<award-group>
<funding-source>The Science and Technology Project of Jiangxi Provincial Health Commission</funding-source>
<award-id>202310052</award-id>
<award-id>202210949</award-id>
</award-group>
<funding-statement>The present study was supported by The National Natural Science Foundation of China (grant no. 82260985), The Natural Science Foundation of Jiangxi Province (grant no. 20242BAB25572), The Science and Technology Project of Ganzhou (grant no. 2022DSYS9969), The Science and Technology Research Project of Education Department of Jiangxi Province (grant nos. GJJ2201459 and GJJ2201415), and The Science and Technology Project of Jiangxi Provincial Health Commission (grant nos. 202310052 and 202210949).</funding-statement>
</funding-group>
</article-meta>
</front>
<body>
<sec sec-type="intro">
<label>1.</label>
<title>Introduction</title>
<p>Lung cancer is one of the most common causes of cancer-related mortality worldwide, accounting for 18.7&#x0025; of all cancer fatalities (<xref rid="b1-ol-32-2-15702" ref-type="bibr">1</xref>). The incidence of lung cancer in China has shown a persistent upward trend since 2016 (<xref rid="b2-ol-32-2-15702" ref-type="bibr">2</xref>). Despite advancements in early detection and standardized treatment protocols for patients with lung cancer, the majority of cases are still diagnosed at advanced stages with poor prognosis (<xref rid="b3-ol-32-2-15702" ref-type="bibr">3</xref>,<xref rid="b4-ol-32-2-15702" ref-type="bibr">4</xref>). Histologically, lung cancer is categorized into two main types: Non-small cell lung cancer (NSCLC; 85&#x0025;) and small cell lung cancer (15&#x0025;) (<xref rid="b1-ol-32-2-15702" ref-type="bibr">1</xref>). One study found that among patients with epidermal growth factor receptor (EGFR)-mutated NSCLC treated with EGFR tyrosine kinase inhibitors, after stratifying patients into risk groups based on a scoring system incorporating age, performance status, metastatic sites (liver, brain, bone, pleura), and disease control rate, the 5-year survival rate in the low-risk group was 23.4&#x0025; (<xref rid="b5-ol-32-2-15702" ref-type="bibr">5</xref>). NSCLC is divided into two principal histological subtypes: Lung squamous cell carcinoma and lung adenocarcinoma (LUAD) (<xref rid="b6-ol-32-2-15702" ref-type="bibr">6</xref>). Currently, the mechanisms of drug action against NSCLC include promoting apoptosis (<xref rid="b7-ol-32-2-15702" ref-type="bibr">7</xref>) and inducing cellular autophagy in tumor cells (<xref rid="b8-ol-32-2-15702" ref-type="bibr">8</xref>). However, early-stage NSCLC is typically asymptomatic and often diagnosed at advanced stages, resulting in more challenging treatment processes with a median survival period of &#x003C;1 year (<xref rid="b9-ol-32-2-15702" ref-type="bibr">9</xref>). Therefore, establishing in vitro biological models that are rapid and efficient, relatively low-cost, operationally simple, and capable of accurately replicating both the genetic characteristics of in vivo tumors and their responses to therapeutic agents holds notable importance for oncology research.</p>
<p>Three-dimensional (3D) culture is recognized as the most promising in vitro model for oncological drug testing, as it can recapitulate key in vivo tumor features, including the cellular heterogeneity, intercellular signaling, structural architecture, extracellular microenvironment, growth kinetics, gene expression profiles and drug resistance mechanisms (<xref rid="b10-ol-32-2-15702" ref-type="bibr">10</xref>,<xref rid="b11-ol-32-2-15702" ref-type="bibr">11</xref>). Spheroids represent one of the simplest and most effective 3D culture models, and are formed through the self-assembly of multiple cell types (e.g., tumor cells, stromal fibroblasts and immune cells) (<xref rid="b12-ol-32-2-15702" ref-type="bibr">12</xref>). The complex niche environment surrounding neoplastic cells, referred to as the tumor microenvironment (TME), comprises diverse cellular components (such as tumor endothelial cells, cancer-associated fibroblasts and immune cells) and extracellular constituents (such as cytokines, growth factors, hormones and exosomes) (<xref rid="b13-ol-32-2-15702" ref-type="bibr">13</xref>). Tumor-stroma interactions dynamically regulate multiple biological characteristics of tumor cells, including proliferation, migration and drug resistance (<xref rid="b14-ol-32-2-15702" ref-type="bibr">14</xref>). The TME governs fundamental processes of tumorigenesis, progression and metastasis, and profoundly impacts pharmacological therapeutic efficacy (<xref rid="b15-ol-32-2-15702" ref-type="bibr">15</xref>). Due to their enhanced controllability of microenvironmental variables, 3D cell culture systems are increasingly being employed in biomedical research domains such as developmental biology, regenerative medicine, tissue engineering and oncology (<xref rid="b16-ol-32-2-15702" ref-type="bibr">16</xref>,<xref rid="b17-ol-32-2-15702" ref-type="bibr">17</xref>). Therefore, the present review aims to summarize the different 3D culture methods and the research progress on their use for drug screening in lung cancer.</p>
<p>The present review is a narrative overview of advances in 3D culture systems for lung cancer drug screening. The literature search was performed in three electronic databases, including PubMed (<uri xlink:href="https://pubmed.ncbi.nlm.nih.gov">https://pubmed.ncbi.nlm.nih.gov</uri>), Web of Science (<uri xlink:href="https://www.webofscience.com">https://www.webofscience.com</uri>) and ScienceDirect (<uri xlink:href="https://www.sciencedirect.com">https://www.sciencedirect.com</uri>). The search period covered publications from June 1997 to April 2026. The main key words used were &#x2018;3D culture&#x2019;, &#x2018;lung cancer&#x2019;, &#x2018;MCTS&#x2019;, &#x2018;LCO&#x2019; and &#x2018;drug screening&#x2019;. Articles were initially screened by reviewing the titles and abstracts, after which 115 relevant publications were selected for detailed full-text examination. All of these were ultimately included in the present review.</p>
</sec>
<sec>
<label>2.</label>
<title>Research models</title>
<sec>
<title/>
<sec>
<title>Two-dimensional (2D) culture models</title>
<p>The current mainstream method for in vitro cell culture is 2D culture. Cells grown in 2D monolayers have equal access to nutrients and growth factors present in the culture medium, resulting in uniform growth and proliferation (<xref rid="b18-ol-32-2-15702" ref-type="bibr">18</xref>). Although the preferred in vitro 2D culture model is standardized and simple, it is a monolayer. The cells cultured using this method exhibit notable differences in both morphology and architecture compared with their in vivo counterparts under physiological conditions. The 2D culture model cannot reproduce the TME to mimic the real cellular environment of tumors in the human body (<xref rid="b19-ol-32-2-15702" ref-type="bibr">19</xref>). In addition, it cannot mimic cell-cell and cell-extracellular matrix (ECM) interactions, nor be used to study the complex spatial organization of cells and cell interactions (<xref rid="b20-ol-32-2-15702" ref-type="bibr">20</xref>). Cells cultured in 2D systems experience homogeneous access to nutrients, oxygen and pharmaceutical agents within the culture medium (<xref rid="b21-ol-32-2-15702" ref-type="bibr">21</xref>). Consequently, when utilizing monolayer-cultured tumor cells as in vitro models for anticancer drug testing, substantial discrepancies emerge compared with in vivo models. These differences compromise the efficiency of drug screening processes, potentially leading to miscalculations of therapeutic dosages and subsequent impairment of clinical efficacy (<xref rid="b19-ol-32-2-15702" ref-type="bibr">19</xref>).</p>
</sec>
<sec>
<title>Animal models</title>
<p>Animal models provide a more physiologically relevant system, since the tumor develops within a complex and dynamic microenvironment (<xref rid="b22-ol-32-2-15702" ref-type="bibr">22</xref>). Animal models recapitulate the in vivo context, including the complex TME. Common examples include genetically engineered mice (<xref rid="b23-ol-32-2-15702" ref-type="bibr">23</xref>), zebrafish (<xref rid="b24-ol-32-2-15702" ref-type="bibr">24</xref>), xenografts (<xref rid="b25-ol-32-2-15702" ref-type="bibr">25</xref>) and allografts (<xref rid="b26-ol-32-2-15702" ref-type="bibr">26</xref>). Animal models are indispensable for lung cancer research, providing critical insights into the biology and progression of the disease, and potential therapeutic strategies. By utilizing these models, researchers can shed light on the intricate interactions between cancer cells and the TME, which is vital for understanding tumor dynamics and treatment efficacy (<xref rid="b27-ol-32-2-15702" ref-type="bibr">27</xref>). While animal models can simulate physiological complexity at the whole-organism level, they present insurmountable challenges in terms of external validity due to poor applicability to clinical settings and inherent interspecies differences between animals and humans (<xref rid="b28-ol-32-2-15702" ref-type="bibr">28</xref>). Systematic studies on the predictive value of animal models have revealed weak associations between animal-derived data and human clinical outcomes (<xref rid="b29-ol-32-2-15702" ref-type="bibr">29</xref>,<xref rid="b30-ol-32-2-15702" ref-type="bibr">30</xref>). The reliability of animal models for drug screening is further compromised by variables such as animal sex, sample size, age and stress levels in experimental animals (<xref rid="b30-ol-32-2-15702" ref-type="bibr">30</xref>). Furthermore, clinical trial failures often stem from patient heterogeneity, a critical factor that conventional methodologies and animal models fail to assess adequately (<xref rid="b31-ol-32-2-15702" ref-type="bibr">31</xref>). These limitations have driven the development of precision medicine and corresponding advanced drug screening approaches (<xref rid="b32-ol-32-2-15702" ref-type="bibr">32</xref>).</p>
</sec>
<sec>
<title>3D culture models</title>
<p>Current mainstream 3D cancer models primarily include multicellular tumor spheroids (MCTSs), organotypic multicellular spheroids, tumor-derived organoids and tumor spheroids (<xref rid="b33-ol-32-2-15702" ref-type="bibr">33</xref>). As illustrated in <xref rid="f1-ol-32-2-15702" ref-type="fig">Fig. 1</xref>, these lung cancer models can be generated from different cellular sources-such as cancer cell lines, patient tissues or circulating tumor cells - and can be further co-cultured with other cell types to increase complexity, ultimately serving as powerful platforms for biomedical applications including drug screening and personalized medicine. Organoids and tumor spheroids are 3D culture models that provide more physiologically relevant insights into tumor biology than traditional 2D cultures (<xref rid="b34-ol-32-2-15702" ref-type="bibr">34</xref>). However, organoids and tumor spheroids differ notably in their culture methods, structural characteristics and applications. Spheroids generally form through the self-assembly of single-cell suspensions and do not require exogenous scaffolding. By contrast, organoids represent more complex 3D structures that typically rely on scaffold-based culture systems (<xref rid="b35-ol-32-2-15702" ref-type="bibr">35</xref>). Organoids closely mimic the architecture and function of native tumors and often incorporate multiple cell types along with elements of the TME (<xref rid="b36-ol-32-2-15702" ref-type="bibr">36</xref>). Organotypic culture is a culture method in which undamaged organs in the living body are isolated and cultured in vitro, so that they can maintain 3D growth in vitro and maintain the original tissue structure. Organotypic culture can successfully preserve the intact TME (<xref rid="b37-ol-32-2-15702" ref-type="bibr">37</xref>). However, organ culture has inherent limitations: First, obtaining organ tissues is severely restricted by their limited availability. Second, once the organ is isolated and cultured, the proliferative activity of its cells decreases notably and the proliferative vigor is challenging to maintain (<xref rid="b38-ol-32-2-15702" ref-type="bibr">38</xref>). To solve the aforementioned complications, a 3D culture model in which tumor cells grow and proliferate in vitro to form tumor spheroids has emerged. The method is usually applied to cell lines from solid tumor spheroids. Notably, such cell lines from solid tumor spheroids survive well in avascular conditions (<xref rid="b39-ol-32-2-15702" ref-type="bibr">39</xref>). In vitro-constructed MCTSs are of great value in cancer research, with applications including, but not limited to, radiobiological studies (<xref rid="b40-ol-32-2-15702" ref-type="bibr">40</xref>) and novel chemotherapeutic drug development (<xref rid="b41-ol-32-2-15702" ref-type="bibr">41</xref>).</p>
<p>3D culture technology represents an advancement beyond conventional 2D culture systems. Compared with 2D systems, 3D culture establishes more physiologically relevant gradients of oxygen, nutrients, metabolic wastes and signaling molecules. 3D culture facilitates comprehensive cell adhesion, signal transduction and differentiation, while promoting cell-cell and cell-matrix interactions, creating a microenvironment that is an improved simulation of in vivo conditions. This enables cultured tumor cells to exhibit characteristics closely resembling those of solid tumors in vivo (<xref rid="b16-ol-32-2-15702" ref-type="bibr">16</xref>). As shown in <xref rid="f2-ol-32-2-15702" ref-type="fig">Fig. 2</xref>, these characteristics include spatial gradients of oxygen, nutrients and drugs from the periphery to the core, as well as the coexistence of proliferating, quiescent and necrotic cell populations (<xref rid="b42-ol-32-2-15702" ref-type="bibr">42</xref>). Consequently, in vitro 3D cell culture models are being progressively developed and implemented for chemotherapeutic drug screening applications. Compared with animal studies, 3D cell culture systems offer distinct advantages. Firstly, they circumvent ethical concerns associated with human experimentation while addressing the critical discordance observed between animal models and clinical outcomes (with &#x007E;90&#x0025; of in vivo animal experiment results failing to align with clinical trial findings) (<xref rid="b43-ol-32-2-15702" ref-type="bibr">43</xref>). Furthermore, 3D cultures substantially reduce drug screening costs, shorten the screening timeline, and enable the incorporation of diverse cell types and enhanced physiological complexity. Additionally, this approach overcomes the limitations inherent to animal models, including prolonged experimental cycles, high costs and incompatibility with high-throughput screening approaches (<xref rid="b44-ol-32-2-15702" ref-type="bibr">44</xref>).</p>
</sec>
</sec>
</sec>
<sec>
<label>3.</label>
<title>Spheroid culture methods</title>
<p>MCTSs are commonly referred to as 3D in vitro models that can mimic the tissue microenvironment. MCTSs are spherical structures of a specific diameter with a dense core, composed of a population of tumor cells. The central region of an MCTS typically becomes hypoxic due to the limited access of cells to oxygen and nutrients. By contrast, the cells at the edge of the spheroid can grow normally (<xref rid="b45-ol-32-2-15702" ref-type="bibr">45</xref>). By combining advantages such as ease of construction, high reproducibility and compatibility with high-throughput drug screening, MCTSs have become a commonly used model for preclinical antitumor drug evaluation (<xref rid="b46-ol-32-2-15702" ref-type="bibr">46</xref>&#x2013;<xref rid="b49-ol-32-2-15702" ref-type="bibr">49</xref>). The formation of an MCTS is roughly divided into the following three steps (<xref rid="f3-ol-32-2-15702" ref-type="fig">Fig. 3</xref>) (<xref rid="b50-ol-32-2-15702" ref-type="bibr">50</xref>,<xref rid="b51-ol-32-2-15702" ref-type="bibr">51</xref>). First, cells form loose aggregates through integrin-ECM interactions. Then, cadherin expression is upregulated, initiating cell compaction. Finally, homophilic cadherin-cadherin interactions mediate the formation of discrete, dense spheroids that continue to grow. Current construction methods include the spinner culture, pellet culture and hanging-drop method. The advantages and disadvantages of different MCTS construction methods are summarized in <xref rid="tI-ol-32-2-15702" ref-type="table">Table I</xref> (<xref rid="b52-ol-32-2-15702" ref-type="bibr">52</xref>&#x2013;<xref rid="b59-ol-32-2-15702" ref-type="bibr">59</xref>).</p>
<p>Lung cancer organoids (LCOs) are generated by culturing lung cancer stem cells derived from patient tissue samples in an ECM such as Matrigel, with the addition of growth factors to promote their proliferation and differentiation (<xref rid="b60-ol-32-2-15702" ref-type="bibr">60</xref>). As the same malignant tumor shows different genetic characteristics and phenotypic heterogeneity among different patients, and tumor tissues in different parts of the body of the same patient, personalized precision medicine has become a novel trend in tumor treatment, and the emergence of tumor organoids provides an opportunity for precision medicine (<xref rid="b61-ol-32-2-15702" ref-type="bibr">61</xref>). Individualized therapy is the latest concept in lung cancer treatment, which refers to the development of an individualized treatment plan with the best efficacy and the least toxicity according to the biological characteristics of the tumor, in order to maximize the clinical benefit to the patient (<xref rid="b62-ol-32-2-15702" ref-type="bibr">62</xref>,<xref rid="b63-ol-32-2-15702" ref-type="bibr">63</xref>).</p>
<p>As early as 2009, small intestinal organoids with intestinal structure were successfully cultured using adult stem cells derived from the mouse intestine, which led to an increase in organoid research (<xref rid="b64-ol-32-2-15702" ref-type="bibr">64</xref>). Novel 3D cell models have been used for drug screening, predicting patient response to therapy and providing guidance for personalized medication, which has been considered a breakthrough in tumor stem cell technology in the last decade (<xref rid="b65-ol-32-2-15702" ref-type="bibr">65</xref>). Organoid models constructed from tissue samples from patients with lung cancer can reproduce the histomorphology and biomarker characterization of tumors in patients, maintain tumor heterogeneity and exhibit drug sensitivity similar to that of their lung cancer tissues of origin. As illustrated in <xref rid="f4-ol-32-2-15702" ref-type="fig">Fig. 4A</xref>, tumor organoids derived from patient tumor tissues or biopsy samples can be used for high-throughput drug screening, genetic testing, discovery of new therapeutic targets and the establishment of a tumor organoid biobank, thereby supporting basic research and drug development (<xref rid="b66-ol-32-2-15702" ref-type="bibr">66</xref>). In parallel, <xref rid="f4-ol-32-2-15702" ref-type="fig">Fig. 4B</xref> shows the clinical application pathway: Patient-derived tumor organoids are subjected to drug sensitivity screening to guide individualized treatment decisions (<xref rid="b67-ol-32-2-15702" ref-type="bibr">67</xref>). Together, these organoid models serve a key role in individualized drug administration and the prognosis of lung cancer, and have the potential to be used as reliable preclinical models for lung cancer research (<xref rid="b68-ol-32-2-15702" ref-type="bibr">68</xref>). Organoid production methods are generally divided into three categories: Conventional 3D culture, organoid-on-a-chip and 3D bioprinting (<xref rid="b69-ol-32-2-15702" ref-type="bibr">69</xref>).</p>
<sec>
<title/>
<sec>
<title>Hanging-drop method</title>
<p>The hanging-drop method is a commonly used method for 3D culture of tumor spheroids (<xref rid="b70-ol-32-2-15702" ref-type="bibr">70</xref>,<xref rid="b71-ol-32-2-15702" ref-type="bibr">71</xref>). After flipping the lid of a Petri dish with attached cell suspension droplets, the cell suspension will hang on the lid due to surface tension. The tumor cells within the droplets will spontaneously gather at the tip of the droplets due to gravity, which promotes the coalescence of the cell droplets at the air-liquid interface to form a spheroid (<xref rid="b72-ol-32-2-15702" ref-type="bibr">72</xref>). An appropriate amount of PBS must be added to the petri dish to prevent evaporation of the liquid within the droplets. As only one tumor spheroid is formed within each suspension droplet, the application of this method allows for the accurate control of the size and homogeneity of the tumor spheroids (<xref rid="f5-ol-32-2-15702" ref-type="fig">Fig. 5A</xref>) (<xref rid="b73-ol-32-2-15702" ref-type="bibr">73</xref>). In addition to the adjustable size of the spheroids, the suspension droplet culture system also has other advantages. Since it is a small-scale experiment, it does not require expensive or specialized equipment to form spheroids; a multichannel pipette can easily generate numerous spheroids (<xref rid="b74-ol-32-2-15702" ref-type="bibr">74</xref>,<xref rid="b75-ol-32-2-15702" ref-type="bibr">75</xref>). Notably, mesenchymal stem cells (MSCs) cultured using the hanging-drop method can secrete large amounts of anti-inflammatory and antitumor factors, which are important in disease treatment (<xref rid="b76-ol-32-2-15702" ref-type="bibr">76</xref>). However, the traditional hanging-drop method also has notable limitations. These include the inability to change the medium level frequently and the likely evaporation of the culture solution within the suspension droplet, which causes inconvenience in the subsequent experimental work, and thus, this method is only suitable for short-term culture (<xref rid="b77-ol-32-2-15702" ref-type="bibr">77</xref>).</p>
<p>The 96-well spheroid plate minimizes manual handling and transfer of spheroids, and prevents their fusion. This shift in cultivation methodology enhances the spheroid formation throughput, improves spheroid uniformity and reduces the skill required to generate consistent spheroids (<xref rid="b78-ol-32-2-15702" ref-type="bibr">78</xref>). For applications demanding a large number of spheroids (ranging from 100 to 1,000) or substantial biomaterial, alternative methods utilizing agarose micromolds or agarose stamps may be preferable. These methods offer several key advantages: i) High throughput and scalability; ii) production of highly uniform spheroids; iii) cost-effectiveness and reusability of the molds; and iv) easy integration with standard multi-well plates for downstream analyses (<xref rid="b78-ol-32-2-15702" ref-type="bibr">78</xref>,<xref rid="b79-ol-32-2-15702" ref-type="bibr">79</xref>). Conventional 3D culture methods often require tedious liquid handling steps to separate chimeric antigen receptor (CAR)-T cells and tumor cells killed by CAR-T cells from the spheroids when performing cytotoxicity assays (<xref rid="b80-ol-32-2-15702" ref-type="bibr">80</xref>). The advent of the 3D hanging spheroid plate has addressed this challenge by facilitating both spheroid formation and the subsequent separation of unbound and dead cells from the spheroids during the assay (<xref rid="b81-ol-32-2-15702" ref-type="bibr">81</xref>). The 3D hanging spheroid plate features a unique design where each well comprises a hanging dripper, spheroid wells and waste wells (<xref rid="b82-ol-32-2-15702" ref-type="bibr">82</xref>). The process begins in the hanging-drop reservoir, where tumor spheroids are formed and subsequently co-cultured with CAR-T cells. For the cytotoxicity readout, the droplet containing the spheroid is deposited into the spheroid separation well (<xref rid="b81-ol-32-2-15702" ref-type="bibr">81</xref>). A key innovation of this system is that by tilting the plate beyond an angle of 20&#x00B0;, unbound CAR-T cells and dead tumor cells are efficiently transferred into the adjacent waste well through a connecting channel, leaving the intact spheroid isolated for further analysis (<xref rid="b82-ol-32-2-15702" ref-type="bibr">82</xref>). The traditional 3D culture method, whilst simple and easy to use, offers limited precise control and low reproducibility (<xref rid="b83-ol-32-2-15702" ref-type="bibr">83</xref>).</p>
</sec>
<sec>
<title>Pellet culture</title>
<p>The pellet culture method is a simpler approach for tumor spheroid formation compared with the hanging-drop method. In this method, cells are incubated on a shaker for 1 h to maximize cell-cell contact and interaction, promoting tumor spheroid formation. Subsequently, the cell suspension is centrifuged at a low speed (28 &#x00D7; g for 5 min), concentrating the cells at the bottom of a conical-shaped test tube via centrifugal force (<xref rid="f5-ol-32-2-15702" ref-type="fig">Fig. 5B</xref>). Afterwards, the supernatant is removed to harvest the cell pellet, and the pellet is resuspended in a spheroid-forming culture medium. After estimating the cell count, the cells in the medium are dispensed into 96-well U-bottom plates with a cell-rejecting surface (<xref rid="b74-ol-32-2-15702" ref-type="bibr">74</xref>,<xref rid="b84-ol-32-2-15702" ref-type="bibr">84</xref>). Pellet culture can be used to induce MSC differentiation. This system is particularly suitable for stem cell differentiation through chondrogenesis, as the cell-cell interactions within the pellet microenvironment mimic pre-chondrogenic cell cohesion during embryogenesis. MSCs can change their morphology in pellet culture from fibroblasts to polygonal shapes similar to chondrocytes. Thus, pellet culture can be used to study cartilage formation signaling pathways and assess stem cell chondrogenic potential (<xref rid="b85-ol-32-2-15702" ref-type="bibr">85</xref>,<xref rid="b86-ol-32-2-15702" ref-type="bibr">86</xref>). Although the pellet culture method has the advantage of generating uniformly sized and shaped spheroids in a short period, it requires a large number of cell culture flasks to fill the porous plate, making it difficult to generate spheroids on a large scale and unsuitable for high-throughput screening (<xref rid="b53-ol-32-2-15702" ref-type="bibr">53</xref>).</p>
</sec>
<sec>
<title>Microfluidic chip method</title>
<p>Microfluidic chip technology, as a novel culture method, has attracted increasing attention for its prospects in the pharmaceutical industry (<xref rid="b87-ol-32-2-15702" ref-type="bibr">87</xref>,<xref rid="b88-ol-32-2-15702" ref-type="bibr">88</xref>). Integrating the 3D culture of tumor cells onto a microfluidic chip provides a novel platform for high-throughput screening of antitumor drugs (<xref rid="b89-ol-32-2-15702" ref-type="bibr">89</xref>). To facilitate cell aggregation, the microfluidic microwells are first functionalized with a layer of cell-ECM material. Subsequently, a controlled flow rate is applied to generate hydrodynamic forces within the device. This induces a rotational motion that keeps the cells in suspension, thereby promoting their organization into aggregates within the coated microwells. The appropriate concentration of the cell suspension is infused through the microchannels into microwells, and then the cells are cultured on the chip to form the tumor spheroids (<xref rid="f5-ol-32-2-15702" ref-type="fig">Fig. 5C</xref>) (<xref rid="b90-ol-32-2-15702" ref-type="bibr">90</xref>). The advantages of this method compared with conventional spheroid culture methods (e.g., the hanging-drop or liquid overlay method) are that more homogeneous tumor spheroids can be formed quickly, the cell culture environment can be precisely controlled, and the tumor spheroids can be observed and imaged in real time by biosensors (<xref rid="b91-ol-32-2-15702" ref-type="bibr">91</xref>). The disadvantage is that the design and processing of the chip are more complicated, and it is difficult to remove the formed tumor spheroids for further experimental analysis (<xref rid="b92-ol-32-2-15702" ref-type="bibr">92</xref>,<xref rid="b93-ol-32-2-15702" ref-type="bibr">93</xref>).</p>
<p>Organ-on-a-chip models refer to microfluidic-based platforms that mimic the microarchitecture and functionality of human organs, recreating various physiological milieus (<xref rid="b94-ol-32-2-15702" ref-type="bibr">94</xref>,<xref rid="b95-ol-32-2-15702" ref-type="bibr">95</xref>). These platforms are also termed &#x2018;microphysiological systems&#x2019; (<xref rid="b96-ol-32-2-15702" ref-type="bibr">96</xref>). The cells utilized in these models can be derived from primary cells, cell lines or stem cells. Specifically, &#x2018;organoid-on-a-chip&#x2019; denotes the integration of organoids into microfluidic devices. This hybrid approach not only preserves the biological complexity inherent to organoids but also leverages the controlled microenvironments of the chip to enhance the maturity and functionality of the organoids (<xref rid="b97-ol-32-2-15702" ref-type="bibr">97</xref>). Therefore, microfluidics, a technology characterized by sub-millimeter fluid engineering operations, is important as an ideal technological platform for in vitro cellular research, and has future applications in disease diagnosis and treatment and clinical biology research (<xref rid="b98-ol-32-2-15702" ref-type="bibr">98</xref>).</p>
</sec>
<sec>
<title>3D bioprinting</title>
<p>3D bioprinting, an additive manufacturing technique, is an emerging technology that converts computer aided designs into physical objects (<xref rid="f5-ol-32-2-15702" ref-type="fig">Fig. 5D</xref>) (<xref rid="b99-ol-32-2-15702" ref-type="bibr">99</xref>). The advancement of 3D bioprinting technology and its integration with biomaterials have provided unprecedented opportunities for constructing in vitro tumor models (<xref rid="b100-ol-32-2-15702" ref-type="bibr">100</xref>). 3D bioprinting uses bioinks (mainly consisting of biomaterials, cells and growth factors) to construct 3D tumor models layer by layer and obtain functional organoids through subsequent in vitro culture (<xref rid="b101-ol-32-2-15702" ref-type="bibr">101</xref>,<xref rid="b102-ol-32-2-15702" ref-type="bibr">102</xref>). Inkjet-based 3D printing is suitable for encapsulating organoids within bioinks to form stable, isolated niches that facilitate the self-assembly of organoids. This technique enables high-precision droplet deposition, making it applicable in scenarios demanding meticulous placement of cells and biomaterials (<xref rid="b103-ol-32-2-15702" ref-type="bibr">103</xref>). The advantages of this method are the ability to form tumor spheroids of the desired size and shape that can be easily controlled in a short period of time, and that the technology can be used for high-throughput rapid screening due to its precision, controllability, versatility, flexibility and rapidity (<xref rid="b104-ol-32-2-15702" ref-type="bibr">104</xref>). Furthermore, the method shows great potential for geometrical and spatial control because 3D bioprinting allows the precise layer-by-layer deposition of bioinks, enabling the fabrication of tumor spheroids with customized sizes, shapes and internal architectures that mimic the complex spatial organization of native tumors. The disadvantages are the complexity of the technique and the high cost of the instrumentation. 3D bioprinting technology has led to the emergence of a novel era of biomedical engineering, and its multiple advantages have become a major driver for the rapid development of drug screening methods and drug delivery systems (<xref rid="b105-ol-32-2-15702" ref-type="bibr">105</xref>).</p>
</sec>
<sec>
<title>Rotating wall vessel method</title>
<p>In the rotating wall vessel method, the culture system is rotated horizontally around the x-axis to create a microgravity environment, which promotes the aggregation of cells into spheroids (<xref rid="f5-ol-32-2-15702" ref-type="fig">Fig. 5E</xref>) (<xref rid="b106-ol-32-2-15702" ref-type="bibr">106</xref>). Studies have shown that this microgravity affects gene expression in MSCs (<xref rid="b107-ol-32-2-15702" ref-type="bibr">107</xref>,<xref rid="b108-ol-32-2-15702" ref-type="bibr">108</xref>). Under microgravity conditions, chondrogenic and osteogenic gene expression is reduced in stem cells, while adipogenic gene expression is elevated (<xref rid="b109-ol-32-2-15702" ref-type="bibr">109</xref>). The literature suggests that initially the rotational speed is &#x007E;15 rpm, and as the tumor spheroids gather into progressively larger clusters, the rotational speed is increased to 25 rpm to keep the cell clusters in suspension (<xref rid="b110-ol-32-2-15702" ref-type="bibr">110</xref>). Compared with conventional static culture, the culture environment of the rotating microgravity bioreactor can enhance the promotion of cell proliferation and differentiation, providing an effective platform for studying disease pathogenesis and exploring novel therapeutic strategies (<xref rid="b111-ol-32-2-15702" ref-type="bibr">111</xref>). The method can be applied to a variety of cell lines and is capable of generating a large number of usable tumor spheroids in an environment characterized by low shear stress, high dissolved oxygen levels and low nutrient concentration, with the disadvantage that the self-assembly of tumor spheroids cannot be observed in real time (<xref rid="b112-ol-32-2-15702" ref-type="bibr">112</xref>).</p>
</sec>
<sec>
<title>Liquid overlay method</title>
<p>The liquid overlay method, also referred to as static suspension culture, involves culturing cells on specially designed plates coated with polyhydroxyethyl methacrylate (<xref rid="b113-ol-32-2-15702" ref-type="bibr">113</xref>) or agarose (<xref rid="b114-ol-32-2-15702" ref-type="bibr">114</xref>), which results in the formation of spheroids by reducing cell adhesion to the non-adherent culture plate (<xref rid="f5-ol-32-2-15702" ref-type="fig">Fig. 5F</xref>). As cell adhesion is inhibited, the liquid overlay method enables the rapid cultivation of reproducible, morphologically uniformly sized and well-defined spheroids in an automated manner (<xref rid="b115-ol-32-2-15702" ref-type="bibr">115</xref>). This method is more convenient for changing the cell culture solution and drug administration without interfering with tumor spheroid formation compared with the hanging-drop method. In addition, the liquid overlay method can be performed using 96-well ultra-low adsorbent plates, making it ideal for inoculating cells at the desired density. However, the preparation of culture plates used in the liquid overlay method is labor-intensive, requires skilled personnel, is relatively costly and the plates (or their non-adherent coating) are not reusable (<xref rid="b112-ol-32-2-15702" ref-type="bibr">112</xref>). Despite the non-adhesive properties of agarose, this biomaterial still has drawbacks in culturing cancer cells; agarose has difficulty interacting with tumor cells and is unable to activate specific signaling pathways associated with the response of tumor cells to therapeutic processes because agarose lacks the bioactive adhesive motifs that engage cell surface receptors (e.g., integrins) (<xref rid="b116-ol-32-2-15702" ref-type="bibr">116</xref>).</p>
</sec>
<sec>
<title>Spinner culture</title>
<p>The spinner culture method generates 3D aggregates by using a magnetic stir bar to create a turbulent flow field that mixes air and nutrients-a process driven by magnetic force, which was initially used to study the effects of microgravity on cells and tissues (<xref rid="b117-ol-32-2-15702" ref-type="bibr">117</xref>). The spinner culture method has been successfully applied for the large-scale cultivation of bacteria and yeast to produce vaccines, recombinant proteins and other metabolites, and in tissue engineering for generating cartilage constructs as well as for expanding mesenchymal stem cells on microcarriers (<xref rid="f5-ol-32-2-15702" ref-type="fig">Fig. 5G</xref>) (<xref rid="b118-ol-32-2-15702" ref-type="bibr">118</xref>,<xref rid="b119-ol-32-2-15702" ref-type="bibr">119</xref>). During system operation, a constant rotational speed regulation serves as the critical parameter (<xref rid="b120-ol-32-2-15702" ref-type="bibr">120</xref>). The advantage of this method is that the fluid environment helps exchange substances between the tumor spheroids and allows for the formation of multiple tumor spheroids (<xref rid="b121-ol-32-2-15702" ref-type="bibr">121</xref>). In addition to reducing the stirring speed, the tumor spheroids were studied by changing the medium to add drugs or growth factors to the spheroids (<xref rid="b48-ol-32-2-15702" ref-type="bibr">48</xref>). A notable drawback of this method is that the mechanical stirring device in the culture system imposes substantial fluid shear stress on the cells, thereby causing a certain degree of cellular damage. Consequently, this approach is likely unsuitable for cells with low adhesion strength or high sensitivity to shear forces, or those that are anchorage-dependent and prone to anoikis when in suspension (<xref rid="b122-ol-32-2-15702" ref-type="bibr">122</xref>).</p>
</sec>
<sec>
<title>External force method</title>
<p>The external force method uses external forces such as magnetic fields, electric fields and ultrasound to concentrate dispersed cell suspensions into high-density solutions, thereby promoting cell aggregation into spheroids. This method relies on magnetic forces termed magnetic levitation, which improves upon traditional suspension techniques by enabling more rapid and uniform spheroid formation without the need for mechanical agitation, generating higher yields with better reproducibility and allowing co-culture of multiple cell types (<xref rid="f5-ol-32-2-15702" ref-type="fig">Fig. 5H</xref>) (<xref rid="b123-ol-32-2-15702" ref-type="bibr">123</xref>,<xref rid="b124-ol-32-2-15702" ref-type="bibr">124</xref>). For example, cells are incubated with magnetic cationic liposomes containing Fe3O4 magnetic nuclei, and when the magnetic nanoparticles are endocytosed by the cells, the cells become magnetic under the influence of the magnetic nanoparticles. The magnetized cells are then attracted to the center to form a tumor spheroid by the force of an external magnetic field (<xref rid="b59-ol-32-2-15702" ref-type="bibr">59</xref>). This method allows for high yields and applications for long-term culture of tumor spheroids, but the resulting tumor spheroids are usually not uniform in size (<xref rid="b125-ol-32-2-15702" ref-type="bibr">125</xref>). The use of magnetic forces to induce the aggregation of cells into spheroids can be used to elucidate the interactions between cells. However, the introduction of foreign materials (e.g., magnetic nanoparticles) may raise safety concerns, which limits their potential for future clinical applications (e.g., in vivo cell therapy or tissue implantation), although this method remains valuable for in vitro 3D culture (<xref rid="b120-ol-32-2-15702" ref-type="bibr">120</xref>).</p>
</sec>
</sec>
</sec>
<sec>
<label>4.</label>
<title>Application of 3D culture technology in the field of lung cancer research</title>
<sec>
<title/>
<sec>
<title>Advances in MCTS modeling for lung cancer drug screening</title>
<p>A previous study has analyzed and compared the morphological characteristics, protein expression, ECM distribution and drug resistance of scaffold-free and scaffold-based A549 spheroids, and found that compared with monolayer A549 cell cultures, scaffold-free and scaffold-based A549 spheroids exhibited elevated levels of epithelial-mesenchymal transition (EMT) markers and protein expression levels associated with drug resistance (<xref rid="b126-ol-32-2-15702" ref-type="bibr">126</xref>). Drug resistance is a leading cause of treatment failure and mortality in patients with cancer. Among patients who succumb to cancer due to metastasis or recurrence, &#x003E;90&#x0025; of cases are closely associated with multidrug resistance, a phenomenon commonly observed in both traditional chemotherapy and novel targeted therapies (<xref rid="b127-ol-32-2-15702" ref-type="bibr">127</xref>).</p>
<p>Notably, 3D culture systems generally exhibit more potent drug resistance properties, with most compounds showing notably reduced efficacy in a 3D environment compared with 2D culture (<xref rid="b128-ol-32-2-15702" ref-type="bibr">128</xref>,<xref rid="b129-ol-32-2-15702" ref-type="bibr">129</xref>). Huang and Hsu (<xref rid="b130-ol-32-2-15702" ref-type="bibr">130</xref>) successfully accelerated the formation of tumor spheroids of NSCLC cells using an easy-to-prepare chitosan-hyaluronic acid composite membrane as a 3D culture platform. By comparing the biological properties of 3D tumor spheroids formed by this composite membrane with those of 2D-cultured cells, it was found that the expression levels of tumor stem cell-related markers (such as CD133 and CD44) and EMT markers were notably upregulated in the 3D culture system, and that cell viability and invasive capacity were enhanced 2- to 4-fold compared with those in 2D culture. Notably, 3D-cultured cells showed a 5&#x2013;6-fold enhancement of cisplatin resistance and an even greater 16-56-fold increase in methotrexate resistance, confirming that the composite membrane could provide an efficient 3D culture platform for tumor stem cell research and anticancer drug screening.</p>
<p>In addition, Huang et al (<xref rid="b131-ol-32-2-15702" ref-type="bibr">131</xref>) cultured human A549-iRFP NSCLC cells into MCTSs and inoculated them into the lungs of male nude mice. An orthotopic xenograft model of lung cancer was established via intrapulmonary injection of tumor spheroids to simulate the progression of NSCLC in four clinical stages within 1 month. Tumor resection in this orthotopic xenograft model resulted in a high postoperative survival rate. The establishment of this novel in situ xenograft model of NSCLC opens up numerous opportunities for clinical evaluation of potential anticancer drugs for the treatment of different stages of lung cancer. Zhang et al (<xref rid="b132-ol-32-2-15702" ref-type="bibr">132</xref>) established a patient-derived 3D tumor spheroid culture system using NSCLC patient samples. Under long-term culture conditions, these patient-derived tumor spheroids reproduced the cytological features and markers of the primary tumors. The study also demonstrated the utility of this patient-derived spheroid system for drug screening. The results of the study support the establishment of scalable 3D in vitro models of NSCLC for drug screening and allow for potential long-term studies, including studies modeling drug resistance. MCTSs are gradually becoming an important method for novel drug testing and personalized anticancer therapy (<xref rid="b133-ol-32-2-15702" ref-type="bibr">133</xref>,<xref rid="b134-ol-32-2-15702" ref-type="bibr">134</xref>).</p>
<p>Gupta et al (<xref rid="b135-ol-32-2-15702" ref-type="bibr">135</xref>) developed a novel air-grown MCTS model for simulating tumors in vivo to understand lung cancer biology. In the 3D MCTS model constructed from the A549 cell line, tumor-penetrating peptide iRGD peptide co-application notably enhanced the tumor permeability of paclitaxel (PTX). Notably, the cytotoxic effect of PTX was confined to the outer layer of proliferating active cells, suggesting a barrier effect of the 3D structure on drug diffusion. Guzman et al (<xref rid="b136-ol-32-2-15702" ref-type="bibr">136</xref>) developed a dry powder of nanoparticles containing a PTX nanocomposite microparticle (nCmP) aerosol delivered to the lungs via a dry powder inhaler to treat NSCLC. In a liquid 3D tumor spheroids model, PTX nCmP exhibited growth inhibition effects comparable to free PTX, but the nCmP drug delivery system showed a superior cytotoxicity profile. The 3D air-interface culture platform could be used to evaluate PTX nCmP, showing its potential as an in vitro model that exhibits improved simulation of the lung environment and facilitating its further application for evaluating other aerosol preparations.</p>
<p>A similar effect on the growth of NSCLC was demonstrated using a multicellular spheroid chip. H1650 NSCLC cell suspensions were incubated in the chip under a pressure range of 145&#x2013;155 Pa. The chip, which was equipped with a removable cell capture barrier, was capable of forming and extracting 3D tumor spheroids (<xref rid="b92-ol-32-2-15702" ref-type="bibr">92</xref>). The study provided a simple and effective method for obtaining uniform and small-sized 3D tumor spheroids for the next steps in cell-based biomedical research, including gene expression analysis and tumor spheroid inoculation in animal models. Ganguli et al (<xref rid="b137-ol-32-2-15702" ref-type="bibr">137</xref>) designed a modular and versatile microchip 3D droplet culture platform that allows for reproducible and high-content drug screening. The droplets were designed to form a predetermined geometry, thus enabling manipulation of the geometry of the cultured cell clusters, which can be performed directly on the chip in real time using high-resolution confocal microscopy. In addition, the cells in the micro-platform aggregated into MCTSs notably faster (forming tumor spheroids in 1 day) compared with the conventional hanging-drop culture. Fully automated 3D screening of MCTSs has been demonstrated using a novel angle plate adapter technology that facilitates efficient liquid handling in a 1,536-well format. This approach identified active natural products from the microbial Natural Products Library at UF Scripps (<xref rid="b138-ol-32-2-15702" ref-type="bibr">138</xref>). Because this method enables high-throughput, automated screening of 3D tumor models in a physiologically relevant microenvironment, thereby improving the predictive accuracy of drug responses and reducing reliance on animal models, it may continue to serve an important role in drug discovery and development for the foreseeable future (<xref rid="b139-ol-32-2-15702" ref-type="bibr">139</xref>). 3D tumor spheroids are critical for understanding the mechanisms by which the TME contributes to cancer onset and progression, which can lead to metastasis, and can help identify novel molecular therapeutic approaches (<xref rid="b140-ol-32-2-15702" ref-type="bibr">140</xref>). 3D tumor spheroid models have led to a renewed appreciation of MCTSs due to their ability to mimic the complexity of in vivo tumors and serve as a potential bridge between traditional 2D culture and in vivo studies (<xref rid="b141-ol-32-2-15702" ref-type="bibr">141</xref>).</p>
<p>3D in vitro co-culture models improve the study of cell-cell and cell-matrix interactions, as well as the role of the microenvironment in cell differentiation, proliferation, apoptosis, gene expression, and tumor cell drug resistance (<xref rid="b142-ol-32-2-15702" ref-type="bibr">142</xref>). In tumor cell culture for drug screening, co-culture of normal cells with tumor cells could be a potential technique to reconstitute the heterogeneous multicellular environment of solid tumors and to promote tumor migration (<xref rid="b53-ol-32-2-15702" ref-type="bibr">53</xref>). Due to the multi-component and multi-target action characteristics of Traditional Chinese Medicine, the traditional 2D monolayer cell model is too oversimplified to comprehensively reflect its overall regulatory effects. By contrast, the 3D tumor spheroids model with multi-cell co-culture can more accurately mimic the in vivo microenvironment (<xref rid="b143-ol-32-2-15702" ref-type="bibr">143</xref>). Lamichhane et al (<xref rid="b144-ol-32-2-15702" ref-type="bibr">144</xref>) used the hanging-drop method to establish a tumor spheroid model consisting of epithelial cells, endothelial cells and bone marrow MSCs in lung cancer, and to study the different cell distributions and interactions within the tumor spheroids to investigate the effects of therapeutic drugs on different cells. Tumor spheroids constructed with a mixture of different cells were a good model to study the interactions between cells within the tumor, and it was found that the composition of real tumor tissues could be further simulated by adjusting the ratio of different cells.</p>
<p>MCTSs are an inevitable choice for simulating the TME. However, relatively few cell types and compositions are currently used to construct MCTSs, partly due to the difficulty of co-culturing multiple cells in vitro (<xref rid="b145-ol-32-2-15702" ref-type="bibr">145</xref>). One study found that using fibroblasts, endothelial cells and immune cells in a feeder-layer-like manner as the external microenvironment of tumor spheroids effectively explores stromal cell effects and overcomes co-culture challenges (<xref rid="b146-ol-32-2-15702" ref-type="bibr">146</xref>). Han and Hsu (<xref rid="b147-ol-32-2-15702" ref-type="bibr">147</xref>) constructed a co-culture system of MSCs and A549 lung cancer cells on ultra-thin (2 &#x00B5;m) hyaluronan-grafted chitosan, and the cells successfully self-assembled to form 3D tumor co-spheroids with a core-shell structure. To verify the different degrees of tumorigenicity, A549 cells or cells co-cultured with MSCs were transplanted into zebrafish embryos for in vivo evaluation, and the tumorigenicity obtained in the zebrafish xenograft model was consistent with that observed in vitro. This evidence suggests that a 3D co-culture platform of cancer cells and MSCs based on hyaluronan-grafted chitosan substrates may be a convenient tool for studying cell-cell interactions in tumor-like microenvironments and could potentially be used for in vitro cancer drug testing. With the continuous development of precision medicine, MCTSs may be further developed into a reliable platform that can simulate solid tumors to a greater extent than conventional 2D cultures. This platform opens up a valuable pathway for subsequent high-throughput and high-resolution analyses. Compared with traditional preclinical models, it can more accurately predict clinical outcomes and become an effective tool for real-world drug-based research and individualized tumor treatment.</p>
</sec>
<sec>
<title>Research progress on LCOs in personalized precision medicine</title>
<p>Currently, a variety of tumor organoid models have been successfully constructed, including colorectal cancer organoid models (<xref rid="b148-ol-32-2-15702" ref-type="bibr">148</xref>), gastric cancer organoid models (<xref rid="b149-ol-32-2-15702" ref-type="bibr">149</xref>), hepatocellular carcinoma organoid models (<xref rid="b150-ol-32-2-15702" ref-type="bibr">150</xref>), pancreatic cancer organoid models (<xref rid="b151-ol-32-2-15702" ref-type="bibr">151</xref>), bladder cancer organoid models (<xref rid="b152-ol-32-2-15702" ref-type="bibr">152</xref>), ovarian cancer organoid models (<xref rid="b153-ol-32-2-15702" ref-type="bibr">153</xref>), prostate cancer organoid models (<xref rid="b154-ol-32-2-15702" ref-type="bibr">154</xref>), lung cancer organoid models (<xref rid="b155-ol-32-2-15702" ref-type="bibr">155</xref>) and breast cancer organoid models (<xref rid="b156-ol-32-2-15702" ref-type="bibr">156</xref>). These 3D culture systems successfully mimic the biological characteristics of the source tissues in terms of gene expression profiles, tissue structural features and physiological functions, and provide a promising technological platform for developmental biology research, disease modeling, drug screening and cell therapy (<xref rid="b157-ol-32-2-15702" ref-type="bibr">157</xref>). Several laboratories have successfully established LCO biosample libraries for lung cancer research, including organoid models derived from the tissues of patients with LUAD (<xref rid="b158-ol-32-2-15702" ref-type="bibr">158</xref>,<xref rid="b159-ol-32-2-15702" ref-type="bibr">159</xref>). Systematic analyses have shown that such models completely retained the histological architecture (verified by H&#x0026;E staining), genomic features (confirmed by whole-exome sequencing) and gene expression profiles (analyzed by RNA-sequencing) of the parental tumors (<xref rid="b160-ol-32-2-15702" ref-type="bibr">160</xref>,<xref rid="b161-ol-32-2-15702" ref-type="bibr">161</xref>). The models can be used for high-throughput drug screening to further understand the pathophysiology of lung cancer and to facilitate personalized medicine by predicting individual patient responses to anticancer drugs (<xref rid="b162-ol-32-2-15702" ref-type="bibr">162</xref>).</p>
<p>Lung cancer exhibits notable genetic and phenotypic heterogeneity among individuals, which drives the need for personalized medicine (<xref rid="b108-ol-32-2-15702" ref-type="bibr">108</xref>). LCOs can be generated from tumor cells isolated from patient tissues (<xref rid="b163-ol-32-2-15702" ref-type="bibr">163</xref>). The response of LCOs to drugs is based on their genomic alterations. Specifically, olaparib is effective against breast cancer gene 2-mutant-like organoids, erlotinib is effective against EGFR-mutant organoids and crizotinib is effective against EGFR mutation/mesenchymal-epithelial transition factor amplification organoids. LCOs exhibit the functional heterogeneity of tumors that is difficult to capture with traditional techniques (<xref rid="b108-ol-32-2-15702" ref-type="bibr">108</xref>). One study identified Wnt-dependent and Wnt-independent subtypes in LUAD, regulated by the alveolar factor NK2 homeobox 1 (NKX2-1). Loss of NKX2-1 triggers lineage reprogramming, leading to Wnt dependency and sensitivity to porcupine inhibitors (<xref rid="b159-ol-32-2-15702" ref-type="bibr">159</xref>). This organoid-based classification model links specific molecular phenotypes (Wnt-dependent vs. Wnt-independent LUAD subtypes defined by NKX2-1 status) to targeted therapies (e.g., porcupine inhibitors for Wnt-dependent tumors), thereby advancing a novel paradigm for precision medicine in lung cancer. Additionally, EGFR-mutated LCOs have been constructed, revealing the mechanisms of resistance to EGFR-tyrosine kinase inhibitors (<xref rid="b164-ol-32-2-15702" ref-type="bibr">164</xref>). Kim et al (<xref rid="b165-ol-32-2-15702" ref-type="bibr">165</xref>) established LCOs using five cancer tissue subtypes, and surgically resected lung cancer tissues were separated into individual cells or clusters of cells, embedded in Matrigel, and cultured in Wnt3a- and Noggin-free medium. The organoids of different lung cancer subtypes were obtained in &#x007E;4 weeks. H&#x0026;E staining and immunohistochemical analysis showed that the organoids of the five lung cancer subtypes retained LUAD markers (e.g., napsin-A), as well as the histological features of the cancerous tissues. The lung cancer tissues retained the genetic features of cancer tissues as demonstrated by gene-targeted sequencing, single nucleotide polymorphisms genotyping and mutation concordance analysis. Meanwhile, some related studies have confirmed that patient-derived organoids retained the histological and genetic features of primary tumors, and were reliable models for evaluating drug sensitivity and predicting therapeutic responses in NSCLC, thereby guiding personalized precision medicine (<xref rid="b166-ol-32-2-15702" ref-type="bibr">166</xref>,<xref rid="b167-ol-32-2-15702" ref-type="bibr">167</xref>).</p>
<p>With the advent of precision therapy, in vitro drug sensitivity prediction of tumors is an important research direction for individualized treatment (<xref rid="b168-ol-32-2-15702" ref-type="bibr">168</xref>). Tumor organoid technology has advanced significantly, enabling the development of in vitro models that can predict patient responses to anticancer drugs across various cancer types (<xref rid="b169-ol-32-2-15702" ref-type="bibr">169</xref>). However, in lung cancer, the construction and application of LCO models are more difficult than those in other tumor organoid models due to efficiency and time consumption limitations (<xref rid="b170-ol-32-2-15702" ref-type="bibr">170</xref>). Hu et al (<xref rid="b171-ol-32-2-15702" ref-type="bibr">171</xref>) used a novel integrated superhydrophobic microtiter array chip, instead of the traditional 96-well plate, for high-throughput 3D cultivation and analysis of LCOs. A week-long drug sensitivity test on LCO microarrays demonstrated great potential in predicting patient treatment response and drug screening. Importantly, the one-week drug test results were cross-validated against three independent benchmarks: i) The drug responses of LCOs correlated with the in vivo anti-tumor efficacy observed in patient-derived xenografts; ii) the sensitivity patterns aligned with the specific genetic mutation profiles of the tumors (e.g., EGFR-TKI sensitivity in EGFR-mutant cases); and iii) the test predictions effectively reflected the actual clinical outcomes (e.g., progression-free survival and objective response rates) of the matched patients, establishing the InSMAR-chip platform as a technically feasible means for rapid patient-specific drug response prediction in clinical settings. The cutting-edge technology of combining LCO models with microfluidic chips provides an effective and reliable technological tool for predicting patient-specific drug responses in a clinical setting. A recent study detailed a novel tumor-on-a-chip platform incorporating organoids, which was designed to model the physiological processes of tumor growth and metastasis in vivo. This platform enabled practical evaluation of the invasive and proliferative capacities of patient-derived tumor cells, thereby serving as a valuable tool for investigating metastatic mechanisms, and advancing targeted cancer therapies and drug discovery (<xref rid="b172-ol-32-2-15702" ref-type="bibr">172</xref>).</p>
<p>Although the development of organoids has progressed to some extent, in vitro cancer models that can simultaneously reproduce the complexity of the TME and its diverse ECM and genetic properties remain challenging to establish. The emergence of 3D bioprinting technology offers a promising approach to address this limitation, although its full potential has not yet been realized. Dong et al (<xref rid="b173-ol-32-2-15702" ref-type="bibr">173</xref>) utilized 3D bioprinting technology to establish a 3D bioprinting strategy based on a bioink system (sodium alginate, hyaluronic acid and arginine-glycine-aspartic acid peptide) in vitro, and successfully constructed an array of LCOs for drug evaluation. Hydrogel, as a support material for cells in 3D models, is essential for achieving important cell-cell and cell-matrix interactions that induce cells to form tissues and organoids (<xref rid="b174-ol-32-2-15702" ref-type="bibr">174</xref>). 3D bioprinting allows precise control of the spatial deposition of biomaterials and cells based on predefined positions to create personalized tumor models, enabling the establishment of animal-free and personalized drug-screening platforms (<xref rid="b175-ol-32-2-15702" ref-type="bibr">175</xref>).</p>
<p>Despite progress in the establishment of LCOs, a large proportion of patients remain unresponsive to current immunotherapies (<xref rid="b176-ol-32-2-15702" ref-type="bibr">176</xref>). To better recapitulate the living TME, a cell co-culture system can be established by adding stromal cells, adipocytes or lymphocytes to the culture system (<xref rid="b177-ol-32-2-15702" ref-type="bibr">177</xref>). Dijkstra et al (<xref rid="b178-ol-32-2-15702" ref-type="bibr">178</xref>) demonstrated that the co-culture of autologous tumor-like organs and peripheral blood lymphocytes could be used to enrich tumor-reactive T cells. In addition, the killing efficiency of these T cells against matched tumor organoids could be assessed. A recent study has demonstrated that a gel-liquid interface co-culture model, established between LCOs and matched peripheral blood mononuclear cells, could enhance the interaction between immune cells and tumor organoids (<xref rid="b155-ol-32-2-15702" ref-type="bibr">155</xref>). This model thereby allows for an improved recapitulation of the systemic antitumor immune response observed in vivo.</p>
</sec>
</sec>
</sec>
<sec sec-type="conclusion">
<label>5.</label>
<title>Conclusion and prospects</title>
<p>The present review systematically examines the advantages and research progress of 3D culture systems, including MCTSs and organoids, for lung cancer drug screening, providing a theoretical basis for their application in preclinical drug development. Nevertheless, translating these findings into routine clinical practice remains challenging. To advance this field and enable clinical translation, future research should prioritize the standardization of culture protocols and the integration of emerging analytical technologies. Currently, considerable heterogeneity exists across studies in terms of cell sources, ECM components, spheroid formation methods and culture durations, which limits the comparability and reproducibility of drug response data (<xref rid="b179-ol-32-2-15702" ref-type="bibr">179</xref>). Furthermore, although 3D models improve the recapitulation of the TME compared with traditional 2D cultures, they still lack key physiological features such as functional vasculature, dynamic immune cell infiltration and complex stromal interactions (<xref rid="b180-ol-32-2-15702" ref-type="bibr">180</xref>). The majority of existing studies rely on bulk analyses of spheroids or organoids, which may obscure the intrinsic heterogeneity of tumor cell populations and their differential drug responses (<xref rid="b181-ol-32-2-15702" ref-type="bibr">181</xref>). Integrating patient-derived organoid biobanks with single-cell and spatial multi-omics technologies holds considerable potential for dissecting intratumoral heterogeneity at high resolution and mapping the spatial distribution of drug-resistant subclones (<xref rid="b182-ol-32-2-15702" ref-type="bibr">182</xref>). Furthermore, combining 3D culture systems with microfluidic organ-on-a-chip platforms and 3D bioprinting will enable the construction of more physiologically relevant models that incorporate multiple cell types and recapitulate tissue perfusion. Addressing these limitations through technological refinement and standardization will accelerate the translation of 3D culture systems from bench to bedside.</p>
<p>The application of spheroids and organoids represents a notable advancement in lung cancer research. They are crucial for studying cancer biology, drug responses and resistance mechanisms. Despite these advancements, challenges remain, including the variability in organoid cultures, the need for enhanced standardization and the difficulty in fully recapitulating the TME. Nevertheless, the continuous refinement of these models holds promise for improving their clinical relevance, facilitating drug development and enhancing the present understanding of cancer progression. These models provide a promising pathway for personalized cancer therapy, reducing reliance on animal models and improving the prediction of human-specific drug toxicity and efficacy, thereby driving innovation in lung cancer research and treatment.</p>
<p>Although both MCTSs and LCOs are superior to 2D culture techniques, they are not mutually exclusive but rather coexist complementarily. MCTSs provide a robust and scalable system for investigating fundamental mechanisms and large-scale compound screening. By contrast, LCOs, although often more resource-intensive and time-consuming to establish, offer high-fidelity patient-specific models for validating personalized treatment strategies. Recently, it has been demonstrated that malignant pleural effusion can be used as a cell source or medium supplement for LCO model establishment; MPE not only improves the success rate of LCO culture by enabling extended passaging and facilitating the initial formation from difficult-to-culture samples, but also supports the rapid generation of LCOs for personalized drug testing (<xref rid="b183-ol-32-2-15702" ref-type="bibr">183</xref>). Integrating both models through a tiered screening strategy, employing MCTSs for initial high-throughput screening followed by validation with LCOs in a patient-specific context, can effectively optimize the drug development pipeline. In addition, the complementary strengths of tumor spheroids in terms of modeling the TME and organoids in terms of mirroring human tissue specificity, can be leveraged through their integration (<xref rid="b184-ol-32-2-15702" ref-type="bibr">184</xref>). This synergistic approach bridges the gap between model systems and deepens research insights.</p>
<p>Despite progress, both MCTSs and LCOs face challenges. For MCTSs, these include standardizing size and cellular composition, as well as incorporating complex TME components. Ongoing advances regarding scaffold materials, imaging technologies and culture methodologies may help overcome these limitations in the future. For LCOs, limitations include low culture success rates, difficulty in reconstituting a complete TME (including functional vasculature and immune cells), and reducing the associated time and costs of establishment. One recent study successfully integrated multiple organoid modules on a single chip, enabling high-throughput drug testing using this platform (<xref rid="b185-ol-32-2-15702" ref-type="bibr">185</xref>). Future directions may involve converging these models with advanced technologies such as microfluidic organ-on-a-chip systems and 3D bioprinting. This integrative strategy will help construct a more physiologically relevant TME, including stromal and immune components, thereby enhancing the predictive power of 3D in vitro models.</p>
<p>In summary, the synergistic application of MCTSs and LCOs is driving a paradigm shift in lung cancer research. MCTSs serve as versatile tools for fundamental and applied screening, while LCOs provide a powerful means for personalized oncology. Together, they form a comprehensive and complementary toolkit that enhances the capacity to develop novel anticancer strategies and predicts clinical outcomes more accurately than conventional 2D cultures or animal models, ultimately advancing the era of precision medicine for patients with lung cancer.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgements</title>
<p>Not applicable.</p>
</ack>
<sec sec-type="data-availability">
<title>Availability of data and materials</title>
<p>Not applicable.</p>
</sec>
<sec>
<title>Authors&#x0027; contributions</title>
<p>JY and MZ conceived the idea of the study and provided overall supervision for the project. YT and HL collected materials and wrote the manuscript. AC, LS, JZ and HC helped with literature screening and manuscript writing. BW, HH and ML provided constructive guidance and revised the manuscript. Data authentication is not applicable. All authors read and approved the final version of the manuscript.</p>
</sec>
<sec>
<title>Ethics approval and consent to participate</title>
<p>Not applicable.</p>
</sec>
<sec>
<title>Patient consent for publication</title>
<p>Not applicable.</p>
</sec>
<sec sec-type="COI-statement">
<title>Competing interests</title>
<p>The authors declare that they have no competing interests.</p>
</sec>
<glossary>
<def-list>
<title>Abbreviations</title>
<def-item><term>3D</term><def><p>three-dimensional</p></def></def-item>
<def-item><term>MCTS</term><def><p>multicellular tumor spheroid</p></def></def-item>
<def-item><term>NSCLC</term><def><p>non-small cell lung cancer</p></def></def-item>
<def-item><term>EGFR</term><def><p>epidermal growth factor receptor</p></def></def-item>
<def-item><term>LUAD</term><def><p>lung adenocarcinoma</p></def></def-item>
<def-item><term>TME</term><def><p>tumor microenvironment</p></def></def-item>
<def-item><term>ECM</term><def><p>extracellular matrix</p></def></def-item>
<def-item><term>MSC</term><def><p>mesenchymal stem cell</p></def></def-item>
<def-item><term>CAR</term><def><p>chimeric antigen receptor</p></def></def-item>
<def-item><term>PTX</term><def><p>paclitaxel</p></def></def-item>
<def-item><term>nCmP</term><def><p>nanocomposite microparticle</p></def></def-item>
<def-item><term>LCO</term><def><p>lung cancer organoid</p></def></def-item>
</def-list>
</glossary>
<ref-list>
<title>References</title>
<ref id="b1-ol-32-2-15702"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smolarz</surname><given-names>B</given-names></name><name><surname>&#x0141;ukasiewicz</surname><given-names>H</given-names></name><name><surname>Samulak</surname><given-names>D</given-names></name><name><surname>Piekarska</surname><given-names>E</given-names></name><name><surname>Ko&#x0142;aci&#x0144;ski</surname><given-names>R</given-names></name><name><surname>Romanowicz</surname><given-names>H</given-names></name></person-group><article-title>Lung Cancer-Epidemiology, pathogenesis, treatment and molecular aspect (Review of Literature)</article-title><source>Int J Mol Sci</source><volume>26</volume><fpage>2049</fpage><year>2025</year><pub-id pub-id-type="doi">10.3390/ijms26052049</pub-id><pub-id pub-id-type="pmid">40076671</pub-id></element-citation></ref>
<ref id="b2-ol-32-2-15702"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrari Ardicini</surname><given-names>G</given-names></name><name><surname>Matetic</surname><given-names>A</given-names></name><name><surname>Kontopantelis</surname><given-names>E</given-names></name><name><surname>Chieffo</surname><given-names>A</given-names></name><name><surname>Moldovan</surname><given-names>CM</given-names></name><name><surname>Raisi-Estabragh</surname><given-names>Z</given-names></name><name><surname>Asher</surname><given-names>E</given-names></name><name><surname>Mallen</surname><given-names>C</given-names></name><name><surname>Mamas</surname><given-names>MA</given-names></name></person-group><article-title>Trends and future projections of cancer prevalence in patients with cardiovascular admissions</article-title><source>Eur Heart J</source><volume>6</volume><fpage>oeag030</fpage><year>2026</year><pub-id pub-id-type="doi">10.1093/ehjopen/oeag030</pub-id><pub-id pub-id-type="pmid">41847688</pub-id></element-citation></ref>
<ref id="b3-ol-32-2-15702"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>LW</given-names></name><name><surname>Lyu</surname><given-names>ZY</given-names></name><name><surname>Meng</surname><given-names>QC</given-names></name><name><surname>Zheng</surname><given-names>LY</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>HF</given-names></name><name><surname>Kang</surname><given-names>RH</given-names></name><name><surname>Zhang</surname><given-names>LY</given-names></name><name><surname>Cao</surname><given-names>XQ</given-names></name><etal/></person-group><article-title>A risk prediction model for selecting high-risk population for computed tomography lung cancer screening in China</article-title><source>Lung Cancer</source><volume>163</volume><fpage>27</fpage><lpage>34</lpage><year>2022</year><pub-id pub-id-type="doi">10.1016/j.lungcan.2021.11.015</pub-id><pub-id pub-id-type="pmid">34894456</pub-id></element-citation></ref>
<ref id="b4-ol-32-2-15702"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>M</given-names></name><name><surname>Sun</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name></person-group><article-title>KAT2A accelerates lung cancer progression through succinylation of TGF&#x03B2;R2</article-title><source>Tissue Cell</source><volume>99</volume><fpage>103254</fpage><year>2026</year><pub-id pub-id-type="doi">10.1016/j.tice.2025.103254</pub-id><pub-id pub-id-type="pmid">41338129</pub-id></element-citation></ref>
<ref id="b5-ol-32-2-15702"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>QA</given-names></name><name><surname>Tsai</surname><given-names>IL</given-names></name><name><surname>Lin</surname><given-names>CY</given-names></name><name><surname>Su</surname><given-names>PL</given-names></name><name><surname>Lin</surname><given-names>CC</given-names></name><name><surname>Chang</surname><given-names>JW</given-names></name><name><surname>Huang</surname><given-names>CY</given-names></name><name><surname>Fang</surname><given-names>YF</given-names></name><name><surname>Chang</surname><given-names>CF</given-names></name><name><surname>Kuo</surname><given-names>CS</given-names></name><etal/></person-group><article-title>Multivariable model for predicting 5-year survival in patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: A retrospective study</article-title><source>Ther Adv Med Oncol</source><volume>17</volume><fpage>17588359251321901</fpage><year>2025</year><pub-id pub-id-type="doi">10.1177/17588359251321901</pub-id><pub-id pub-id-type="pmid">40093976</pub-id></element-citation></ref>
<ref id="b6-ol-32-2-15702"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>KJ</given-names></name><name><surname>Choi</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>K</given-names></name><name><surname>Hwang</surname><given-names>HS</given-names></name><name><surname>Chang</surname><given-names>E</given-names></name><name><surname>Park</surname><given-names>JS</given-names></name><name><surname>Shim</surname><given-names>SB</given-names></name><name><surname>Choi</surname><given-names>S</given-names></name><name><surname>Heo</surname><given-names>YJ</given-names></name><name><surname>An</surname><given-names>WJ</given-names></name><etal/></person-group><article-title>Proteogenomic analysis reveals non-small cell lung cancer subtypes predicting chromosome instability, and tumor microenvironment</article-title><source>Nat Commun</source><volume>15</volume><fpage>10164</fpage><year>2024</year><pub-id pub-id-type="doi">10.1038/s41467-024-54434-4</pub-id><pub-id pub-id-type="pmid">39580524</pub-id></element-citation></ref>
<ref id="b7-ol-32-2-15702"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Cao</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Ma</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Yuan</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name></person-group><article-title>Gracillin Isolated from Reineckia carnea induces apoptosis of A549 cells via the mitochondrial pathway</article-title><source>Drug Des Devel Ther</source><volume>15</volume><fpage>233</fpage><lpage>243</lpage><year>2021</year><pub-id pub-id-type="doi">10.2147/DDDT.S278975</pub-id><pub-id pub-id-type="pmid">33505158</pub-id></element-citation></ref>
<ref id="b8-ol-32-2-15702"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Xiao</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Luo</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name></person-group><article-title>Gracillin shows potential efficacy against Non-small cell lung cancer through inhibiting the mTOR pathway</article-title><source>Front Oncol</source><volume>12</volume><fpage>851300</fpage><year>2022</year><pub-id pub-id-type="doi">10.3389/fonc.2022.851300</pub-id><pub-id pub-id-type="pmid">35392243</pub-id></element-citation></ref>
<ref id="b9-ol-32-2-15702"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosell</surname><given-names>R</given-names></name><name><surname>Moran</surname><given-names>T</given-names></name><name><surname>Viteri</surname><given-names>S</given-names></name><name><surname>Carcereny</surname><given-names>E</given-names></name><name><surname>Gasco</surname><given-names>A</given-names></name><name><surname>Quiroga</surname><given-names>V</given-names></name><name><surname>Wei</surname><given-names>J</given-names></name><name><surname>Camps</surname><given-names>C</given-names></name><name><surname>Massuti</surname><given-names>B</given-names></name></person-group><article-title>Optimization of genetics to create therapies for metastatic (stage IV) non-small-cell lung cancer</article-title><source>Expert Opin Pharmacother</source><volume>11</volume><fpage>1683</fpage><lpage>1693</lpage><year>2010</year><pub-id pub-id-type="doi">10.1517/14656566.2010.482101</pub-id><pub-id pub-id-type="pmid">20486827</pub-id></element-citation></ref>
<ref id="b10-ol-32-2-15702"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Breslin</surname><given-names>S</given-names></name><name><surname>O&#x0027;Driscoll</surname><given-names>L</given-names></name></person-group><article-title>The relevance of using 3D cell cultures, in addition to 2D monolayer cultures, when evaluating breast cancer drug sensitivity and resistance</article-title><source>Oncotarget</source><volume>7</volume><fpage>45745</fpage><lpage>45756</lpage><year>2016</year><pub-id pub-id-type="doi">10.18632/oncotarget.9935</pub-id><pub-id pub-id-type="pmid">27304190</pub-id></element-citation></ref>
<ref id="b11-ol-32-2-15702"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arnaldi</surname><given-names>P</given-names></name><name><surname>Zotti</surname><given-names>VD</given-names></name><name><surname>Bellese</surname><given-names>G</given-names></name><name><surname>Gagliani</surname><given-names>MC</given-names></name><name><surname>Orecchia</surname><given-names>P</given-names></name><name><surname>Castagnola</surname><given-names>P</given-names></name><name><surname>Cortese</surname><given-names>K</given-names></name></person-group><article-title>3D breast cancer spheroids reveal Architecture-dependent HER2 expression and signaling</article-title><source>Biology (Basel)</source><volume>14</volume><fpage>1654</fpage><year>2025</year><pub-id pub-id-type="pmid">41463429</pub-id></element-citation></ref>
<ref id="b12-ol-32-2-15702"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>An</surname><given-names>HJ</given-names></name><name><surname>Kim</surname><given-names>HS</given-names></name><name><surname>Kwon</surname><given-names>JA</given-names></name><name><surname>Song</surname><given-names>J</given-names></name><name><surname>Choi</surname><given-names>I</given-names></name></person-group><article-title>Adjustable and versatile 3D tumor spheroid culture platform with interfacial elastomeric wells</article-title><source>ACS Appl Mater Interfaces</source><volume>12</volume><fpage>6924</fpage><lpage>6932</lpage><year>2020</year><pub-id pub-id-type="doi">10.1021/acsami.9b21471</pub-id><pub-id pub-id-type="pmid">31958950</pub-id></element-citation></ref>
<ref id="b13-ol-32-2-15702"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumari</surname><given-names>S</given-names></name><name><surname>Advani</surname><given-names>D</given-names></name><name><surname>Sharma</surname><given-names>S</given-names></name><name><surname>Ambasta</surname><given-names>RK</given-names></name><name><surname>Kumar</surname><given-names>P</given-names></name></person-group><article-title>Combinatorial therapy in tumor microenvironment: Where do we stand?</article-title><source>Biochim Biophys Acta Rev Cancer</source><volume>1876</volume><fpage>188585</fpage><year>2021</year><pub-id pub-id-type="doi">10.1016/j.bbcan.2021.188585</pub-id><pub-id pub-id-type="pmid">34224836</pub-id></element-citation></ref>
<ref id="b14-ol-32-2-15702"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xue</surname><given-names>X</given-names></name><name><surname>Ji</surname><given-names>D</given-names></name><name><surname>Xue</surname><given-names>L</given-names></name><name><surname>Tan</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Ma</surname><given-names>F</given-names></name><name><surname>Luo</surname><given-names>Y</given-names></name><name><surname>Lan</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><etal/></person-group><article-title>Spatially resolved transcriptomics identifies tumor-stroma-immune networks and therapeutic targets in endocrine-resistant advanced breast cancer treated with Everolimus&#x002B;Letrozole: Insights from the MIRACLE trial</article-title><source>Cancer Lett</source><volume>645</volume><fpage>218327</fpage><year>2026</year><pub-id pub-id-type="doi">10.1016/j.canlet.2026.218327</pub-id><pub-id pub-id-type="pmid">41720449</pub-id></element-citation></ref>
<ref id="b15-ol-32-2-15702"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheik</surname><given-names>A</given-names></name><name><surname>Farani</surname><given-names>MR</given-names></name><name><surname>Kim</surname><given-names>E</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Gupta</surname><given-names>VK</given-names></name><name><surname>Kumar</surname><given-names>K</given-names></name><name><surname>Huh</surname><given-names>YS</given-names></name></person-group><article-title>Therapeutic targeting of the tumor microenvironments with cannabinoids and their analogs: Update on clinical trials</article-title><source>Environ Res</source><volume>231</volume><fpage>115862</fpage><year>2023</year><pub-id pub-id-type="doi">10.1016/j.envres.2023.115862</pub-id><pub-id pub-id-type="pmid">37146933</pub-id></element-citation></ref>
<ref id="b16-ol-32-2-15702"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pampaloni</surname><given-names>F</given-names></name><name><surname>Reynaud</surname><given-names>EG</given-names></name><name><surname>Stelzer</surname><given-names>EH</given-names></name></person-group><article-title>The third dimension bridges the gap between cell culture and live tissue</article-title><source>Nat Rev Mol Cell Biol</source><volume>8</volume><fpage>839</fpage><lpage>845</lpage><year>2007</year><pub-id pub-id-type="doi">10.1038/nrm2236</pub-id><pub-id pub-id-type="pmid">17684528</pub-id></element-citation></ref>
<ref id="b17-ol-32-2-15702"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weiswald</surname><given-names>LB</given-names></name><name><surname>Bellet</surname><given-names>D</given-names></name><name><surname>Dangles-Marie</surname><given-names>V</given-names></name></person-group><article-title>Spherical cancer models in tumor biology</article-title><source>Neoplasia</source><volume>17</volume><fpage>1</fpage><lpage>15</lpage><year>2015</year><pub-id pub-id-type="doi">10.1016/j.neo.2014.12.004</pub-id><pub-id pub-id-type="pmid">25622895</pub-id></element-citation></ref>
<ref id="b18-ol-32-2-15702"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Breslin</surname><given-names>S</given-names></name><name><surname>O&#x0027;Driscoll</surname><given-names>L</given-names></name></person-group><article-title>Three-dimensional cell culture: The missing link in drug discovery</article-title><source>Drug Discovery Today</source><volume>18</volume><fpage>240</fpage><lpage>249</lpage><year>2013</year><pub-id pub-id-type="doi">10.1016/j.drudis.2012.10.003</pub-id><pub-id pub-id-type="pmid">23073387</pub-id></element-citation></ref>
<ref id="b19-ol-32-2-15702"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bia&#x0142;kowska</surname><given-names>K</given-names></name><name><surname>Komorowski</surname><given-names>P</given-names></name><name><surname>Bryszewska</surname><given-names>M</given-names></name><name><surname>Mi&#x0142;owska</surname><given-names>K</given-names></name></person-group><article-title>Spheroids as a type of Three-dimensional cell Cultures-examples of methods of preparation and the most important application</article-title><source>Int J Mol Sci</source><volume>21</volume><fpage>6225</fpage><year>2020</year><pub-id pub-id-type="doi">10.3390/ijms21176225</pub-id><pub-id pub-id-type="pmid">32872135</pub-id></element-citation></ref>
<ref id="b20-ol-32-2-15702"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boinapalli</surname><given-names>Y</given-names></name><name><surname>Shankar Pandey</surname><given-names>R</given-names></name><name><surname>Singh Chauhan</surname><given-names>A</given-names></name><name><surname>Sudheesh</surname><given-names>MS</given-names></name></person-group><article-title>Physiological relevance of in-vitro cell-nanoparticle interaction studies as a predictive tool in cancer nanomedicine research</article-title><source>Int J Pharm</source><volume>632</volume><fpage>122579</fpage><year>2023</year><pub-id pub-id-type="doi">10.1016/j.ijpharm.2022.122579</pub-id><pub-id pub-id-type="pmid">36603671</pub-id></element-citation></ref>
<ref id="b21-ol-32-2-15702"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moghadas</surname><given-names>H</given-names></name><name><surname>Saidi</surname><given-names>MS</given-names></name><name><surname>Kashaninejad</surname><given-names>N</given-names></name><name><surname>Nguyen</surname><given-names>NT</given-names></name></person-group><article-title>Challenge in particle delivery to cells in a microfluidic device</article-title><source>Drug Deliv Transl Res</source><volume>8</volume><fpage>830</fpage><lpage>842</lpage><year>2017</year><pub-id pub-id-type="doi">10.1007/s13346-017-0467-3</pub-id><pub-id pub-id-type="pmid">29270808</pub-id></element-citation></ref>
<ref id="b22-ol-32-2-15702"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jubelin</surname><given-names>C</given-names></name><name><surname>Mu&#x00F1;oz-Garcia</surname><given-names>J</given-names></name><name><surname>Griscom</surname><given-names>L</given-names></name><name><surname>Cochonneau</surname><given-names>D</given-names></name><name><surname>Ollivier</surname><given-names>E</given-names></name><name><surname>Heymann</surname><given-names>MF</given-names></name><name><surname>Vallette</surname><given-names>FM</given-names></name><name><surname>Oliver</surname><given-names>L</given-names></name><name><surname>Heymann</surname><given-names>D</given-names></name></person-group><article-title>Three-dimensional in vitro culture models in oncology research</article-title><source>Cell Biosci</source><volume>12</volume><fpage>155</fpage><year>2022</year><pub-id pub-id-type="doi">10.1186/s13578-022-00887-3</pub-id><pub-id pub-id-type="pmid">36089610</pub-id></element-citation></ref>
<ref id="b23-ol-32-2-15702"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kadariya</surname><given-names>Y</given-names></name><name><surname>Sementino</surname><given-names>E</given-names></name><name><surname>Hua</surname><given-names>X</given-names></name><name><surname>Kappes</surname><given-names>DJ</given-names></name><name><surname>Testa</surname><given-names>JR</given-names></name></person-group><article-title>Modeling malignant mesothelioma in genetically engineered mice</article-title><source>Curr Protoc</source><volume>5</volume><fpage>e70086</fpage><year>2025</year><pub-id pub-id-type="doi">10.1002/cpz1.70086</pub-id><pub-id pub-id-type="pmid">39791266</pub-id></element-citation></ref>
<ref id="b24-ol-32-2-15702"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szychlinska</surname><given-names>MA</given-names></name><name><surname>Marino Gammazza</surname><given-names>A</given-names></name></person-group><article-title>The zebrafish model in animal and human health research</article-title><source>Int J Mol Sci</source><volume>26</volume><fpage>1945</fpage><year>2025</year><pub-id pub-id-type="doi">10.3390/ijms26051945</pub-id><pub-id pub-id-type="pmid">40076570</pub-id></element-citation></ref>
<ref id="b25-ol-32-2-15702"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiao</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Zhong</surname><given-names>Q</given-names></name><name><surname>Zhu</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Xiang</surname><given-names>M</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>G</given-names></name><etal/></person-group><article-title>Sequential treatment with PARPi and WEE1i enhances antitumor immune responses in preclinical models of ovarian cancer</article-title><source>Sci Transl Med</source><volume>17</volume><fpage>eadu6989</fpage><year>2025</year><pub-id pub-id-type="doi">10.1126/scitranslmed.adu6989</pub-id><pub-id pub-id-type="pmid">40802736</pub-id></element-citation></ref>
<ref id="b26-ol-32-2-15702"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jebran</surname><given-names>AF</given-names></name><name><surname>Seidler</surname><given-names>T</given-names></name><name><surname>Tiburcy</surname><given-names>M</given-names></name><name><surname>Daskalaki</surname><given-names>M</given-names></name><name><surname>Kutschka</surname><given-names>I</given-names></name><name><surname>Fujita</surname><given-names>B</given-names></name><name><surname>Ensminger</surname><given-names>S</given-names></name><name><surname>Bremmer</surname><given-names>F</given-names></name><name><surname>Moussavi</surname><given-names>A</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><etal/></person-group><article-title>Engineered heart muscle allografts for heart repair in primates and humans</article-title><source>Nature</source><volume>639</volume><fpage>503</fpage><lpage>511</lpage><year>2025</year><pub-id pub-id-type="doi">10.1038/s41586-024-08463-0</pub-id><pub-id pub-id-type="pmid">39880949</pub-id></element-citation></ref>
<ref id="b27-ol-32-2-15702"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Cui</surname><given-names>A</given-names></name><name><surname>Tian</surname><given-names>Y</given-names></name><name><surname>Tang</surname><given-names>F</given-names></name><name><surname>Liao</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Peng</surname><given-names>W</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name></person-group><article-title>Study on the mechanism of gracillin inhibiting the proliferation of lung cancer NCI-H1299 cells based on MAPK signaling pathway</article-title><source>J Cancer</source><volume>16</volume><fpage>3048</fpage><lpage>3064</lpage><year>2025</year><pub-id pub-id-type="doi">10.7150/jca.113694</pub-id><pub-id pub-id-type="pmid">40740238</pub-id></element-citation></ref>
<ref id="b28-ol-32-2-15702"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pound</surname><given-names>P</given-names></name><name><surname>Ritskes-Hoitinga</surname><given-names>M</given-names></name></person-group><article-title>Is it possible to overcome issues of external validity in preclinical animal research? Why most animal models are bound to fail</article-title><source>J Transl Med</source><volume>16</volume><fpage>304</fpage><year>2018</year><pub-id pub-id-type="doi">10.1186/s12967-018-1678-1</pub-id><pub-id pub-id-type="pmid">30404629</pub-id></element-citation></ref>
<ref id="b29-ol-32-2-15702"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Namdari</surname><given-names>R</given-names></name><name><surname>Jones</surname><given-names>K</given-names></name><name><surname>Chuang</surname><given-names>SS</given-names></name><name><surname>Van Cruchten</surname><given-names>S</given-names></name><name><surname>Dincer</surname><given-names>Z</given-names></name><name><surname>Downes</surname><given-names>N</given-names></name><name><surname>Mikkelsen</surname><given-names>LF</given-names></name><name><surname>Harding</surname><given-names>J</given-names></name><name><surname>J&#x00E4;ckel</surname><given-names>S</given-names></name><name><surname>Jacobsen</surname><given-names>B</given-names></name><etal/></person-group><article-title>Species selection for nonclinical safety assessment of drug candidates: Examples of current industry practice</article-title><source>Regul Toxicol Pharmacol</source><volume>126</volume><fpage>105029</fpage><year>2021</year><pub-id pub-id-type="doi">10.1016/j.yrtph.2021.105029</pub-id><pub-id pub-id-type="pmid">34455009</pub-id></element-citation></ref>
<ref id="b30-ol-32-2-15702"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malaney</surname><given-names>P</given-names></name><name><surname>Nicosia</surname><given-names>SV</given-names></name><name><surname>Dav&#x00E9;</surname><given-names>V</given-names></name></person-group><article-title>One mouse, one patient paradigm: New avatars of personalized cancer therapy</article-title><source>Cancer Lett</source><volume>344</volume><fpage>1</fpage><lpage>12</lpage><year>2014</year><pub-id pub-id-type="doi">10.1016/j.canlet.2013.10.010</pub-id><pub-id pub-id-type="pmid">24157811</pub-id></element-citation></ref>
<ref id="b31-ol-32-2-15702"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>S</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>H</given-names></name><name><surname>Hu</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>An automated organoid platform with Inter-organoid Homogeneity and Inter-patient Heterogeneity</article-title><source>Cell Rep Med</source><volume>1</volume><fpage>100161</fpage><year>2020</year><pub-id pub-id-type="doi">10.1016/j.xcrm.2020.100161</pub-id><pub-id pub-id-type="pmid">33377132</pub-id></element-citation></ref>
<ref id="b32-ol-32-2-15702"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lensink</surname><given-names>MA</given-names></name><name><surname>Boers</surname><given-names>SN</given-names></name><name><surname>Jongsma</surname><given-names>KR</given-names></name><name><surname>Carter</surname><given-names>SE</given-names></name><name><surname>van der Ent</surname><given-names>CK</given-names></name><name><surname>Bredenoord</surname><given-names>AL</given-names></name></person-group><article-title>Organoids for personalized treatment of Cystic Fibrosis: Professional perspectives on the ethics and governance of organoid biobanking</article-title><source>J Cyst Fibros</source><volume>20</volume><fpage>443</fpage><lpage>451</lpage><year>2021</year><pub-id pub-id-type="doi">10.1016/j.jcf.2020.11.015</pub-id><pub-id pub-id-type="pmid">33303364</pub-id></element-citation></ref>
<ref id="b33-ol-32-2-15702"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishiguro</surname><given-names>T</given-names></name><name><surname>Ohata</surname><given-names>H</given-names></name><name><surname>Sato</surname><given-names>A</given-names></name><name><surname>Yamawaki</surname><given-names>K</given-names></name><name><surname>Enomoto</surname><given-names>T</given-names></name><name><surname>Okamoto</surname><given-names>K</given-names></name></person-group><article-title>Tumor-derived spheroids: Relevance to cancer stem cells and clinical applications</article-title><source>Cancer Sci</source><volume>108</volume><fpage>283</fpage><lpage>289</lpage><year>2017</year><pub-id pub-id-type="doi">10.1111/cas.13155</pub-id><pub-id pub-id-type="pmid">28064442</pub-id></element-citation></ref>
<ref id="b34-ol-32-2-15702"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yousafzai</surname><given-names>NA</given-names></name><name><surname>El Khalki</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Szpendyk</surname><given-names>J</given-names></name><name><surname>Sossey-Alaoui</surname><given-names>K</given-names></name></person-group><article-title>Advances in 3D culture models to study exosomes in Triple-negative breast cancer</article-title><source>Cancers (Basel)</source><volume>16</volume><fpage>883</fpage><year>2024</year><pub-id pub-id-type="doi">10.3390/cancers16050883</pub-id><pub-id pub-id-type="pmid">38473244</pub-id></element-citation></ref>
<ref id="b35-ol-32-2-15702"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wheeler</surname><given-names>NH</given-names></name><name><surname>Dada</surname><given-names>KA</given-names></name><name><surname>Minnaar</surname><given-names>CA</given-names></name></person-group><article-title>An overview of the developments in 3D cancer cell models, assay techniques, and imaging modalities</article-title><source>Human Cell</source><volume>39</volume><fpage>59</fpage><year>2026</year><pub-id pub-id-type="doi">10.1007/s13577-026-01375-3</pub-id><pub-id pub-id-type="pmid">41934569</pub-id></element-citation></ref>
<ref id="b36-ol-32-2-15702"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El Harane</surname><given-names>S</given-names></name><name><surname>Zidi</surname><given-names>B</given-names></name><name><surname>El Harane</surname><given-names>N</given-names></name><name><surname>Krause</surname><given-names>KH</given-names></name><name><surname>Matthes</surname><given-names>T</given-names></name><name><surname>Preynat-Seauve</surname><given-names>O</given-names></name></person-group><article-title>Cancer spheroids and organoids as novel tools for research and therapy: State of the art and challenges to guide precision medicine</article-title><source>Cells</source><volume>12</volume><fpage>1001</fpage><year>2023</year><pub-id pub-id-type="doi">10.3390/cells12071001</pub-id><pub-id pub-id-type="pmid">37048073</pub-id></element-citation></ref>
<ref id="b37-ol-32-2-15702"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haga</surname><given-names>K</given-names></name><name><surname>Kamimura</surname><given-names>Y</given-names></name><name><surname>Yamazaki</surname><given-names>M</given-names></name><name><surname>Funayama</surname><given-names>A</given-names></name><name><surname>Saito</surname><given-names>Y</given-names></name><name><surname>Kida</surname><given-names>M</given-names></name><name><surname>Tanuma</surname><given-names>JI</given-names></name><name><surname>Izumi</surname><given-names>K</given-names></name></person-group><article-title>Quantitative and longitudinal monitoring of cancer cell invasion in a three-dimensional in vitro model of oral cancer using optical coherence tomography</article-title><source>Sci Rep</source><volume>15</volume><fpage>45449</fpage><year>2025</year><pub-id pub-id-type="doi">10.1038/s41598-025-28471-y</pub-id><pub-id pub-id-type="pmid">41309958</pub-id></element-citation></ref>
<ref id="b38-ol-32-2-15702"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Page</surname><given-names>H</given-names></name><name><surname>Flood</surname><given-names>P</given-names></name><name><surname>Reynaud</surname><given-names>EG</given-names></name></person-group><article-title>Three-dimensional tissue cultures: Current trends and beyond</article-title><source>Cell Tissue Res</source><volume>352</volume><fpage>123</fpage><lpage>131</lpage><year>2012</year><pub-id pub-id-type="doi">10.1007/s00441-012-1441-5</pub-id><pub-id pub-id-type="pmid">22729488</pub-id></element-citation></ref>
<ref id="b39-ol-32-2-15702"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shannon</surname><given-names>AE</given-names></name><name><surname>Boos</surname><given-names>CE</given-names></name><name><surname>Searle</surname><given-names>BC</given-names></name><name><surname>Hummon</surname><given-names>AB</given-names></name></person-group><article-title>Gas-phase fractionation Data-Independent acquisition analysis of 3D cocultured spheroid tumor model reveals altered translational processes and signaling using proteomics</article-title><source>J Proteome Res</source><volume>23</volume><fpage>3188</fpage><lpage>3199</lpage><year>2024</year><pub-id pub-id-type="doi">10.1021/acs.jproteome.3c00786</pub-id><pub-id pub-id-type="pmid">38412258</pub-id></element-citation></ref>
<ref id="b40-ol-32-2-15702"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raitanen</surname><given-names>J</given-names></name><name><surname>Barta</surname><given-names>B</given-names></name><name><surname>Fuchs</surname><given-names>H</given-names></name><name><surname>Hacker</surname><given-names>M</given-names></name><name><surname>Balber</surname><given-names>T</given-names></name><name><surname>Georg</surname><given-names>D</given-names></name><name><surname>Mitterhauser</surname><given-names>M</given-names></name></person-group><article-title>Radiobiological assessment of targeted radionuclide therapy with [177Lu]Lu-PSMA-I&#x0026;T in 2D vs. 3D cell culture models</article-title><source>Int J Mol Scie</source><volume>24</volume><fpage>17015</fpage><year>2023</year><pub-id pub-id-type="doi">10.3390/ijms242317015</pub-id></element-citation></ref>
<ref id="b41-ol-32-2-15702"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Domingues</surname><given-names>M</given-names></name><name><surname>Leite Pereira</surname><given-names>C</given-names></name><name><surname>Sarmento</surname><given-names>B</given-names></name><name><surname>Castro</surname><given-names>F</given-names></name></person-group><article-title>Mimicking 3D breast tumor-stromal interactions to screen novel cancer therapeutics</article-title><source>Eur J Pharm Sci</source><volume>190</volume><fpage>106560</fpage><year>2023</year><pub-id pub-id-type="doi">10.1016/j.ejps.2023.106560</pub-id><pub-id pub-id-type="pmid">37557927</pub-id></element-citation></ref>
<ref id="b42-ol-32-2-15702"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Canha-Borges</surname><given-names>A</given-names></name><name><surname>Nunes</surname><given-names>B</given-names></name><name><surname>Estev&#x00E3;o</surname><given-names>D</given-names></name><name><surname>Fernandes</surname><given-names>R</given-names></name><name><surname>Mondini</surname><given-names>M</given-names></name><name><surname>Cruz</surname><given-names>T</given-names></name><name><surname>Jer&#x00F3;nimo</surname><given-names>C</given-names></name><name><surname>Lencart</surname><given-names>J</given-names></name><name><surname>Paredes</surname><given-names>J</given-names></name><name><surname>Deutsch</surname><given-names>E</given-names></name><etal/></person-group><article-title>Radiotherapy induces layer-specific molecular and ultrastructural alterations in triple-negative breast cancer spheroids</article-title><source>Radiother Oncol</source><volume>219</volume><fpage>111518</fpage><year>2026</year><pub-id pub-id-type="doi">10.1016/j.radonc.2026.111518</pub-id><pub-id pub-id-type="pmid">41921672</pub-id></element-citation></ref>
<ref id="b43-ol-32-2-15702"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tipple</surname><given-names>E</given-names></name><name><surname>Slay</surname><given-names>E</given-names></name><name><surname>Tsigkou</surname><given-names>O</given-names></name><name><surname>Choudhury</surname><given-names>A</given-names></name><name><surname>Gough</surname><given-names>J</given-names></name></person-group><article-title>Using biomaterial-based 3D in vitro cancer models to solve current clinical problems</article-title><source>Br J Cancer</source><month>Apr</month><day>9</day><year>2026</year><comment>(Epub ahead of print). doi: 10.1038/s41416-026-03392-3</comment><pub-id pub-id-type="doi">10.1038/s41416-026-03392-3</pub-id><pub-id pub-id-type="pmid">41957140</pub-id></element-citation></ref>
<ref id="b44-ol-32-2-15702"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mirahmad</surname><given-names>M</given-names></name><name><surname>Sabourian</surname><given-names>R</given-names></name><name><surname>Mahdavi</surname><given-names>M</given-names></name><name><surname>Larijani</surname><given-names>B</given-names></name><name><surname>Safavi</surname><given-names>M</given-names></name></person-group><article-title>In vitro cell-based models of drug-induced hepatotoxicity screening: Progress and limitation</article-title><source>Drug Metab Rev</source><volume>54</volume><fpage>161</fpage><lpage>193</lpage><year>2022</year><pub-id pub-id-type="doi">10.1080/03602532.2022.2064487</pub-id><pub-id pub-id-type="pmid">35403528</pub-id></element-citation></ref>
<ref id="b45-ol-32-2-15702"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>S</given-names></name><name><surname>D&#x0027;Souza</surname><given-names>GGM</given-names></name></person-group><article-title>Modeling tumor microenvironment complexity in vitro: Spheroids as physiologically relevant tumor models and strategies for their analysis</article-title><source>Cells</source><volume>14</volume><fpage>732</fpage><year>2025</year><pub-id pub-id-type="doi">10.3390/cells14100732</pub-id><pub-id pub-id-type="pmid">40422235</pub-id></element-citation></ref>
<ref id="b46-ol-32-2-15702"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Kumacheva</surname><given-names>E</given-names></name></person-group><article-title>Hydrogel microenvironments for cancer spheroid growth and drug screening</article-title><source>Sci Adv</source><volume>4</volume><fpage>eaas8998</fpage><year>2018</year><pub-id pub-id-type="doi">10.1126/sciadv.aas8998</pub-id><pub-id pub-id-type="pmid">29719868</pub-id></element-citation></ref>
<ref id="b47-ol-32-2-15702"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferreira</surname><given-names>LP</given-names></name><name><surname>Gaspar</surname><given-names>VM</given-names></name><name><surname>Mano</surname><given-names>JF</given-names></name></person-group><article-title>Design of spherically structured 3D in vitro tumor models-Advances and prospects</article-title><source>Acta Biomater</source><volume>75</volume><fpage>11</fpage><lpage>34</lpage><year>2018</year><pub-id pub-id-type="doi">10.1016/j.actbio.2018.05.034</pub-id><pub-id pub-id-type="pmid">29803007</pub-id></element-citation></ref>
<ref id="b48-ol-32-2-15702"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sant</surname><given-names>S</given-names></name><name><surname>Johnston</surname><given-names>PA</given-names></name></person-group><article-title>The production of 3D tumor spheroids for cancer drug discovery</article-title><source>Drug Discov Today Technol</source><volume>23</volume><fpage>27</fpage><lpage>36</lpage><year>2017</year><pub-id pub-id-type="doi">10.1016/j.ddtec.2017.03.002</pub-id><pub-id pub-id-type="pmid">28647083</pub-id></element-citation></ref>
<ref id="b49-ol-32-2-15702"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Viegas</surname><given-names>J</given-names></name><name><surname>Costa</surname><given-names>S</given-names></name><name><surname>Dias</surname><given-names>S</given-names></name><name><surname>Pereira</surname><given-names>CL</given-names></name><name><surname>Sarmento</surname><given-names>B</given-names></name></person-group><article-title>Patient-derived melanoma Immune-Tumoroids as a platform for precise high throughput drug screening</article-title><source>Adv Sci (Weinh)</source><volume>11</volume><fpage>e2408707</fpage><year>2024</year><pub-id pub-id-type="doi">10.1002/advs.202408707</pub-id><pub-id pub-id-type="pmid">39475010</pub-id></element-citation></ref>
<ref id="b50-ol-32-2-15702"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsai</surname><given-names>AC</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Yuan</surname><given-names>X</given-names></name><name><surname>Ma</surname><given-names>T</given-names></name></person-group><article-title>Compaction, fusion, and functional activation of Three-dimensional human mesenchymal stem cell aggregate</article-title><source>Tissue Eng Part A</source><volume>21</volume><fpage>1705</fpage><lpage>1719</lpage><year>2015</year><pub-id pub-id-type="doi">10.1089/ten.tea.2014.0314</pub-id><pub-id pub-id-type="pmid">25661745</pub-id></element-citation></ref>
<ref id="b51-ol-32-2-15702"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>RZ</given-names></name><name><surname>Chou</surname><given-names>LF</given-names></name><name><surname>Chien</surname><given-names>CCM</given-names></name><name><surname>Chang</surname><given-names>HY</given-names></name></person-group><article-title>Dynamic analysis of hepatoma spheroid formation: Roles of E-cadherin and beta1-integrin</article-title><source>Cell Tissue Res</source><volume>324</volume><fpage>411</fpage><lpage>422</lpage><year>2006</year><pub-id pub-id-type="doi">10.1007/s00441-005-0148-2</pub-id><pub-id pub-id-type="pmid">16489443</pub-id></element-citation></ref>
<ref id="b52-ol-32-2-15702"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baral</surname><given-names>T</given-names></name><name><surname>Kirtana</surname><given-names>R</given-names></name><name><surname>Manna</surname><given-names>S</given-names></name><name><surname>Mishra</surname><given-names>J</given-names></name><name><surname>Chakraborty</surname><given-names>S</given-names></name><name><surname>Nandi</surname><given-names>P</given-names></name><name><surname>Niharika Roy</surname><given-names>A</given-names></name><name><surname>Mishra</surname><given-names>P</given-names></name><name><surname>Pradhan</surname><given-names>B</given-names></name><etal/></person-group><article-title>Cholesterol in glioblastoma: Impaired Hh signaling enhances epigenetic modifiers and decreases CAV1</article-title><source>Cell Struct Funct</source><volume>51</volume><fpage>121</fpage><lpage>137</lpage><year>2026</year><pub-id pub-id-type="doi">10.1247/csf.25168</pub-id><pub-id pub-id-type="pmid">41605664</pub-id></element-citation></ref>
<ref id="b53-ol-32-2-15702"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryu</surname><given-names>NE</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Park</surname><given-names>H</given-names></name></person-group><article-title>Spheroid culture system methods and applications for mesenchymal stem cells</article-title><source>Cells</source><volume>8</volume><fpage>1620</fpage><year>2019</year><pub-id pub-id-type="doi">10.3390/cells8121620</pub-id><pub-id pub-id-type="pmid">31842346</pub-id></element-citation></ref>
<ref id="b54-ol-32-2-15702"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pang</surname><given-names>L</given-names></name><name><surname>Tian</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Zhao</surname><given-names>Z</given-names></name><name><surname>Pan</surname><given-names>B</given-names></name><name><surname>Luo</surname><given-names>Z</given-names></name><name><surname>Wu</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Fan</surname><given-names>J</given-names></name></person-group><article-title>An integrating microfluidic system for concentration gradient generation of exosomes and Exosome-assisted Single-Cell-Derived tumor-sphere formation</article-title><source>ACS Sens</source><volume>10</volume><fpage>678</fpage><lpage>688</lpage><year>2025</year><pub-id pub-id-type="doi">10.1021/acssensors.4c01542</pub-id><pub-id pub-id-type="pmid">39866075</pub-id></element-citation></ref>
<ref id="b55-ol-32-2-15702"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Sheng</surname><given-names>S</given-names></name><name><surname>Cai</surname><given-names>W</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Niu</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>Q</given-names></name><name><surname>Gao</surname><given-names>C</given-names></name><etal/></person-group><article-title>3-D bioprinted human-derived skin organoids accelerate full-thickness skin defects repair</article-title><source>Bioact Mater</source><volume>42</volume><fpage>257</fpage><lpage>269</lpage><year>2024</year><pub-id pub-id-type="pmid">39285913</pub-id></element-citation></ref>
<ref id="b56-ol-32-2-15702"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moghe</surname><given-names>AS</given-names></name><name><surname>Nandi</surname><given-names>SS</given-names></name><name><surname>Bhonde</surname><given-names>RR</given-names></name><name><surname>Kamyab</surname><given-names>SS</given-names></name><name><surname>Sawant</surname><given-names>SA</given-names></name><name><surname>Karandikar</surname><given-names>MN</given-names></name></person-group><article-title>Engineering of cell line assembled enteric organoid for enterovirus infection</article-title><source>Arch Virol</source><volume>171</volume><fpage>118</fpage><year>2026</year><pub-id pub-id-type="doi">10.1007/s00705-026-06541-4</pub-id><pub-id pub-id-type="pmid">41805869</pub-id></element-citation></ref>
<ref id="b57-ol-32-2-15702"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Depresle</surname><given-names>M</given-names></name><name><surname>Daumar</surname><given-names>P</given-names></name><name><surname>Goisnard</surname><given-names>A</given-names></name><name><surname>Roux</surname><given-names>M</given-names></name><name><surname>Aubel</surname><given-names>C</given-names></name><name><surname>Penault-Llorca</surname><given-names>F</given-names></name><name><surname>Mounetou</surname><given-names>E</given-names></name><name><surname>Bamdad</surname><given-names>M</given-names></name></person-group><article-title>Development of a liquid overlay-based three-dimensional cell culture panel for drug screening applications</article-title><source>Sci Rep</source><volume>15</volume><fpage>42989</fpage><year>2025</year><pub-id pub-id-type="doi">10.1038/s41598-025-26985-z</pub-id><pub-id pub-id-type="pmid">41331275</pub-id></element-citation></ref>
<ref id="b58-ol-32-2-15702"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dauphin</surname><given-names>T</given-names></name><name><surname>de Beaurepaire</surname><given-names>L</given-names></name><name><surname>Salama</surname><given-names>A</given-names></name><name><surname>Pruvost</surname><given-names>Q</given-names></name><name><surname>Claire</surname><given-names>C</given-names></name><name><surname>Haurogn&#x00E9;</surname><given-names>K</given-names></name><name><surname>Sourice</surname><given-names>S</given-names></name><name><surname>Dupont</surname><given-names>A</given-names></name><name><surname>Bach</surname><given-names>JM</given-names></name><name><surname>Herv&#x00E9;</surname><given-names>J</given-names></name><etal/></person-group><article-title>Scalability of spheroid-derived small extracellular vesicles production in stirred systems</article-title><source>Front Bioeng Biotechnol</source><volume>13</volume><fpage>1516482</fpage><year>2025</year><pub-id pub-id-type="doi">10.3389/fbioe.2025.1516482</pub-id><pub-id pub-id-type="pmid">40365014</pub-id></element-citation></ref>
<ref id="b59-ol-32-2-15702"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haisler</surname><given-names>WL</given-names></name><name><surname>Timm</surname><given-names>DM</given-names></name><name><surname>Gage</surname><given-names>JA</given-names></name><name><surname>Tseng</surname><given-names>H</given-names></name><name><surname>Killian</surname><given-names>TC</given-names></name><name><surname>Souza</surname><given-names>GR</given-names></name></person-group><article-title>Three-dimensional cell culturing by magnetic levitation</article-title><source>Nat Protoc</source><volume>8</volume><fpage>1940</fpage><lpage>1949</lpage><year>2013</year><pub-id pub-id-type="doi">10.1038/nprot.2013.125</pub-id><pub-id pub-id-type="pmid">24030442</pub-id></element-citation></ref>
<ref id="b60-ol-32-2-15702"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Vaart</surname><given-names>J</given-names></name><name><surname>Clevers</surname><given-names>H</given-names></name></person-group><article-title>Airway organoids as models of human disease</article-title><source>J Intern Med</source><volume>289</volume><fpage>604</fpage><lpage>613</lpage><year>2020</year><pub-id pub-id-type="doi">10.1111/joim.13075</pub-id><pub-id pub-id-type="pmid">32350962</pub-id></element-citation></ref>
<ref id="b61-ol-32-2-15702"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>Q</given-names></name><name><surname>Liao</surname><given-names>E</given-names></name><name><surname>Chen</surname><given-names>D</given-names></name><name><surname>Shan</surname><given-names>G</given-names></name></person-group><article-title>Bladder cancer organoids: Bridging pathological features and drug response for precision oncology</article-title><source>Int Urol Nephrol</source><month>Mar</month><day>8</day><year>2026</year><comment>(Epub ahead of print). doi: 10.1007/s11255-026-05081-9</comment><pub-id pub-id-type="doi">10.1007/s11255-026-05081-9</pub-id></element-citation></ref>
<ref id="b62-ol-32-2-15702"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>HS</given-names></name><name><surname>Mitsudomi</surname><given-names>T</given-names></name><name><surname>Soo</surname><given-names>RA</given-names></name><name><surname>Cho</surname><given-names>BC</given-names></name></person-group><article-title>Personalized therapy on the horizon for squamous cell carcinoma of the lung</article-title><source>Lung Cancer</source><volume>80</volume><fpage>249</fpage><lpage>255</lpage><year>2013</year><pub-id pub-id-type="doi">10.1016/j.lungcan.2013.02.015</pub-id><pub-id pub-id-type="pmid">23489560</pub-id></element-citation></ref>
<ref id="b63-ol-32-2-15702"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tahayneh</surname><given-names>K</given-names></name><name><surname>Idkedek</surname><given-names>M</given-names></name><name><surname>Abu Akar</surname><given-names>F</given-names></name></person-group><article-title>NSCLC: Current evidence on its pathogenesis, integrated treatment, and future perspectives</article-title><source>J Clin Med</source><volume>14</volume><fpage>1025</fpage><year>2025</year><pub-id pub-id-type="doi">10.3390/jcm14031025</pub-id><pub-id pub-id-type="pmid">39941694</pub-id></element-citation></ref>
<ref id="b64-ol-32-2-15702"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname><given-names>T</given-names></name><name><surname>Vries</surname><given-names>RG</given-names></name><name><surname>Snippert</surname><given-names>HJ</given-names></name><name><surname>van de Wetering</surname><given-names>M</given-names></name><name><surname>Barker</surname><given-names>N</given-names></name><name><surname>Stange</surname><given-names>DE</given-names></name><name><surname>van Es</surname><given-names>JH</given-names></name><name><surname>Abo</surname><given-names>A</given-names></name><name><surname>Kujala</surname><given-names>P</given-names></name><name><surname>Peters</surname><given-names>PJ</given-names></name><name><surname>Clevers</surname><given-names>H</given-names></name></person-group><article-title>Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche</article-title><source>Nature</source><volume>459</volume><fpage>262</fpage><lpage>265</lpage><year>2009</year><pub-id pub-id-type="doi">10.1038/nature07935</pub-id><pub-id pub-id-type="pmid">19329995</pub-id></element-citation></ref>
<ref id="b65-ol-32-2-15702"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>L</given-names></name><name><surname>Cheng</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Han</surname><given-names>P</given-names></name><name><surname>Cui</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name></person-group><article-title>Advancements and application prospects of three-dimensional models for primary liver cancer: A comprehensive review</article-title><source>Front Bioeng Biotechnol</source><volume>11</volume><fpage>1343177</fpage><year>2023</year><pub-id pub-id-type="doi">10.3389/fbioe.2023.1343177</pub-id><pub-id pub-id-type="pmid">38188493</pub-id></element-citation></ref>
<ref id="b66-ol-32-2-15702"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerhards</surname><given-names>NM</given-names></name><name><surname>Rottenberg</surname><given-names>S</given-names></name></person-group><article-title>New tools for old drugs: Functional genetic screens to optimize current chemotherapy</article-title><source>Drug Resist Updat</source><volume>36</volume><fpage>30</fpage><lpage>46</lpage><year>2018</year><pub-id pub-id-type="doi">10.1016/j.drup.2018.01.001</pub-id><pub-id pub-id-type="pmid">29499836</pub-id></element-citation></ref>
<ref id="b67-ol-32-2-15702"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Xing</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Shen</surname><given-names>J</given-names></name><name><surname>Jiang</surname><given-names>W</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Qiu</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>K</given-names></name><name><surname>Yang</surname><given-names>S</given-names></name><name><surname>Zhu</surname><given-names>L</given-names></name><etal/></person-group><article-title>Patient-derived malignant effusion organoids guide tailored therapy and dissect third-generation EGFR-tyrosine kinase inhibitor resistance mechanisms in lung cancer</article-title><source>Cancer Lett</source><volume>645</volume><fpage>218356</fpage><year>2026</year><pub-id pub-id-type="doi">10.1016/j.canlet.2026.218356</pub-id><pub-id pub-id-type="pmid">41740831</pub-id></element-citation></ref>
<ref id="b68-ol-32-2-15702"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>Q</given-names></name><name><surname>Fang</surname><given-names>S</given-names></name><name><surname>Hu</surname><given-names>Z</given-names></name><name><surname>Yu</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Song</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name></person-group><article-title>Organoid-based modeling unveils Dnmt3a-driven epigenetic regulation of phenotypic plasticity in small cell lung cancer</article-title><source>Cancer Lett</source><volume>650</volume><fpage>218516</fpage><year>2026</year><pub-id pub-id-type="doi">10.1016/j.canlet.2026.218516</pub-id><pub-id pub-id-type="pmid">42000030</pub-id></element-citation></ref>
<ref id="b69-ol-32-2-15702"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baskar</surname><given-names>G</given-names></name><name><surname>Palaniyandi</surname><given-names>T</given-names></name><name><surname>Viswanathan</surname><given-names>S</given-names></name><name><surname>Wahab</surname><given-names>MRA</given-names></name><name><surname>Surendran</surname><given-names>H</given-names></name><name><surname>Ravi</surname><given-names>M</given-names></name><name><surname>Sivaji</surname><given-names>A</given-names></name><name><surname>Rajendran</surname><given-names>BK</given-names></name><name><surname>Natarajan</surname><given-names>S</given-names></name><name><surname>Govindasamy</surname><given-names>G</given-names></name></person-group><article-title>Recent and advanced therapy for oral cancer</article-title><source>Biotechnol Bioeng</source><volume>120</volume><fpage>3105</fpage><lpage>3115</lpage><year>2023</year><pub-id pub-id-type="doi">10.1002/bit.28452</pub-id><pub-id pub-id-type="pmid">37243814</pub-id></element-citation></ref>
<ref id="b70-ol-32-2-15702"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohamedahmed</surname><given-names>SM</given-names></name><name><surname>Kamarudin</surname><given-names>MNA</given-names></name><name><surname>Ramdas</surname><given-names>P</given-names></name><name><surname>Sundralingam</surname><given-names>U</given-names></name><name><surname>Radhakrishnan</surname><given-names>AK</given-names></name></person-group><article-title>Optimising the method to develop spheroids from MDA-MB-468 human triple negative breast cancer cells</article-title><source>Mol Biol Rep</source><volume>53</volume><fpage>322</fpage><year>2026</year><pub-id pub-id-type="doi">10.1007/s11033-026-11451-4</pub-id><pub-id pub-id-type="pmid">41579217</pub-id></element-citation></ref>
<ref id="b71-ol-32-2-15702"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fallah</surname><given-names>A</given-names></name><name><surname>Zgheib</surname><given-names>A</given-names></name><name><surname>Zilinski</surname><given-names>R</given-names></name><name><surname>Danalache</surname><given-names>BA</given-names></name><name><surname>Eliopoulos</surname><given-names>N</given-names></name><name><surname>Annabi</surname><given-names>B</given-names></name></person-group><article-title>HIF-1&#x03B1; silencing downregulates SLC37A2, SLC37A3, and G6PC3 gene expression and impacts glioblastoma stemness features in 3D neurospheres</article-title><source>Biochem Biophys Res Commun</source><volume>794</volume><fpage>153050</fpage><year>2026</year><pub-id pub-id-type="doi">10.1016/j.bbrc.2025.153050</pub-id><pub-id pub-id-type="pmid">41317711</pub-id></element-citation></ref>
<ref id="b72-ol-32-2-15702"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>SW</given-names></name><name><surname>Tzeng</surname><given-names>SC</given-names></name><name><surname>Chen</surname><given-names>JK</given-names></name><name><surname>Sun</surname><given-names>JS</given-names></name><name><surname>Lin</surname><given-names>FH</given-names></name></person-group><article-title>A dynamic hanging-drop system for mesenchymal stem cell culture</article-title><source>Int J Mol Sci</source><volume>21</volume><fpage>4298</fpage><year>2020</year><pub-id pub-id-type="doi">10.3390/ijms21124298</pub-id><pub-id pub-id-type="pmid">32560269</pub-id></element-citation></ref>
<ref id="b73-ol-32-2-15702"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartosh</surname><given-names>TJ</given-names></name><name><surname>Ylostalo</surname><given-names>JH</given-names></name></person-group><article-title>Preparation of anti-inflammatory mesenchymal stem/precursor cells (MSCs) through sphere formation using hanging-drop culture technique</article-title><source>Curr Protoc Stem Cell Biol</source><volume>28</volume><fpage>2B.6.1</fpage><lpage>2B.6.23</lpage><year>2014</year><pub-id pub-id-type="doi">10.1002/9780470151808.sc02b06s28</pub-id><pub-id pub-id-type="pmid">24510769</pub-id></element-citation></ref>
<ref id="b74-ol-32-2-15702"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Achilli</surname><given-names>TM</given-names></name><name><surname>Meyer</surname><given-names>J</given-names></name><name><surname>Morgan</surname><given-names>JR</given-names></name></person-group><article-title>Advances in the formation, use and understanding of multi-cellular spheroids</article-title><source>Expert Opini Biol Ther</source><volume>12</volume><fpage>1347</fpage><lpage>1360</lpage><year>2012</year><pub-id pub-id-type="doi">10.1517/14712598.2012.707181</pub-id><pub-id pub-id-type="pmid">22784238</pub-id></element-citation></ref>
<ref id="b75-ol-32-2-15702"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kelm</surname><given-names>JM</given-names></name><name><surname>Timmins</surname><given-names>NE</given-names></name><name><surname>Brown</surname><given-names>CJ</given-names></name><name><surname>Fussenegger</surname><given-names>M</given-names></name><name><surname>Nielsen</surname><given-names>LK</given-names></name></person-group><article-title>Method for generation of homogeneous multicellular tumor spheroids applicable to a wide variety of cell types</article-title><source>Biotechnol Bioeng</source><volume>83</volume><fpage>173</fpage><lpage>180</lpage><year>2003</year><pub-id pub-id-type="doi">10.1002/bit.10655</pub-id><pub-id pub-id-type="pmid">12768623</pub-id></element-citation></ref>
<ref id="b76-ol-32-2-15702"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartosh</surname><given-names>TJ</given-names></name><name><surname>Yl&#x00F6;stalo</surname><given-names>JH</given-names></name><name><surname>Mohammadipoor</surname><given-names>A</given-names></name><name><surname>Bazhanov</surname><given-names>N</given-names></name><name><surname>Coble</surname><given-names>K</given-names></name><name><surname>Claypool</surname><given-names>K</given-names></name><name><surname>Lee</surname><given-names>RH</given-names></name><name><surname>Choi</surname><given-names>H</given-names></name><name><surname>Prockop</surname><given-names>DJ</given-names></name></person-group><article-title>Aggregation of human mesenchymal stromal cells (MSCs) into 3D spheroids enhances their antiinflammatory properties</article-title><source>Proc Natl Acad Sci USA</source><volume>107</volume><fpage>13724</fpage><lpage>13729</lpage><year>2010</year><pub-id pub-id-type="doi">10.1073/pnas.1008117107</pub-id><pub-id pub-id-type="pmid">20643923</pub-id></element-citation></ref>
<ref id="b77-ol-32-2-15702"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>BW</given-names></name><name><surname>Gao</surname><given-names>JQ</given-names></name></person-group><article-title>Application of 3D cultured multicellular spheroid tumor models in tumor-targeted drug delivery system research</article-title><source>J Control Release</source><volume>270</volume><fpage>246</fpage><lpage>259</lpage><year>2018</year><pub-id pub-id-type="doi">10.1016/j.jconrel.2017.12.005</pub-id><pub-id pub-id-type="pmid">29233763</pub-id></element-citation></ref>
<ref id="b78-ol-32-2-15702"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liszewski</surname><given-names>J</given-names></name><name><surname>Klingelhutz</surname><given-names>A</given-names></name><name><surname>Sander</surname><given-names>EA</given-names></name><name><surname>Ankrum</surname><given-names>J</given-names></name></person-group><article-title>Development and analysis of scaffold-free adipose spheroids</article-title><source>Adipocyte</source><volume>13</volume><fpage>2347215</fpage><year>2024</year><pub-id pub-id-type="doi">10.1080/21623945.2024.2347215</pub-id><pub-id pub-id-type="pmid">38864486</pub-id></element-citation></ref>
<ref id="b79-ol-32-2-15702"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Basu</surname><given-names>A</given-names></name><name><surname>Dydowiczov&#x00E1;</surname><given-names>A</given-names></name><name><surname>Trosko</surname><given-names>JE</given-names></name><name><surname>Bl&#x00E1;ha</surname><given-names>L</given-names></name><name><surname>Babica</surname><given-names>P</given-names></name></person-group><article-title>Ready to go 3D? A semi-automated protocol for microwell spheroid arrays to increase scalability and throughput of 3D cell culture testing</article-title><source>Toxicol Mech Methods</source><volume>30</volume><fpage>590</fpage><lpage>604</lpage><year>2020</year><pub-id pub-id-type="doi">10.1080/15376516.2020.1800881</pub-id><pub-id pub-id-type="pmid">32713235</pub-id></element-citation></ref>
<ref id="b80-ol-32-2-15702"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Park</surname><given-names>S</given-names></name></person-group><article-title>Three-dimensional hanging drop spheroid plates for easy chimeric antigen receptor (CAR) T cytotoxicity assay</article-title><source>Methods Mol Biol</source><volume>2764</volume><fpage>35</fpage><lpage>42</lpage><year>2024</year><pub-id pub-id-type="doi">10.1007/978-1-0716-3674-9_4</pub-id><pub-id pub-id-type="pmid">38393587</pub-id></element-citation></ref>
<ref id="b81-ol-32-2-15702"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Han</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>C</given-names></name><name><surname>Sanny</surname><given-names>A</given-names></name><name><surname>Tan</surname><given-names>AH</given-names></name><name><surname>Park</surname><given-names>S</given-names></name></person-group><article-title>A 3D hanging spheroid-filter plate for high-throughput drug testing and CAR T cell cytotoxicity assay</article-title><source>Analyst</source><volume>149</volume><fpage>475</fpage><lpage>481</lpage><year>2024</year><pub-id pub-id-type="doi">10.1039/D3AN01904G</pub-id><pub-id pub-id-type="pmid">38050728</pub-id></element-citation></ref>
<ref id="b82-ol-32-2-15702"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Han</surname><given-names>S</given-names></name><name><surname>Sanny</surname><given-names>A</given-names></name><name><surname>Chan</surname><given-names>DL</given-names></name><name><surname>van Noort</surname><given-names>D</given-names></name><name><surname>Lim</surname><given-names>W</given-names></name><name><surname>Tan</surname><given-names>AH</given-names></name><name><surname>Park</surname><given-names>S</given-names></name></person-group><article-title>3D hanging spheroid plate for high-throughput CAR T cell cytotoxicity assay</article-title><source>J Nanobiotechnol</source><volume>20</volume><fpage>30</fpage><year>2022</year><pub-id pub-id-type="doi">10.1186/s12951-021-01213-8</pub-id></element-citation></ref>
<ref id="b83-ol-32-2-15702"><label>83</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banerjee</surname><given-names>D</given-names></name><name><surname>Singh</surname><given-names>YP</given-names></name><name><surname>Datta</surname><given-names>P</given-names></name><name><surname>Ozbolat</surname><given-names>V</given-names></name><name><surname>O&#x0027;Donnell</surname><given-names>A</given-names></name><name><surname>Yeo</surname><given-names>M</given-names></name><name><surname>Ozbolat</surname><given-names>IT</given-names></name></person-group><article-title>Strategies for 3D bioprinting of spheroids: A comprehensive review</article-title><source>Biomaterials</source><volume>291</volume><fpage>121881</fpage><year>2022</year><pub-id pub-id-type="doi">10.1016/j.biomaterials.2022.121881</pub-id><pub-id pub-id-type="pmid">36335718</pub-id></element-citation></ref>
<ref id="b84-ol-32-2-15702"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mulligan</surname><given-names>LM</given-names></name><name><surname>Lian</surname><given-names>EY</given-names></name><name><surname>Maritan</surname><given-names>SM</given-names></name></person-group><article-title>An efficient and flexible cell aggregation method for 3D spheroid production</article-title><source>J Vis Exp</source><month>Mar</month><day>27</day><year>2017</year><comment>(Epub ahead of print). doi: 10.3791/55544</comment><pub-id pub-id-type="pmid">28448014</pub-id></element-citation></ref>
<ref id="b85-ol-32-2-15702"><label>85</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Pei</surname><given-names>F</given-names></name><name><surname>Zhao</surname><given-names>Z</given-names></name><name><surname>Cen</surname><given-names>X</given-names></name></person-group><article-title>miR-20a-5p regulated SMAD6 to inhibit chondrogenesis of hDPSCs</article-title><source>Oral Diseases</source><volume>29</volume><fpage>3433</fpage><lpage>3446</lpage><year>2022</year><pub-id pub-id-type="doi">10.1111/odi.14331</pub-id><pub-id pub-id-type="pmid">35917232</pub-id></element-citation></ref>
<ref id="b86-ol-32-2-15702"><label>86</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Su</surname><given-names>P</given-names></name><name><surname>Xu</surname><given-names>C</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>W</given-names></name><name><surname>Huang</surname><given-names>D</given-names></name></person-group><article-title>Chondrogenic differentiation of human mesenchymal stem cells: a comparison between micromass and pellet culture systems</article-title><source>Biotechnol Lett</source><volume>32</volume><fpage>1339</fpage><lpage>1346</lpage><year>2010</year><pub-id pub-id-type="doi">10.1007/s10529-010-0293-x</pub-id><pub-id pub-id-type="pmid">20464452</pub-id></element-citation></ref>
<ref id="b87-ol-32-2-15702"><label>87</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fuchs</surname><given-names>S</given-names></name><name><surname>Johansson</surname><given-names>S</given-names></name><name><surname>Tjell</surname><given-names>A&#x00D8;</given-names></name><name><surname>Werr</surname><given-names>G</given-names></name><name><surname>Mayr</surname><given-names>T</given-names></name><name><surname>Tenje</surname><given-names>M</given-names></name></person-group><article-title>In-line analysis of Organ-on-Chip systems with sensors: Integration, fabrication, challenges, and potential</article-title><source>ACS Biomat Sci Eng</source><volume>7</volume><fpage>2926</fpage><lpage>2948</lpage><year>2021</year><pub-id pub-id-type="doi">10.1021/acsbiomaterials.0c01110</pub-id><pub-id pub-id-type="pmid">34133114</pub-id></element-citation></ref>
<ref id="b88-ol-32-2-15702"><label>88</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernandez-Carro</surname><given-names>E</given-names></name><name><surname>Angenent</surname><given-names>M</given-names></name><name><surname>Gracia-Caza&#x00F1;a</surname><given-names>T</given-names></name><name><surname>Gilaberte</surname><given-names>Y</given-names></name><name><surname>Alcaine</surname><given-names>C</given-names></name><name><surname>Ciriza</surname><given-names>J</given-names></name></person-group><article-title>Modeling an optimal 3D Skin-on-Chip within microfluidic devices for pharmacological studies</article-title><source>Pharmaceutics</source><volume>14</volume><fpage>1417</fpage><year>2022</year><pub-id pub-id-type="doi">10.3390/pharmaceutics14071417</pub-id><pub-id pub-id-type="pmid">35890312</pub-id></element-citation></ref>
<ref id="b89-ol-32-2-15702"><label>89</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akbari</surname><given-names>M</given-names></name></person-group><article-title>Transforming drug discovery with miniaturized predictive tissue models</article-title><source>Micromachines (Basel)</source><volume>16</volume><fpage>299</fpage><year>2025</year><pub-id pub-id-type="doi">10.3390/mi16030299</pub-id><pub-id pub-id-type="pmid">40141910</pub-id></element-citation></ref>
<ref id="b90-ol-32-2-15702"><label>90</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lipreri</surname><given-names>MV</given-names></name><name><surname>Totaro</surname><given-names>MT</given-names></name><name><surname>Baldini</surname><given-names>N</given-names></name><name><surname>Avnet</surname><given-names>S</given-names></name></person-group><article-title>From spheroids to Tumor-on-a-Chip for cancer modeling and therapeutic testing</article-title><source>Micromachines</source><volume>16</volume><fpage>1343</fpage><year>2025</year><pub-id pub-id-type="doi">10.3390/mi16121343</pub-id><pub-id pub-id-type="pmid">41470509</pub-id></element-citation></ref>
<ref id="b91-ol-32-2-15702"><label>91</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sabhachandani</surname><given-names>P</given-names></name><name><surname>Motwani</surname><given-names>V</given-names></name><name><surname>Cohen</surname><given-names>N</given-names></name><name><surname>Sarkar</surname><given-names>S</given-names></name><name><surname>Torchilin</surname><given-names>V</given-names></name><name><surname>Konry</surname><given-names>T</given-names></name></person-group><article-title>Generation and functional assessment of 3D multicellular spheroids in droplet based microfluidics platform</article-title><source>Lab Chip</source><volume>16</volume><fpage>497</fpage><lpage>505</lpage><year>2016</year><pub-id pub-id-type="doi">10.1039/C5LC01139F</pub-id><pub-id pub-id-type="pmid">26686985</pub-id></element-citation></ref>
<ref id="b92-ol-32-2-15702"><label>92</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>HJ</given-names></name><name><surname>Cho</surname><given-names>YH</given-names></name><name><surname>Gu</surname><given-names>JM</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Oh</surname><given-names>YS</given-names></name></person-group><article-title>A multicellular spheroid formation and extraction chip using removable cell trapping barriers</article-title><source>Lab Chip</source><volume>11</volume><fpage>115</fpage><lpage>119</lpage><year>2011</year><pub-id pub-id-type="doi">10.1039/C0LC00134A</pub-id><pub-id pub-id-type="pmid">21038070</pub-id></element-citation></ref>
<ref id="b93-ol-32-2-15702"><label>93</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Tian</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Fan</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name></person-group><article-title>Active fluidic chip produced using 3D-printing for combinatorial therapeutic screening on liver tumor spheroid</article-title><source>Biosens Bioelectron</source><volume>151</volume><fpage>111966</fpage><year>2020</year><pub-id pub-id-type="doi">10.1016/j.bios.2019.111966</pub-id><pub-id pub-id-type="pmid">31999576</pub-id></element-citation></ref>
<ref id="b94-ol-32-2-15702"><label>94</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mao</surname><given-names>M</given-names></name><name><surname>Meng</surname><given-names>Z</given-names></name><name><surname>He</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>D</given-names></name></person-group><article-title>Microphysiological systems inspired by leaf venation</article-title><source>Trends Biotechnol</source><volume>42</volume><fpage>1331</fpage><lpage>1334</lpage><year>2024</year><pub-id pub-id-type="doi">10.1016/j.tibtech.2024.03.011</pub-id><pub-id pub-id-type="pmid">38643041</pub-id></element-citation></ref>
<ref id="b95-ol-32-2-15702"><label>95</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>UMN</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Sayson</surname><given-names>D</given-names></name><name><surname>Pillai</surname><given-names>S</given-names></name><name><surname>Tran</surname><given-names>SD</given-names></name></person-group><article-title>Microfluidic Organ-on-A-chip: A guide to biomaterial choice and fabrication</article-title><source>Int J Mol Sci</source><volume>24</volume><fpage>3232</fpage><year>2023</year><pub-id pub-id-type="doi">10.3390/ijms24043232</pub-id><pub-id pub-id-type="pmid">36834645</pub-id></element-citation></ref>
<ref id="b96-ol-32-2-15702"><label>96</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhatia</surname><given-names>SN</given-names></name><name><surname>Ingber</surname><given-names>DE</given-names></name></person-group><article-title>Microfluidic organs-on-chips</article-title><source>Nat Biotechnol</source><volume>32</volume><fpage>760</fpage><lpage>772</lpage><year>2014</year><pub-id pub-id-type="doi">10.1038/nbt.2989</pub-id><pub-id pub-id-type="pmid">25093883</pub-id></element-citation></ref>
<ref id="b97-ol-32-2-15702"><label>97</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhong</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Yan</surname><given-names>K</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name></person-group><article-title>Integrating organoids and organ-on-a-chip in dental research</article-title><source>Biomaterials</source><volume>330</volume><fpage>124065</fpage><year>2026</year><pub-id pub-id-type="doi">10.1016/j.biomaterials.2026.124065</pub-id><pub-id pub-id-type="pmid">41691795</pub-id></element-citation></ref>
<ref id="b98-ol-32-2-15702"><label>98</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whitesides</surname><given-names>GM</given-names></name></person-group><article-title>The origins and the future of microfluidics</article-title><source>Nature</source><volume>442</volume><fpage>368</fpage><lpage>373</lpage><year>2006</year><pub-id pub-id-type="doi">10.1038/nature05058</pub-id><pub-id pub-id-type="pmid">16871203</pub-id></element-citation></ref>
<ref id="b99-ol-32-2-15702"><label>99</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>JTY</given-names></name><name><surname>Tan</surname><given-names>ECK</given-names></name><name><surname>Kang</surname><given-names>L</given-names></name></person-group><article-title>Pharmacy 3D printing</article-title><source>Biofabrication</source><fpage>17</fpage><year>2024</year><comment>doi: 10.1088/1758-5090/ad837a</comment></element-citation></ref>
<ref id="b100-ol-32-2-15702"><label>100</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Ran</surname><given-names>R</given-names></name><name><surname>Kong</surname><given-names>Z</given-names></name><name><surname>Zhao</surname><given-names>D</given-names></name><name><surname>Zhao</surname><given-names>W</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Gao</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name></person-group><article-title>Research progress in the field of tumor model construction using bioprinting: A review</article-title><source>Int J Nanomedicine</source><volume>19</volume><fpage>6547</fpage><lpage>6575</lpage><year>2024</year><pub-id pub-id-type="doi">10.2147/IJN.S460387</pub-id><pub-id pub-id-type="pmid">38957180</pub-id></element-citation></ref>
<ref id="b101-ol-32-2-15702"><label>101</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matai</surname><given-names>I</given-names></name><name><surname>Kaur</surname><given-names>G</given-names></name><name><surname>Seyedsalehi</surname><given-names>A</given-names></name><name><surname>McClinton</surname><given-names>A</given-names></name><name><surname>Laurencin</surname><given-names>CT</given-names></name></person-group><article-title>Progress in 3D bioprinting technology for tissue/organ regenerative engineering</article-title><source>Biomaterials</source><volume>226</volume><fpage>119536</fpage><year>2020</year><pub-id pub-id-type="doi">10.1016/j.biomaterials.2019.119536</pub-id><pub-id pub-id-type="pmid">31648135</pub-id></element-citation></ref>
<ref id="b102-ol-32-2-15702"><label>102</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jian</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Dong</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Ren</surname><given-names>P</given-names></name><name><surname>Bai</surname><given-names>S</given-names></name></person-group><article-title>Dipeptide Self-assembled hydrogels with tunable mechanical properties and degradability for 3D bioprinting</article-title><source>ACS Appl Mater Interfaces</source><volume>11</volume><fpage>46419</fpage><lpage>46426</lpage><year>2019</year><pub-id pub-id-type="doi">10.1021/acsami.9b13905</pub-id><pub-id pub-id-type="pmid">31769283</pub-id></element-citation></ref>
<ref id="b103-ol-32-2-15702"><label>103</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>W</given-names></name><name><surname>Lee</surname><given-names>Y</given-names></name><name><surname>Kang</surname><given-names>D</given-names></name><name><surname>Kwak</surname><given-names>T</given-names></name><name><surname>Lee</surname><given-names>HR</given-names></name><name><surname>Jung</surname><given-names>S</given-names></name></person-group><article-title>3D Inkjet-Bioprinted Lung-on-a-Chip</article-title><source>ACS Biomater Sci Eng</source><volume>9</volume><fpage>2806</fpage><lpage>2815</lpage><year>2023</year><pub-id pub-id-type="doi">10.1021/acsbiomaterials.3c00089</pub-id><pub-id pub-id-type="pmid">37079915</pub-id></element-citation></ref>
<ref id="b104-ol-32-2-15702"><label>104</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurz&#x0105;tkowska</surname><given-names>M</given-names></name><name><surname>Frankowski</surname><given-names>J</given-names></name><name><surname>Sobczak</surname><given-names>M</given-names></name><name><surname>Piotrowska</surname><given-names>U</given-names></name></person-group><article-title>3D bioprinting of cancer models: A game-changer in drug discovery and development</article-title><source>Int J Pharm</source><volume>682</volume><fpage>125915</fpage><year>2025</year><pub-id pub-id-type="doi">10.1016/j.ijpharm.2025.125915</pub-id><pub-id pub-id-type="pmid">40588082</pub-id></element-citation></ref>
<ref id="b105-ol-32-2-15702"><label>105</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mihaylova</surname><given-names>A</given-names></name><name><surname>Shopova</surname><given-names>D</given-names></name><name><surname>Parahuleva</surname><given-names>N</given-names></name><name><surname>Yaneva</surname><given-names>A</given-names></name><name><surname>Bakova</surname><given-names>D</given-names></name></person-group><article-title>(3D) Bioprinting-next dimension of the pharmaceutical sector</article-title><source>Pharmaceuticals (Basel)</source><volume>17</volume><fpage>797</fpage><year>2024</year><pub-id pub-id-type="doi">10.3390/ph17060797</pub-id><pub-id pub-id-type="pmid">38931464</pub-id></element-citation></ref>
<ref id="b106-ol-32-2-15702"><label>106</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steinwerth</surname><given-names>P</given-names></name><name><surname>Bertrand</surname><given-names>J</given-names></name><name><surname>Sandt</surname><given-names>V</given-names></name><name><surname>Marchal</surname><given-names>S</given-names></name><name><surname>Sahana</surname><given-names>J</given-names></name><name><surname>Bollmann</surname><given-names>M</given-names></name><name><surname>Schulz</surname><given-names>H</given-names></name><name><surname>Kopp</surname><given-names>S</given-names></name><name><surname>Grimm</surname><given-names>D</given-names></name><name><surname>Wehland</surname><given-names>M</given-names></name></person-group><article-title>Structural and molecular changes of human chondrocytes exposed to the rotating wall vessel bioreactor</article-title><source>Biomolecules</source><volume>14</volume><fpage>25</fpage><year>2023</year><pub-id pub-id-type="doi">10.3390/biom14010025</pub-id><pub-id pub-id-type="pmid">38254625</pub-id></element-citation></ref>
<ref id="b107-ol-32-2-15702"><label>107</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mayer-Wagner</surname><given-names>S</given-names></name><name><surname>Hammerschmid</surname><given-names>F</given-names></name><name><surname>Redeker</surname><given-names>JI</given-names></name><name><surname>Schmitt</surname><given-names>B</given-names></name><name><surname>Holzapfel</surname><given-names>BM</given-names></name><name><surname>Jansson</surname><given-names>V</given-names></name><name><surname>Betz</surname><given-names>OB</given-names></name><name><surname>M&#x00FC;ller</surname><given-names>PE</given-names></name></person-group><article-title>Simulated microgravity affects chondrogenesis and hypertrophy of human mesenchymal stem cells</article-title><source>Int Orthop</source><volume>38</volume><fpage>2615</fpage><lpage>2621</lpage><year>2014</year><pub-id pub-id-type="doi">10.1007/s00264-014-2454-3</pub-id><pub-id pub-id-type="pmid">25030964</pub-id></element-citation></ref>
<ref id="b108-ol-32-2-15702"><label>108</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishi</surname><given-names>M</given-names></name><name><surname>Matsumoto</surname><given-names>R</given-names></name><name><surname>Dong</surname><given-names>J</given-names></name><name><surname>Uemura</surname><given-names>T</given-names></name></person-group><article-title>Engineered bone tissue associated with vascularization utilizing a rotating wall vessel bioreactor</article-title><source>J Biomed Mater Res Part A</source><volume>101</volume><fpage>421</fpage><lpage>427</lpage><year>2012</year><pub-id pub-id-type="pmid">22865391</pub-id></element-citation></ref>
<ref id="b109-ol-32-2-15702"><label>109</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheyn</surname><given-names>D</given-names></name><name><surname>Pelled</surname><given-names>G</given-names></name><name><surname>Netanely</surname><given-names>D</given-names></name><name><surname>Domany</surname><given-names>E</given-names></name><name><surname>Gazit</surname><given-names>D</given-names></name></person-group><article-title>The effect of simulated microgravity on human mesenchymal stem cells cultured in an osteogenic differentiation system: A bioinformatics study</article-title><source>Tissue Eng Part A</source><volume>16</volume><fpage>3403</fpage><lpage>3412</lpage><year>2010</year><pub-id pub-id-type="doi">10.1089/ten.tea.2009.0834</pub-id><pub-id pub-id-type="pmid">20807102</pub-id></element-citation></ref>
<ref id="b110-ol-32-2-15702"><label>110</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ingram</surname><given-names>M</given-names></name><name><surname>Techy</surname><given-names>GB</given-names></name><name><surname>Saroufeem</surname><given-names>R</given-names></name><name><surname>Yazan</surname><given-names>O</given-names></name><name><surname>Narayan</surname><given-names>KS</given-names></name><name><surname>Goodwin</surname><given-names>TJ</given-names></name><name><surname>Spaulding</surname><given-names>GF</given-names></name></person-group><article-title>Three-dimensional growth patterns of various human tumor cell lines in simulated microgravity of a NASA bioreactor</article-title><source>In Vitro Cell Dev Biol Anim</source><volume>33</volume><fpage>459</fpage><lpage>466</lpage><year>1997</year><pub-id pub-id-type="doi">10.1007/s11626-997-0064-8</pub-id><pub-id pub-id-type="pmid">9201514</pub-id></element-citation></ref>
<ref id="b111-ol-32-2-15702"><label>111</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grimm</surname><given-names>D</given-names></name><name><surname>Egli</surname><given-names>M</given-names></name><name><surname>Kr&#x00FC;ger</surname><given-names>M</given-names></name><name><surname>Riwaldt</surname><given-names>S</given-names></name><name><surname>Corydon</surname><given-names>TJ</given-names></name><name><surname>Kopp</surname><given-names>S</given-names></name><name><surname>Wehland</surname><given-names>M</given-names></name><name><surname>Wise</surname><given-names>P</given-names></name><name><surname>Infanger</surname><given-names>M</given-names></name><name><surname>Mann</surname><given-names>V</given-names></name><name><surname>Sundaresan</surname><given-names>A</given-names></name></person-group><article-title>Tissue engineering under microgravity conditions-use of stem cells and specialized cells</article-title><source>Stem Cells Dev</source><volume>27</volume><fpage>787</fpage><lpage>804</lpage><year>2018</year><pub-id pub-id-type="doi">10.1089/scd.2017.0242</pub-id><pub-id pub-id-type="pmid">29596037</pub-id></element-citation></ref>
<ref id="b112-ol-32-2-15702"><label>112</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phelan</surname><given-names>MA</given-names></name><name><surname>Gianforcaro</surname><given-names>AL</given-names></name><name><surname>Gerstenhaber</surname><given-names>JA</given-names></name><name><surname>Lelkes</surname><given-names>PI</given-names></name></person-group><article-title>An air bubble-isolating rotating wall vessel bioreactor for improved Spheroid/Organoid formation</article-title><source>Tissue Eng Part C Methods</source><volume>25</volume><fpage>479</fpage><lpage>488</lpage><year>2019</year><pub-id pub-id-type="doi">10.1089/ten.tec.2019.0088</pub-id><pub-id pub-id-type="pmid">31328683</pub-id></element-citation></ref>
<ref id="b113-ol-32-2-15702"><label>113</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zare</surname><given-names>M</given-names></name><name><surname>Bigham</surname><given-names>A</given-names></name><name><surname>Zare</surname><given-names>M</given-names></name><name><surname>Luo</surname><given-names>H</given-names></name><name><surname>Rezvani Ghomi</surname><given-names>E</given-names></name><name><surname>Ramakrishna</surname><given-names>S</given-names></name></person-group><article-title>pHEMA: An1 overview for biomedical applications</article-title><source>Int J Mol Sci</source><volume>22</volume><fpage>6376</fpage><year>2021</year><pub-id pub-id-type="doi">10.3390/ijms22126376</pub-id><pub-id pub-id-type="pmid">34203608</pub-id></element-citation></ref>
<ref id="b114-ol-32-2-15702"><label>114</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khodadadi Yazdi</surname><given-names>M</given-names></name><name><surname>Taghizadeh</surname><given-names>A</given-names></name><name><surname>Taghizadeh</surname><given-names>M</given-names></name><name><surname>Taghizadeh</surname><given-names>M</given-names></name><name><surname>Stadler</surname><given-names>FJ</given-names></name><name><surname>Farokhi</surname><given-names>M</given-names></name><name><surname>Mottaghitalab</surname><given-names>F</given-names></name><name><surname>Zarrintaj</surname><given-names>P</given-names></name><name><surname>Ramsey</surname><given-names>JD</given-names></name><name><surname>Seidi</surname><given-names>F</given-names></name><etal/></person-group><article-title>Agarose-based biomaterials for advanced drug delivery</article-title><source>J Control Release</source><volume>326</volume><fpage>523</fpage><lpage>543</lpage><year>2020</year><pub-id pub-id-type="doi">10.1016/j.jconrel.2020.07.028</pub-id><pub-id pub-id-type="pmid">32702391</pub-id></element-citation></ref>
<ref id="b115-ol-32-2-15702"><label>115</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>R</given-names></name><name><surname>Mandell</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>F</given-names></name><name><surname>Heim</surname><given-names>T</given-names></name><name><surname>Schoedel</surname><given-names>K</given-names></name><name><surname>Duensing</surname><given-names>A</given-names></name><name><surname>Watters</surname><given-names>RJ</given-names></name><name><surname>Weiss</surname><given-names>KR</given-names></name></person-group><article-title>Do Patient-derived spheroid culture models have relevance in chondrosarcoma research?</article-title><source>Clin Orthop Relat Res</source><volume>479</volume><fpage>477</fpage><lpage>490</lpage><year>2021</year><pub-id pub-id-type="doi">10.1097/CORR.0000000000001317</pub-id><pub-id pub-id-type="pmid">32469486</pub-id></element-citation></ref>
<ref id="b116-ol-32-2-15702"><label>116</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piazza</surname><given-names>F</given-names></name><name><surname>Ravaglia</surname><given-names>B</given-names></name><name><surname>Caporale</surname><given-names>A</given-names></name><name><surname>Sveti&#x0107;</surname><given-names>A</given-names></name><name><surname>Parisse</surname><given-names>P</given-names></name><name><surname>Asaro</surname><given-names>F</given-names></name><name><surname>Grassi</surname><given-names>G</given-names></name><name><surname>Secco</surname><given-names>L</given-names></name><name><surname>Sgarra</surname><given-names>R</given-names></name><name><surname>Marsich</surname><given-names>E</given-names></name><etal/></person-group><article-title>Elucidating the unexpected cell adhesive properties of agarose substrates. The effect of mechanics, fetal bovine serum and specific peptide sequences</article-title><source>Acta Biomateri</source><volume>189</volume><fpage>286</fpage><lpage>297</lpage><year>2024</year><pub-id pub-id-type="doi">10.1016/j.actbio.2024.09.042</pub-id></element-citation></ref>
<ref id="b117-ol-32-2-15702"><label>117</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sucosky</surname><given-names>P</given-names></name><name><surname>Osorio</surname><given-names>DF</given-names></name><name><surname>Brown</surname><given-names>JB</given-names></name><name><surname>Neitzel</surname><given-names>GP</given-names></name></person-group><article-title>Fluid mechanics of a spinner-flask bioreactor</article-title><source>Biotechnol Bioeng</source><volume>85</volume><fpage>34</fpage><lpage>46</lpage><year>2003</year><pub-id pub-id-type="doi">10.1002/bit.10788</pub-id><pub-id pub-id-type="pmid">14705010</pub-id></element-citation></ref>
<ref id="b118-ol-32-2-15702"><label>118</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>&#x00C7;olak</surname><given-names>G</given-names></name><name><surname>Uzar</surname><given-names>S</given-names></name><name><surname>Birbir</surname><given-names>M</given-names></name></person-group><article-title>Production of the Bak&#x0131;rk&#x00F6;y strain of sheeppox vaccine virus in spinner flasks using an alternative method with Cytodex 1 microcarriers on Vero cells</article-title><source>BMC Biotechnol</source><volume>26</volume><fpage>9</fpage><year>2025</year><pub-id pub-id-type="doi">10.1186/s12896-025-01089-8</pub-id><pub-id pub-id-type="pmid">41422239</pub-id></element-citation></ref>
<ref id="b119-ol-32-2-15702"><label>119</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loverdou</surname><given-names>N</given-names></name><name><surname>Cuvelier</surname><given-names>M</given-names></name><name><surname>Nilsson Hall</surname><given-names>G</given-names></name><name><surname>Christiaens</surname><given-names>AS</given-names></name><name><surname>Decoene</surname><given-names>I</given-names></name><name><surname>Bernaerts</surname><given-names>K</given-names></name><name><surname>Smeets</surname><given-names>B</given-names></name><name><surname>Ramon</surname><given-names>H</given-names></name><name><surname>Luyten</surname><given-names>FP</given-names></name><name><surname>Geris</surname><given-names>L</given-names></name><name><surname>Papantoniou</surname><given-names>I</given-names></name></person-group><article-title>Stirred culture of cartilaginous microtissues promotes chondrogenic hypertrophy through exposure to intermittent shear stress</article-title><source>Bioeng Transl Med</source><volume>8</volume><fpage>e10468</fpage><year>2022</year><pub-id pub-id-type="doi">10.1002/btm2.10468</pub-id><pub-id pub-id-type="pmid">37206246</pub-id></element-citation></ref>
<ref id="b120-ol-32-2-15702"><label>120</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>NS</given-names></name><name><surname>Lewis</surname><given-names>EEL</given-names></name><name><surname>Mullin</surname><given-names>M</given-names></name><name><surname>Wheadon</surname><given-names>H</given-names></name><name><surname>Dalby</surname><given-names>MJ</given-names></name><name><surname>Berry</surname><given-names>CC</given-names></name></person-group><article-title>Magnetically levitated mesenchymal stem cell spheroids cultured with a collagen gel maintain phenotype and quiescence</article-title><source>J Tissue Eng</source><volume>8</volume><fpage>2041731417704428</fpage><year>2017</year><pub-id pub-id-type="doi">10.1177/2041731417704428</pub-id><pub-id pub-id-type="pmid">28616152</pub-id></element-citation></ref>
<ref id="b121-ol-32-2-15702"><label>121</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yeatts</surname><given-names>AB</given-names></name><name><surname>Fisher</surname><given-names>JP</given-names></name></person-group><article-title>Bone tissue engineering bioreactors: Dynamic culture and the influence of shear stress</article-title><source>Bone</source><volume>48</volume><fpage>171</fpage><lpage>181</lpage><year>2011</year><pub-id pub-id-type="doi">10.1016/j.bone.2010.09.138</pub-id><pub-id pub-id-type="pmid">20932947</pub-id></element-citation></ref>
<ref id="b122-ol-32-2-15702"><label>122</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chisti</surname><given-names>Y</given-names></name></person-group><article-title>Hydrodynamic damage to animal cells</article-title><source>Crit Rev Biotechnol</source><volume>21</volume><fpage>67</fpage><lpage>110</lpage><year>2008</year><pub-id pub-id-type="doi">10.1080/20013891081692</pub-id><pub-id pub-id-type="pmid">11451047</pub-id></element-citation></ref>
<ref id="b123-ol-32-2-15702"><label>123</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seo</surname><given-names>JY</given-names></name><name><surname>Park</surname><given-names>SB</given-names></name><name><surname>Kim</surname><given-names>SY</given-names></name><name><surname>Seo</surname><given-names>GJ</given-names></name><name><surname>Jang</surname><given-names>HK</given-names></name><name><surname>Lee</surname><given-names>TJ</given-names></name></person-group><article-title>Acoustic and magnetic Stimuli-based Three-dimensional cell culture platform for tissue engineering</article-title><source>Tissue Eng Regen Med</source><volume>20</volume><fpage>563</fpage><lpage>580</lpage><year>2023</year><pub-id pub-id-type="doi">10.1007/s13770-023-00539-8</pub-id><pub-id pub-id-type="pmid">37052782</pub-id></element-citation></ref>
<ref id="b124-ol-32-2-15702"><label>124</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tepe</surname><given-names>U</given-names></name><name><surname>Aslanbay Guler</surname><given-names>B</given-names></name><name><surname>Imamoglu</surname><given-names>E</given-names></name></person-group><article-title>Applications and sensory utilizations of magnetic levitation in 3D cell culture for tissue Engineering</article-title><source>Mol Biol Rep</source><volume>50</volume><fpage>7017</fpage><lpage>7025</lpage><year>2023</year><pub-id pub-id-type="doi">10.1007/s11033-023-08585-0</pub-id><pub-id pub-id-type="pmid">37378748</pub-id></element-citation></ref>
<ref id="b125-ol-32-2-15702"><label>125</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jafari</surname><given-names>J</given-names></name><name><surname>Han</surname><given-names>X-l</given-names></name><name><surname>Palmer</surname><given-names>J</given-names></name><name><surname>Tran</surname><given-names>PA</given-names></name><name><surname>O&#x0027;Connor</surname><given-names>AJ</given-names></name></person-group><article-title>Remote control in formation of 3D multicellular assemblies using magnetic forces</article-title><source>ACS Biomat Sci Eng</source><volume>5</volume><fpage>2532</fpage><lpage>2542</lpage><year>2019</year><pub-id pub-id-type="doi">10.1021/acsbiomaterials.9b00297</pub-id><pub-id pub-id-type="pmid">33405759</pub-id></element-citation></ref>
<ref id="b126-ol-32-2-15702"><label>126</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qi</surname><given-names>X</given-names></name><name><surname>Prokhorova</surname><given-names>AV</given-names></name><name><surname>Mezentsev</surname><given-names>AV</given-names></name><name><surname>Shen</surname><given-names>N</given-names></name><name><surname>Trofimenko</surname><given-names>AV</given-names></name><name><surname>Filkov</surname><given-names>GI</given-names></name><name><surname>Sulimanov</surname><given-names>RA</given-names></name><name><surname>Makarov</surname><given-names>VA</given-names></name><name><surname>Durymanov</surname><given-names>MO</given-names></name></person-group><article-title>Comparison of EMT-related and multi-drug resistant gene expression, extracellular matrix production, and drug sensitivity in NSCLC spheroids generated by scaffold-free and scaffold-based methods</article-title><source>Int J Mol Sci</source><volume>23</volume><fpage>13306</fpage><year>2022</year><pub-id pub-id-type="doi">10.3390/ijms232113306</pub-id><pub-id pub-id-type="pmid">36362093</pub-id></element-citation></ref>
<ref id="b127-ol-32-2-15702"><label>127</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Xiao</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name></person-group><article-title>Steroidal saponins: Natural compounds with the potential to reverse tumor drug resistance (Review)</article-title><source>Oncol Lett</source><volume>28</volume><fpage>585</fpage><year>2024</year><pub-id pub-id-type="doi">10.3892/ol.2024.14719</pub-id><pub-id pub-id-type="pmid">39421314</pub-id></element-citation></ref>
<ref id="b128-ol-32-2-15702"><label>128</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Pachnikova</surname><given-names>G</given-names></name><name><surname>Przybilla</surname><given-names>D</given-names></name><name><surname>Sch&#x00E4;fer</surname><given-names>R</given-names></name><name><surname>Cui</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Zhao</surname><given-names>A</given-names></name><name><surname>Keilholz</surname><given-names>U</given-names></name></person-group><article-title>Evaluation of JQ1 combined with docetaxel for the treatment of prostate cancer cells in 2D- and 3D-culture systems</article-title><source>Front Pharmacol</source><volume>13</volume><fpage>839620</fpage><year>2022</year><pub-id pub-id-type="doi">10.3389/fphar.2022.839620</pub-id><pub-id pub-id-type="pmid">35185589</pub-id></element-citation></ref>
<ref id="b129-ol-32-2-15702"><label>129</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alwahsh</surname><given-names>M</given-names></name><name><surname>Al-Doridee</surname><given-names>A</given-names></name><name><surname>Jasim</surname><given-names>S</given-names></name><name><surname>Awwad</surname><given-names>O</given-names></name><name><surname>Hergenr&#x00F6;der</surname><given-names>R</given-names></name><name><surname>Hamadneh</surname><given-names>L</given-names></name></person-group><article-title>Cytotoxic and molecular differences of anticancer agents on 2D and 3D cell culture</article-title><source>Mol Biol Rep</source><volume>51</volume><fpage>721</fpage><year>2024</year><pub-id pub-id-type="doi">10.1007/s11033-024-09669-1</pub-id><pub-id pub-id-type="pmid">38829450</pub-id></element-citation></ref>
<ref id="b130-ol-32-2-15702"><label>130</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>YJ</given-names></name><name><surname>Hsu</surname><given-names>SH</given-names></name></person-group><article-title>Acquisition of epithelial-mesenchymal transition and cancer stem-like phenotypes within chitosan-hyaluronan membrane-derived 3D tumor spheroids</article-title><source>Biomaterials</source><volume>35</volume><fpage>10070</fpage><lpage>10079</lpage><year>2014</year><pub-id pub-id-type="doi">10.1016/j.biomaterials.2014.09.010</pub-id><pub-id pub-id-type="pmid">25282622</pub-id></element-citation></ref>
<ref id="b131-ol-32-2-15702"><label>131</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Vadlamudi</surname><given-names>M</given-names></name><name><surname>Zhao</surname><given-names>S</given-names></name><name><surname>Felmlee</surname><given-names>M</given-names></name><name><surname>Rahimian</surname><given-names>R</given-names></name><name><surname>Guo</surname><given-names>X</given-names></name></person-group><article-title>Intrapulmonary inoculation of multicellular spheroids to construct an orthotopic lung cancer xenograft model that mimics four clinical stages of non-small cell lung cancer</article-title><source>J Pharmacol Toxicol Methods</source><volume>104</volume><fpage>106885</fpage><year>2020</year><pub-id pub-id-type="doi">10.1016/j.vascn.2020.106885</pub-id><pub-id pub-id-type="pmid">32531198</pub-id></element-citation></ref>
<ref id="b132-ol-32-2-15702"><label>132</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Ding</surname><given-names>Q</given-names></name><name><surname>Xing</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>Z</given-names></name><name><surname>Lu</surname><given-names>C</given-names></name><name><surname>Luo</surname><given-names>D</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Xia</surname><given-names>W</given-names></name><name><surname>Zhou</surname><given-names>C</given-names></name><name><surname>Shi</surname><given-names>M</given-names></name></person-group><article-title>Establishment of patient-derived tumor spheroids for non-small cell lung cancer</article-title><source>PLoS One</source><volume>13</volume><fpage>e0194016</fpage><year>2018</year><pub-id pub-id-type="doi">10.1371/journal.pone.0194016</pub-id><pub-id pub-id-type="pmid">29543851</pub-id></element-citation></ref>
<ref id="b133-ol-32-2-15702"><label>133</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Motta</surname><given-names>A</given-names></name><name><surname>Daware</surname><given-names>R</given-names></name><name><surname>Nucci</surname><given-names>A</given-names></name><name><surname>Breuel</surname><given-names>S</given-names></name><name><surname>von Stillfried</surname><given-names>S</given-names></name><name><surname>Maurer</surname><given-names>J</given-names></name><name><surname>Boor</surname><given-names>P</given-names></name><name><surname>Jonigk</surname><given-names>D</given-names></name><name><surname>Kiessling</surname><given-names>F</given-names></name><name><surname>Lammers</surname><given-names>T</given-names></name><etal/></person-group><article-title>Bioengineering multicellular tumor spheroids with tunable extracellular matrix deposition</article-title><source>Acta Biomaterialia</source><volume>212</volume><fpage>357</fpage><lpage>372</lpage><year>2026</year><pub-id pub-id-type="doi">10.1016/j.actbio.2026.01.038</pub-id><pub-id pub-id-type="pmid">41571063</pub-id></element-citation></ref>
<ref id="b134-ol-32-2-15702"><label>134</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pandya</surname><given-names>N</given-names></name><name><surname>Khan</surname><given-names>E</given-names></name><name><surname>Jain</surname><given-names>N</given-names></name><name><surname>Satham</surname><given-names>L</given-names></name><name><surname>Singh</surname><given-names>R</given-names></name><name><surname>Makde</surname><given-names>RD</given-names></name><name><surname>Mishra</surname><given-names>A</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name></person-group><article-title>Curcumin analogs exhibit anti-cancer activity by selectively targeting G-quadruplex forming c-myc promoter sequence</article-title><source>Biochimie</source><volume>180</volume><fpage>205</fpage><lpage>221</lpage><year>2021</year><pub-id pub-id-type="doi">10.1016/j.biochi.2020.11.006</pub-id><pub-id pub-id-type="pmid">33188859</pub-id></element-citation></ref>
<ref id="b135-ol-32-2-15702"><label>135</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>SK</given-names></name><name><surname>Torrico Guzman</surname><given-names>EA</given-names></name><name><surname>Meenach</surname><given-names>SA</given-names></name></person-group><article-title>Coadministration of a tumor-penetrating peptide improves the therapeutic efficacy of paclitaxel in a novel air-grown lung cancer 3D spheroid model</article-title><source>Int J Cancer</source><volume>141</volume><fpage>2143</fpage><lpage>2153</lpage><year>2017</year><pub-id pub-id-type="doi">10.1002/ijc.30913</pub-id><pub-id pub-id-type="pmid">28771722</pub-id></element-citation></ref>
<ref id="b136-ol-32-2-15702"><label>136</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guzman</surname><given-names>EAT</given-names></name><name><surname>Sun</surname><given-names>Q</given-names></name><name><surname>Meenach</surname><given-names>SA</given-names></name></person-group><article-title>Development and evaluation of paclitaxel-loaded aerosol nanocomposite microparticles and their efficacy against air-grown lung cancer tumor spheroids</article-title><source>ACS Biomater Sci Eng</source><volume>5</volume><fpage>6570</fpage><lpage>6580</lpage><year>2019</year><pub-id pub-id-type="doi">10.1021/acsbiomaterials.9b00947</pub-id><pub-id pub-id-type="pmid">32133390</pub-id></element-citation></ref>
<ref id="b137-ol-32-2-15702"><label>137</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ganguli</surname><given-names>A</given-names></name><name><surname>Mostafa</surname><given-names>A</given-names></name><name><surname>Saavedra</surname><given-names>C</given-names></name><name><surname>Kim</surname><given-names>Y</given-names></name><name><surname>Le</surname><given-names>P</given-names></name><name><surname>Faramarzi</surname><given-names>V</given-names></name><name><surname>Feathers</surname><given-names>RW</given-names></name><name><surname>Berger</surname><given-names>J</given-names></name><name><surname>Ramos-Cruz</surname><given-names>KP</given-names></name><name><surname>Adeniba</surname><given-names>O</given-names></name><etal/></person-group><article-title>Three-dimensional microscale hanging drop arrays with geometric control for drug screening and live tissue imaging</article-title><source>Sci Adv</source><volume>7</volume><fpage>eabc1323</fpage><year>2021</year><pub-id pub-id-type="doi">10.1126/sciadv.abc1323</pub-id><pub-id pub-id-type="pmid">33893093</pub-id></element-citation></ref>
<ref id="b138-ol-32-2-15702"><label>138</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vega</surname><given-names>VF</given-names></name><name><surname>Yang</surname><given-names>D</given-names></name><name><surname>Jordan</surname><given-names>LO</given-names></name><name><surname>Ye</surname><given-names>F</given-names></name><name><surname>Conway</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>LY</given-names></name><name><surname>Shumate</surname><given-names>J</given-names></name><name><surname>Baillargeon</surname><given-names>P</given-names></name><name><surname>Scampavia</surname><given-names>L</given-names></name><name><surname>Parker</surname><given-names>C</given-names></name><etal/></person-group><article-title>Protocol for 3D screening of lung cancer spheroids using natural products</article-title><source>SLAS Discov</source><volume>28</volume><fpage>20</fpage><lpage>28</lpage><year>2023</year><pub-id pub-id-type="doi">10.1016/j.slasd.2023.01.005</pub-id><pub-id pub-id-type="pmid">36681384</pub-id></element-citation></ref>
<ref id="b139-ol-32-2-15702"><label>139</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>B</given-names></name><name><surname>Tang</surname><given-names>Y</given-names></name><name><surname>Baltz</surname><given-names>RH</given-names></name><name><surname>Gonzalez</surname><given-names>R</given-names></name></person-group><article-title>Introduction to the special issue: &#x2018;Natural Product Discovery and Development in the Genomic Era: 2021&#x2019;</article-title><source>J Ind Microbiol Biotechnol</source><volume>48</volume><fpage>kuab030</fpage><year>2021</year><pub-id pub-id-type="doi">10.1093/jimb/kuab030</pub-id><pub-id pub-id-type="pmid">33904896</pub-id></element-citation></ref>
<ref id="b140-ol-32-2-15702"><label>140</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>T</given-names></name><name><surname>Jain</surname><given-names>N</given-names></name></person-group><article-title>Multicellular tumor spheroids: A convenient in vitro model for translational cancer research</article-title><source>Life Sci</source><volume>358</volume><fpage>123184</fpage><year>2024</year><pub-id pub-id-type="doi">10.1016/j.lfs.2024.123184</pub-id><pub-id pub-id-type="pmid">39490437</pub-id></element-citation></ref>
<ref id="b141-ol-32-2-15702"><label>141</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodrigues</surname><given-names>DB</given-names></name><name><surname>Reis</surname><given-names>RL</given-names></name><name><surname>Pirraco</surname><given-names>RP</given-names></name></person-group><article-title>Modelling the complex nature of the tumor microenvironment: 3D tumor spheroids as an evolving tool</article-title><source>J Biomed Sci</source><volume>31</volume><fpage>13</fpage><year>2024</year><pub-id pub-id-type="doi">10.1186/s12929-024-00997-9</pub-id><pub-id pub-id-type="pmid">38254117</pub-id></element-citation></ref>
<ref id="b142-ol-32-2-15702"><label>142</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vella</surname><given-names>N</given-names></name><name><surname>Fenech</surname><given-names>AG</given-names></name><name><surname>Petroni Magri</surname><given-names>V</given-names></name></person-group><article-title>3D cell culture models in research: Applications to lung cancer pharmacology</article-title><source>Front Pharmacol</source><volume>15</volume><fpage>1438067</fpage><year>2024</year><pub-id pub-id-type="doi">10.3389/fphar.2024.1438067</pub-id><pub-id pub-id-type="pmid">39376603</pub-id></element-citation></ref>
<ref id="b143-ol-32-2-15702"><label>143</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aydemir</surname><given-names>D</given-names></name><name><surname>Kele&#x015F;</surname><given-names>B</given-names></name><name><surname>Polat</surname><given-names>&#x0130;</given-names></name><name><surname>Metin</surname><given-names>E</given-names></name><name><surname>Sokullu</surname><given-names>E</given-names></name><name><surname>Ulusu</surname><given-names>NN</given-names></name></person-group><article-title>Development and evaluation of a 3D-engineered neural co-culture system: Impacts on oxidative stress, pentose phosphate pathway, trace element and mineral metabolisms</article-title><source>J Neurosci Methods</source><volume>425</volume><fpage>110614</fpage><year>2026</year><pub-id pub-id-type="doi">10.1016/j.jneumeth.2025.110614</pub-id><pub-id pub-id-type="pmid">41176241</pub-id></element-citation></ref>
<ref id="b144-ol-32-2-15702"><label>144</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamichhane</surname><given-names>SP</given-names></name><name><surname>Arya</surname><given-names>N</given-names></name><name><surname>Kohler</surname><given-names>E</given-names></name><name><surname>Xiang</surname><given-names>S</given-names></name><name><surname>Christensen</surname><given-names>J</given-names></name><name><surname>Shastri</surname><given-names>VP</given-names></name></person-group><article-title>Recapitulating epithelial tumor microenvironment in vitro using three dimensional tri-culture of human epithelial, endothelial, and mesenchymal cells</article-title><source>BMC Cancer</source><volume>16</volume><fpage>581</fpage><year>2016</year><pub-id pub-id-type="doi">10.1186/s12885-016-2634-1</pub-id><pub-id pub-id-type="pmid">27484993</pub-id></element-citation></ref>
<ref id="b145-ol-32-2-15702"><label>145</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Cuddihy</surname><given-names>MJ</given-names></name><name><surname>Cater</surname><given-names>GM</given-names></name><name><surname>Kotov</surname><given-names>NA</given-names></name></person-group><article-title>Engineering liver tissue spheroids with inverted colloidal crystal scaffolds</article-title><source>Biomaterials</source><volume>30</volume><fpage>4687</fpage><lpage>4694</lpage><year>2009</year><pub-id pub-id-type="doi">10.1016/j.biomaterials.2009.05.024</pub-id><pub-id pub-id-type="pmid">19524294</pub-id></element-citation></ref>
<ref id="b146-ol-32-2-15702"><label>146</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Estrada</surname><given-names>MF</given-names></name><name><surname>Rebelo</surname><given-names>SP</given-names></name><name><surname>Davies</surname><given-names>EJ</given-names></name><name><surname>Pinto</surname><given-names>MT</given-names></name><name><surname>Pereira</surname><given-names>H</given-names></name><name><surname>Santo</surname><given-names>VE</given-names></name><name><surname>Smalley</surname><given-names>MJ</given-names></name><name><surname>Barry</surname><given-names>ST</given-names></name><name><surname>Gualda</surname><given-names>EJ</given-names></name><name><surname>Alves</surname><given-names>PM</given-names></name><etal/></person-group><article-title>Modelling the tumour microenvironment in long-term microencapsulated 3D co-cultures recapitulates phenotypic features of disease progression</article-title><source>Biomaterials</source><volume>78</volume><fpage>50</fpage><lpage>61</lpage><year>2016</year><pub-id pub-id-type="doi">10.1016/j.biomaterials.2015.11.030</pub-id><pub-id pub-id-type="pmid">26650685</pub-id></element-citation></ref>
<ref id="b147-ol-32-2-15702"><label>147</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>HW</given-names></name><name><surname>Hsu</surname><given-names>SH</given-names></name></person-group><article-title>Chitosan-hyaluronan based 3D co-culture platform for studying the crosstalk of lung cancer cells and mesenchymal stem cells</article-title><source>Acta Biomater</source><volume>42</volume><fpage>157</fpage><lpage>167</lpage><year>2016</year><pub-id pub-id-type="doi">10.1016/j.actbio.2016.06.014</pub-id><pub-id pub-id-type="pmid">27296841</pub-id></element-citation></ref>
<ref id="b148-ol-32-2-15702"><label>148</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Lu</surname><given-names>X</given-names></name><name><surname>Zhuansun</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Wei</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Colorectal carcinoma organoid and cancer-associated fibroblasts co-culture system for drug evaluation</article-title><source>In Vitro Models</source><volume>4</volume><fpage>31</fpage><lpage>44</lpage><year>2025</year><pub-id pub-id-type="doi">10.1007/s44164-025-00084-9</pub-id><pub-id pub-id-type="pmid">40160212</pub-id></element-citation></ref>
<ref id="b149-ol-32-2-15702"><label>149</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yue</surname><given-names>SSK</given-names></name><name><surname>Tong</surname><given-names>Y</given-names></name><name><surname>Siu</surname><given-names>HC</given-names></name><name><surname>Ho</surname><given-names>SL</given-names></name><name><surname>Law</surname><given-names>SYK</given-names></name><name><surname>Tsui</surname><given-names>WY</given-names></name><name><surname>Chan</surname><given-names>D</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Chan</surname><given-names>ASY</given-names></name><name><surname>Yun</surname><given-names>SW</given-names></name><etal/></person-group><article-title>Divergent lineage trajectories and genetic landscapes in human gastric intestinal metaplasia organoids associated with early neoplastic progression</article-title><source>Gut</source><volume>74</volume><fpage>522</fpage><lpage>538</lpage><year>2025</year><pub-id pub-id-type="doi">10.1136/gutjnl-2024-332594</pub-id><pub-id pub-id-type="pmid">39572083</pub-id></element-citation></ref>
<ref id="b150-ol-32-2-15702"><label>150</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Close</surname><given-names>DA</given-names></name><name><surname>Johnston</surname><given-names>PA</given-names></name></person-group><article-title>Miniaturization and characterization of patient derived hepatocellular carcinoma tumor organoid cultures for cancer drug discovery applications</article-title><source>SLAS Discovery</source><volume>30</volume><fpage>100201</fpage><year>2025</year><pub-id pub-id-type="doi">10.1016/j.slasd.2024.100201</pub-id><pub-id pub-id-type="pmid">39662672</pub-id></element-citation></ref>
<ref id="b151-ol-32-2-15702"><label>151</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ely</surname><given-names>ZA</given-names></name><name><surname>Kulstad</surname><given-names>ZJ</given-names></name><name><surname>Gunaydin</surname><given-names>G</given-names></name><name><surname>Addepalli</surname><given-names>S</given-names></name><name><surname>Verzani</surname><given-names>EK</given-names></name><name><surname>Casarrubios</surname><given-names>M</given-names></name><name><surname>Clauser</surname><given-names>KR</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Lippincott</surname><given-names>IE</given-names></name><name><surname>Louvet</surname><given-names>C</given-names></name><etal/></person-group><article-title>Pancreatic cancer-restricted cryptic antigens are targets for T cell recognition</article-title><source>Science</source><volume>388</volume><fpage>eadk3487</fpage><year>2025</year><pub-id pub-id-type="doi">10.1126/science.adk3487</pub-id><pub-id pub-id-type="pmid">40339010</pub-id></element-citation></ref>
<ref id="b152-ol-32-2-15702"><label>152</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Merrill</surname><given-names>NM</given-names></name><name><surname>Kaffenberger</surname><given-names>SD</given-names></name><name><surname>Bao</surname><given-names>L</given-names></name><name><surname>Vandecan</surname><given-names>N</given-names></name><name><surname>Goo</surname><given-names>L</given-names></name><name><surname>Apfel</surname><given-names>A</given-names></name><name><surname>Cheng</surname><given-names>X</given-names></name><name><surname>Qin</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>CJ</given-names></name><name><surname>Bankhead</surname><given-names>A</given-names></name><etal/></person-group><article-title>Integrative drug screening and multiomic characterization of Patient-derived bladder cancer organoids reveal novel molecular correlates of gemcitabine response</article-title><source>Eur Urol</source><volume>86</volume><fpage>434</fpage><lpage>444</lpage><year>2024</year><pub-id pub-id-type="doi">10.1016/j.eururo.2024.05.026</pub-id><pub-id pub-id-type="pmid">39155193</pub-id></element-citation></ref>
<ref id="b153-ol-32-2-15702"><label>153</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomas</surname><given-names>EJ</given-names></name><name><surname>Valdes</surname><given-names>YR</given-names></name><name><surname>Davis</surname><given-names>J</given-names></name><name><surname>Kolendowski</surname><given-names>B</given-names></name><name><surname>Buensuceso</surname><given-names>A</given-names></name><name><surname>DiMattia</surname><given-names>GE</given-names></name><name><surname>Shepherd</surname><given-names>TG</given-names></name></person-group><article-title>Exploiting cancer dormancy signaling mechanisms in epithelial ovarian cancer through spheroid and organoid analysis</article-title><source>Cells</source><volume>14</volume><fpage>133</fpage><year>2025</year><pub-id pub-id-type="doi">10.3390/cells14020133</pub-id><pub-id pub-id-type="pmid">39851561</pub-id></element-citation></ref>
<ref id="b154-ol-32-2-15702"><label>154</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Felice</surname><given-names>D</given-names></name><name><surname>Alaimo</surname><given-names>A</given-names></name><name><surname>Bressan</surname><given-names>D</given-names></name><name><surname>Genovesi</surname><given-names>S</given-names></name><name><surname>Marmocchi</surname><given-names>E</given-names></name><name><surname>Annesi</surname><given-names>N</given-names></name><name><surname>Beccaceci</surname><given-names>G</given-names></name><name><surname>Dalfovo</surname><given-names>D</given-names></name><name><surname>Cutrupi</surname><given-names>F</given-names></name><name><surname>Medaglia</surname><given-names>S</given-names></name><etal/></person-group><article-title>Rar&#x03B3;-Foxa1 signaling promotes luminal identity in prostate progenitors and is disrupted in prostate cancer</article-title><source>EMBO Rep</source><volume>26</volume><fpage>443</fpage><lpage>469</lpage><year>2024</year><pub-id pub-id-type="doi">10.1038/s44319-024-00335-y</pub-id><pub-id pub-id-type="pmid">39633177</pub-id></element-citation></ref>
<ref id="b155-ol-32-2-15702"><label>155</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>K</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Sui</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Zhao</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><etal/></person-group><article-title>An organoid co-culture model for probing systemic anti-tumor immunity in lung cancer</article-title><source>Cell Stem Cell</source><volume>32</volume><fpage>1218</fpage><lpage>1234.e7</lpage><year>2025</year><pub-id pub-id-type="doi">10.1016/j.stem.2025.05.011</pub-id><pub-id pub-id-type="pmid">40513558</pub-id></element-citation></ref>
<ref id="b156-ol-32-2-15702"><label>156</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Lei</surname><given-names>H</given-names></name><name><surname>Zhao</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name></person-group><article-title>Evolution and hotspots in breast cancer organoid research: Insights from a bibliometric and visual knowledge mapping study (2005&#x2013;2024)</article-title><source>Front Oncol</source><volume>15</volume><fpage>1604362</fpage><year>2025</year><pub-id pub-id-type="doi">10.3389/fonc.2025.1604362</pub-id><pub-id pub-id-type="pmid">40969251</pub-id></element-citation></ref>
<ref id="b157-ol-32-2-15702"><label>157</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cacciamali</surname><given-names>A</given-names></name><name><surname>Villa</surname><given-names>R</given-names></name><name><surname>Dotti</surname><given-names>S</given-names></name></person-group><article-title>3D cell cultures: Evolution of an ancient tool for new applications</article-title><source>Front Physiol</source><volume>13</volume><fpage>836480</fpage><year>2022</year><pub-id pub-id-type="doi">10.3389/fphys.2022.836480</pub-id><pub-id pub-id-type="pmid">35936888</pub-id></element-citation></ref>
<ref id="b158-ol-32-2-15702"><label>158</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>S</given-names></name><name><surname>Mu</surname><given-names>Y</given-names></name><name><surname>Shen</surname><given-names>W</given-names></name><name><surname>Tong</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><etal/></person-group><article-title>RBM15 facilitates osimertinib resistance of lung adenocarcinoma through m6A-dependent epigenetic silencing of SPOCK1</article-title><source>Oncogene</source><volume>44</volume><fpage>307</fpage><lpage>321</lpage><year>2024</year><pub-id pub-id-type="doi">10.1038/s41388-024-03220-z</pub-id><pub-id pub-id-type="pmid">39528815</pub-id></element-citation></ref>
<ref id="b159-ol-32-2-15702"><label>159</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ebisudani</surname><given-names>T</given-names></name><name><surname>Hamamoto</surname><given-names>J</given-names></name><name><surname>Togasaki</surname><given-names>K</given-names></name><name><surname>Mitsuishi</surname><given-names>A</given-names></name><name><surname>Sugihara</surname><given-names>K</given-names></name><name><surname>Shinozaki</surname><given-names>T</given-names></name><name><surname>Fukushima</surname><given-names>T</given-names></name><name><surname>Kawasaki</surname><given-names>K</given-names></name><name><surname>Seino</surname><given-names>T</given-names></name><name><surname>Oda</surname><given-names>M</given-names></name><etal/></person-group><article-title>Genotype-phenotype mapping of a patient-derived lung cancer organoid biobank identifies NKX2-1-defined Wnt dependency in lung adenocarcinoma</article-title><source>Cell Rep</source><volume>42</volume><fpage>112212</fpage><year>2023</year><pub-id pub-id-type="doi">10.1016/j.celrep.2023.112212</pub-id><pub-id pub-id-type="pmid">36870059</pub-id></element-citation></ref>
<ref id="b160-ol-32-2-15702"><label>160</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Terai</surname><given-names>H</given-names></name><name><surname>Yasuda</surname><given-names>H</given-names></name><name><surname>Sato</surname><given-names>T</given-names></name></person-group><article-title>Organoid-based precision cancer modeling: New frontier in lung cancer research</article-title><source>Cell Rep</source><volume>44</volume><fpage>116595</fpage><year>2025</year><pub-id pub-id-type="doi">10.1016/j.celrep.2025.116595</pub-id><pub-id pub-id-type="pmid">41273722</pub-id></element-citation></ref>
<ref id="b161-ol-32-2-15702"><label>161</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>R</given-names></name><name><surname>Radulovich</surname><given-names>N</given-names></name><name><surname>Ng</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>N</given-names></name><name><surname>Notsuda</surname><given-names>H</given-names></name><name><surname>Cabanero</surname><given-names>M</given-names></name><name><surname>Martins-Filho</surname><given-names>SN</given-names></name><name><surname>Raghavan</surname><given-names>V</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Mer</surname><given-names>AS</given-names></name><etal/></person-group><article-title>Organoid cultures as preclinical models of non-small cell lung cancer</article-title><source>Clin Cancer Res</source><volume>26</volume><fpage>1162</fpage><lpage>1174</lpage><year>2020</year><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-19-1376</pub-id><pub-id pub-id-type="pmid">31694835</pub-id></element-citation></ref>
<ref id="b162-ol-32-2-15702"><label>162</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>E</given-names></name><name><surname>Lee</surname><given-names>SY</given-names></name><name><surname>Seong</surname><given-names>YJ</given-names></name><name><surname>Ku</surname><given-names>B</given-names></name><name><surname>Cho</surname><given-names>HJ</given-names></name><name><surname>Kim</surname><given-names>K</given-names></name><name><surname>Hwang</surname><given-names>Y</given-names></name><name><surname>Park</surname><given-names>CK</given-names></name><name><surname>Choi</surname><given-names>JY</given-names></name><name><surname>Kim</surname><given-names>SW</given-names></name><etal/></person-group><article-title>Lung cancer organoid-based drug evaluation models and new drug development application trends</article-title><source>Transl Lung Cancer Res</source><volume>13</volume><fpage>3741</fpage><lpage>3763</lpage><year>2024</year><pub-id pub-id-type="doi">10.21037/tlcr-24-603</pub-id><pub-id pub-id-type="pmid">39830742</pub-id></element-citation></ref>
<ref id="b163-ol-32-2-15702"><label>163</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sachs</surname><given-names>N</given-names></name><name><surname>Papaspyropoulos</surname><given-names>A</given-names></name><name><surname>Zomer-van Ommen</surname><given-names>DD</given-names></name><name><surname>Heo</surname><given-names>I</given-names></name><name><surname>B&#x00F6;ttinger</surname><given-names>L</given-names></name><name><surname>Klay</surname><given-names>D</given-names></name><name><surname>Weeber</surname><given-names>F</given-names></name><name><surname>Huelsz-Prince</surname><given-names>G</given-names></name><name><surname>Iakobachvili</surname><given-names>N</given-names></name><name><surname>Amatngalim</surname><given-names>GD</given-names></name><etal/></person-group><article-title>Long-term expanding human airway organoids for disease modeling</article-title><source>EMBO J</source><volume>38</volume><fpage>e100300</fpage><year>2019</year><pub-id pub-id-type="doi">10.15252/embj.2018100300</pub-id><pub-id pub-id-type="pmid">30643021</pub-id></element-citation></ref>
<ref id="b164-ol-32-2-15702"><label>164</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shinozaki</surname><given-names>T</given-names></name><name><surname>Togasaki</surname><given-names>K</given-names></name><name><surname>Hamamoto</surname><given-names>J</given-names></name><name><surname>Mitsuishi</surname><given-names>A</given-names></name><name><surname>Fukushima</surname><given-names>T</given-names></name><name><surname>Sugihara</surname><given-names>K</given-names></name><name><surname>Ebisudani</surname><given-names>T</given-names></name><name><surname>Okada</surname><given-names>M</given-names></name><name><surname>Saito</surname><given-names>A</given-names></name><name><surname>Shigematsu</surname><given-names>L</given-names></name><etal/></person-group><article-title>Basal-shift transformation leads to EGFR therapy-resistance in human lung adenocarcinoma</article-title><source>Nat Commun</source><volume>16</volume><fpage>4369</fpage><year>2025</year><pub-id pub-id-type="doi">10.1038/s41467-025-59623-3</pub-id><pub-id pub-id-type="pmid">40350470</pub-id></element-citation></ref>
<ref id="b165-ol-32-2-15702"><label>165</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>M</given-names></name><name><surname>Mun</surname><given-names>H</given-names></name><name><surname>Sung</surname><given-names>CO</given-names></name><name><surname>Cho</surname><given-names>EJ</given-names></name><name><surname>Jeon</surname><given-names>HJ</given-names></name><name><surname>Chun</surname><given-names>SM</given-names></name><name><surname>Jung</surname><given-names>DJ</given-names></name><name><surname>Shin</surname><given-names>TH</given-names></name><name><surname>Jeong</surname><given-names>GS</given-names></name><name><surname>Kim</surname><given-names>DK</given-names></name><etal/></person-group><article-title>Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening</article-title><source>Nat Commun</source><volume>10</volume><fpage>3991</fpage><year>2019</year><pub-id pub-id-type="doi">10.1038/s41467-019-11867-6</pub-id><pub-id pub-id-type="pmid">31488816</pub-id></element-citation></ref>
<ref id="b166-ol-32-2-15702"><label>166</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>JH</given-names></name><name><surname>Chu</surname><given-names>XP</given-names></name><name><surname>Zhang</surname><given-names>JT</given-names></name><name><surname>Nie</surname><given-names>Q</given-names></name><name><surname>Tang</surname><given-names>WF</given-names></name><name><surname>Su</surname><given-names>J</given-names></name><name><surname>Yan</surname><given-names>HH</given-names></name><name><surname>Zheng</surname><given-names>HP</given-names></name><name><surname>Chen</surname><given-names>ZX</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><etal/></person-group><article-title>Genomic characteristics and drug screening among organoids derived from non-small cell lung cancer patients</article-title><source>Thorac Cancer</source><volume>11</volume><fpage>2279</fpage><lpage>2290</lpage><year>2020</year><pub-id pub-id-type="doi">10.1111/1759-7714.13542</pub-id><pub-id pub-id-type="pmid">32633046</pub-id></element-citation></ref>
<ref id="b167-ol-32-2-15702"><label>167</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Kim</surname><given-names>K</given-names></name><name><surname>Lee</surname><given-names>E</given-names></name><name><surname>Lee</surname><given-names>K</given-names></name><name><surname>Ahn</surname><given-names>KH</given-names></name><name><surname>Park</surname><given-names>H</given-names></name><name><surname>Kim</surname><given-names>Y</given-names></name><name><surname>Shin</surname><given-names>S</given-names></name><name><surname>Jeon</surname><given-names>SY</given-names></name><name><surname>Hwang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Prediction of TKI response in EGFR-mutant lung cancer patients-derived organoids using malignant pleural effusion</article-title><source>NPJ Precis Oncol</source><volume>8</volume><fpage>111</fpage><year>2024</year><pub-id pub-id-type="doi">10.1038/s41698-024-00609-7</pub-id><pub-id pub-id-type="pmid">38773241</pub-id></element-citation></ref>
<ref id="b168-ol-32-2-15702"><label>168</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Renterghem</surname><given-names>AWJ</given-names></name><name><surname>van de Haar</surname><given-names>J</given-names></name><name><surname>Voest</surname><given-names>EE</given-names></name></person-group><article-title>Functional precision oncology using patient-derived assays: Bridging genotype and phenotype</article-title><source>Nat Rev Clin Oncol</source><volume>20</volume><fpage>305</fpage><lpage>317</lpage><year>2023</year><pub-id pub-id-type="doi">10.1038/s41571-023-00745-2</pub-id><pub-id pub-id-type="pmid">36914745</pub-id></element-citation></ref>
<ref id="b169-ol-32-2-15702"><label>169</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chitrangi</surname><given-names>S</given-names></name><name><surname>Vaity</surname><given-names>P</given-names></name><name><surname>Jamdar</surname><given-names>A</given-names></name><name><surname>Bhatt</surname><given-names>S</given-names></name></person-group><article-title>Patient-derived organoids for precision oncology: A platform to facilitate clinical decision making</article-title><source>BMC Cancer</source><volume>23</volume><fpage>689</fpage><year>2023</year><pub-id pub-id-type="doi">10.1186/s12885-023-11078-9</pub-id><pub-id pub-id-type="pmid">37479967</pub-id></element-citation></ref>
<ref id="b170-ol-32-2-15702"><label>170</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Xi</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Xue</surname><given-names>J</given-names></name><name><surname>Liang</surname><given-names>N</given-names></name><name><surname>Wei</surname><given-names>Z</given-names></name></person-group><article-title>A dual-functional microfluidic chip for guiding personalized lung cancer medicine: Combining EGFR mutation detection and organoid-based drug response test</article-title><source>Lab Chip</source><volume>24</volume><fpage>1762</fpage><lpage>1774</lpage><year>2024</year><pub-id pub-id-type="doi">10.1039/D3LC00974B</pub-id><pub-id pub-id-type="pmid">38352981</pub-id></element-citation></ref>
<ref id="b171-ol-32-2-15702"><label>171</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Sui</surname><given-names>X</given-names></name><name><surname>Song</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>F</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Lung cancer organoids analyzed on microwell arrays predict drug responses of patients within a week</article-title><source>Nat Commun</source><volume>12</volume><fpage>2581</fpage><year>2021</year><pub-id pub-id-type="doi">10.1038/s41467-021-22676-1</pub-id><pub-id pub-id-type="pmid">33972544</pub-id></element-citation></ref>
<ref id="b172-ol-32-2-15702"><label>172</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Shan</surname><given-names>H</given-names></name><name><surname>Tao</surname><given-names>Q</given-names></name><name><surname>Hu</surname><given-names>R</given-names></name><name><surname>Sun</surname><given-names>Q</given-names></name><name><surname>Zheng</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Lin</surname><given-names>Q</given-names></name><name><surname>Yin</surname><given-names>M</given-names></name><name><surname>Zhao</surname><given-names>S</given-names></name><etal/></person-group><article-title>Mimicking tumor metastasis using a transwell-integrated Organoids-On-a-Chip platform</article-title><source>Small</source><volume>20</volume><fpage>e2308525</fpage><year>2024</year><pub-id pub-id-type="doi">10.1002/smll.202308525</pub-id><pub-id pub-id-type="pmid">38308351</pub-id></element-citation></ref>
<ref id="b173-ol-32-2-15702"><label>173</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>Q</given-names></name><name><surname>Su</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Jian</surname><given-names>H</given-names></name><name><surname>Bai</surname><given-names>S</given-names></name><name><surname>Yin</surname><given-names>J</given-names></name><name><surname>You</surname><given-names>Q</given-names></name></person-group><article-title>In vitro construction of lung cancer organoids by 3D bioprinting for drug evaluation</article-title><source>Colloids Surf A Physicochemical Eng Aspects</source><volume>666</volume><fpage>131288</fpage><year>2023</year><pub-id pub-id-type="doi">10.1016/j.colsurfa.2023.131288</pub-id></element-citation></ref>
<ref id="b174-ol-32-2-15702"><label>174</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoo</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>HJ</given-names></name></person-group><article-title>Spheroid-hydrogel-integrated biomimetic system: A new frontier in advanced three-dimensional cell culture technology</article-title><source>Cells Tissues Organs</source><volume>214</volume><fpage>128</fpage><lpage>147</lpage><year>2025</year><pub-id pub-id-type="pmid">39265553</pub-id></element-citation></ref>
<ref id="b175-ol-32-2-15702"><label>175</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akbaba</surname><given-names>H</given-names></name><name><surname>Homer</surname><given-names>L</given-names></name><name><surname>Tran</surname><given-names>TBT</given-names></name><name><surname>Bhaskar</surname><given-names>N</given-names></name><name><surname>Sharma</surname><given-names>N</given-names></name><name><surname>Erel-Akbaba</surname><given-names>G</given-names></name><name><surname>Pahal</surname><given-names>S</given-names></name><name><surname>Nguyen</surname><given-names>TD</given-names></name></person-group><article-title>Gene therapy strategies in tissue engineering: Advances and applications for regenerative therapy</article-title><source>Trends Biotechnol</source><month>Nov</month><day>27</day><year>2025</year><comment>(Epub ahead of print). doi: 10.1016/j.tibtech.2025.10.025</comment><pub-id pub-id-type="pmid">41314913</pub-id></element-citation></ref>
<ref id="b176-ol-32-2-15702"><label>176</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>D</given-names></name><name><surname>Kim</surname><given-names>Y</given-names></name><name><surname>Kang</surname><given-names>DH</given-names></name><name><surname>Chung</surname><given-names>C</given-names></name></person-group><article-title>Modeling drug and radiation resistance with patient-derived organoids: Recent progress, unmet needs, and future directions for lung cancer</article-title><source>Cells</source><volume>14</volume><fpage>1994</fpage><year>2025</year><pub-id pub-id-type="doi">10.3390/cells14241994</pub-id><pub-id pub-id-type="pmid">41440014</pub-id></element-citation></ref>
<ref id="b177-ol-32-2-15702"><label>177</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shan</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Zhao</surname><given-names>S</given-names></name><name><surname>Wei</surname><given-names>X</given-names></name><name><surname>Zheng</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Lin</surname><given-names>Q</given-names></name><name><surname>Jiang</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Fei</surname><given-names>C</given-names></name><etal/></person-group><article-title>Acoustic virtual 3D scaffold for direct-interacting tumor organoid-immune cell coculture systems</article-title><source>Sci Adv</source><volume>10</volume><fpage>eadr4831</fpage><year>2024</year><pub-id pub-id-type="doi">10.1126/sciadv.adr4831</pub-id><pub-id pub-id-type="pmid">39576870</pub-id></element-citation></ref>
<ref id="b178-ol-32-2-15702"><label>178</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dijkstra</surname><given-names>KK</given-names></name><name><surname>Cattaneo</surname><given-names>CM</given-names></name><name><surname>Weeber</surname><given-names>F</given-names></name><name><surname>Chalabi</surname><given-names>M</given-names></name><name><surname>van de Haar</surname><given-names>J</given-names></name><name><surname>Fanchi</surname><given-names>LF</given-names></name><name><surname>Slagter</surname><given-names>M</given-names></name><name><surname>van der Velden</surname><given-names>DL</given-names></name><name><surname>Kaing</surname><given-names>S</given-names></name><name><surname>Kelderman</surname><given-names>S</given-names></name><etal/></person-group><article-title>Generation of Tumor-reactive T cells by Co-culture of peripheral blood lymphocytes and tumor organoids</article-title><source>Cell</source><volume>174</volume><fpage>1586</fpage><lpage>1598.e12</lpage><year>2018</year><pub-id pub-id-type="doi">10.1016/j.cell.2018.07.009</pub-id><pub-id pub-id-type="pmid">30100188</pub-id></element-citation></ref>
<ref id="b179-ol-32-2-15702"><label>179</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cordeiro</surname><given-names>S</given-names></name><name><surname>Oliveira</surname><given-names>BB</given-names></name><name><surname>Valente</surname><given-names>R</given-names></name><name><surname>Ferreira</surname><given-names>D</given-names></name><name><surname>Luz</surname><given-names>A</given-names></name><name><surname>Baptista</surname><given-names>PV</given-names></name><name><surname>Fernandes</surname><given-names>AR</given-names></name></person-group><article-title>Breaking the mold: 3D cell cultures reshaping the future of cancer research</article-title><source>Front Cell Dev Biol</source><volume>12</volume><fpage>1507388</fpage><year>2024</year><pub-id pub-id-type="doi">10.3389/fcell.2024.1507388</pub-id><pub-id pub-id-type="pmid">39659521</pub-id></element-citation></ref>
<ref id="b180-ol-32-2-15702"><label>180</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silvestri</surname><given-names>G</given-names></name><name><surname>Chatterjee</surname><given-names>A</given-names></name></person-group><article-title>Rebuilding the marrow in vitro: Translational advances in the 3D modeling of blood cancers</article-title><source>Onco (Basel)</source><volume>5</volume><fpage>51</fpage><year>2025</year><pub-id pub-id-type="pmid">41346447</pub-id></element-citation></ref>
<ref id="b181-ol-32-2-15702"><label>181</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Um</surname><given-names>JH</given-names></name><name><surname>Zheng</surname><given-names>Y</given-names></name><name><surname>Mao</surname><given-names>Q</given-names></name><name><surname>Nam</surname><given-names>C</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Koh</surname><given-names>YW</given-names></name><name><surname>Shin</surname><given-names>SJ</given-names></name><name><surname>Park</surname><given-names>YM</given-names></name><name><surname>Lin</surname><given-names>DC</given-names></name></person-group><article-title>Genomic and Single-cell analyses characterize patient-derived tumor organoids to enable personalized therapy for head and neck squamous cell carcinoma</article-title><source>Cancer Res</source><volume>85</volume><fpage>2726</fpage><lpage>2742</lpage><year>2025</year><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-24-2850</pub-id><pub-id pub-id-type="pmid">40261963</pub-id></element-citation></ref>
<ref id="b182-ol-32-2-15702"><label>182</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kluiver</surname><given-names>TA</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Schubert</surname><given-names>SA</given-names></name><name><surname>Kraaier</surname><given-names>LJ</given-names></name><name><surname>Ringnalda</surname><given-names>F</given-names></name><name><surname>Lijnzaad</surname><given-names>P</given-names></name><name><surname>DeMartino</surname><given-names>J</given-names></name><name><surname>Megchelenbrink</surname><given-names>WL</given-names></name><name><surname>Amo-Addae</surname><given-names>V</given-names></name><name><surname>Eising</surname><given-names>S</given-names></name><etal/></person-group><article-title>Divergent WNT signaling and drug sensitivity profiles within hepatoblastoma tumors and organoids</article-title><source>Nat Commun</source><volume>15</volume><fpage>8576</fpage><year>2024</year><pub-id pub-id-type="doi">10.1038/s41467-024-52757-w</pub-id><pub-id pub-id-type="pmid">39567475</pub-id></element-citation></ref>
<ref id="b183-ol-32-2-15702"><label>183</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Fang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Lv</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Liang</surname><given-names>S</given-names></name></person-group><article-title>Malignant pleural effusion facilitates the establishment and maintenance of tumor organoid biobank with multiple patient-derived lung tumor cell sources</article-title><source>Exp Hematol Oncol</source><volume>13</volume><fpage>115</fpage><year>2024</year><pub-id pub-id-type="doi">10.1186/s40164-024-00581-9</pub-id><pub-id pub-id-type="pmid">39548571</pub-id></element-citation></ref>
<ref id="b184-ol-32-2-15702"><label>184</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benboubker</surname><given-names>V</given-names></name><name><surname>Ramzy</surname><given-names>GM</given-names></name><name><surname>Jacobs</surname><given-names>S</given-names></name><name><surname>Nowak-Sliwinska</surname><given-names>P</given-names></name></person-group><article-title>Challenges in validation of combination treatment strategies for CRC using patient-derived organoids</article-title><source>J Exp Clin Cancer Res</source><volume>43</volume><fpage>259</fpage><year>2024</year><pub-id pub-id-type="doi">10.1186/s13046-024-03173-x</pub-id><pub-id pub-id-type="pmid">39261955</pub-id></element-citation></ref>
<ref id="b185-ol-32-2-15702"><label>185</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qureshi</surname><given-names>AA</given-names></name><name><surname>Wehrle</surname><given-names>CJ</given-names></name><name><surname>Ferreira-Gonzalez</surname><given-names>S</given-names></name><name><surname>Jiao</surname><given-names>C</given-names></name><name><surname>Hong</surname><given-names>H</given-names></name><name><surname>Dadgar</surname><given-names>N</given-names></name><name><surname>Arpi-Palacios</surname><given-names>J</given-names></name><name><surname>Phong</surname><given-names>YP</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>K</given-names></name><etal/></person-group><article-title>Tumor organoids for primary liver cancers: A systematic review of current applications in diagnostics, disease modeling, and drug screening</article-title><source>JHEP Rep</source><volume>6</volume><fpage>101164</fpage><year>2024</year><pub-id pub-id-type="doi">10.1016/j.jhepr.2024.101164</pub-id><pub-id pub-id-type="pmid">39583095</pub-id></element-citation></ref>
</ref-list>
</back>
<floats-group>
<fig id="f1-ol-32-2-15702" position="float">
<label>Figure 1.</label>
<caption><p>Schematic diagram of constructing 3D tumor models from different cellular sources for drug screening. Primary pathways are illustrated for developing physiologically relevant 3D tumor models. Lung cancer cell lines serve as a reproducible source for generating spheroids using multiple cultivation methods. The complexity and relevance of these spheroids can be enhanced through co-culture with other cell types (such as fibroblasts and immune cells) to form advanced multicellular tumor spheroids. Alternatively, clinically relevant models with preserved tumor heterogeneity can be established directly from patient or xenograft-derived tissue or CTCs, yielding organoids or tumoroids. Both types of advanced 3D models constitute powerful platforms for a broad spectrum of biomedical applications, including drug discovery, personalized medicine and fundamental cancer research. 3D, three-dimensional; CTC, circulating tumor cell.</p></caption>
<alt-text>Schematic diagram of constructing 3D tumor models from different cellular sources for drug screening. Primary pathways are illustrated for developing physiologically relevant 3D tumor...</alt-text>
<graphic xlink:href="ol-32-02-15702-g00.tif"/>
</fig>
<fig id="f2-ol-32-2-15702" position="float">
<label>Figure 2.</label>
<caption><p>Physiological characteristics of solid tumors in vivo and basic structure of three-dimensional tumor spheroids. (A) Schematic representation of the in vivo solid tumor microenvironment, illustrating gradients of oxygen concentration (decreasing partial pressure of oxygen), nutrients/energy depletion and decreasing drug concentration from blood vessels toward the tumor interior. (B) Corresponding cellular heterogeneity and physicochemical gradients within the tumor, showing proliferating cells near vessels, quiescent cells in intermediate regions, necrotic cells in the core and accumulation of metabolic waste.</p></caption>
<alt-text>Physiological characteristics of solid tumors in vivo and basic structure of three-dimensional tumor spheroids. (A) Schematic representation of the in vivo solid tumor microenvironment...</alt-text>
<graphic xlink:href="ol-32-02-15702-g01.tif"/>
</fig>
<fig id="f3-ol-32-2-15702" position="float">
<label>Figure 3.</label>
<caption><p>Formation process of MCTSs. This figure illustrates the sequential stages and underlying cellular mechanisms involved in the formation of a MCTS. Firstly, a suspension of individual cells begins to aggregate and gradually form loosely adherent tumor spheroids. In this step, interactions between cell surface integrins and extracellular matrix components facilitate the initial aggregation of individual cells. Second, E-calmodulin enhances the strong adhesion of the initial cell aggregates by binding to peripheral cellular calmodulin, promoting further aggregation of loosely adherent spheroids. In addition, the &#x03B2;-catenin complex promotes cell signaling, and actin also affects aggregation and stemness by facilitating contact between neighboring cells, resulting in the formation of MCTSs with strong adhesion. MCTS, multicellular tumor spheroid.</p></caption>
<alt-text>Formation process of MCTSs. This figure illustrates the sequential stages and underlying cellular mechanisms involved in the formation of a MCTS. Firstly, a suspension of individual...</alt-text>
<graphic xlink:href="ol-32-02-15702-g02.tif"/>
</fig>
<fig id="f4-ol-32-2-15702" position="float">
<label>Figure 4.</label>
<caption><p>Application pathways of tumor organoids in basic research and clinical translation. The figure is primarily divided into two directions: (A) Application in personalized precision medicine and drug development. Tumor tissue or biopsy samples are obtained from patients with cancer for tumor organoid culture. Successfully cultured organoids can be used for high-throughput drug screening to guide personalized clinical treatment or for genetic testing to discover novel therapeutic targets, thereby advancing targeted drug development. (B) Personalized clinical application. Tumor specimens and biopsy samples from an individual patient with cancer are used to generate patient-derived tumor organoids, which are then subjected to drug sensitivity screening to guide clinical treatment decisions.</p></caption>
<alt-text>Application pathways of tumor organoids in basic research and clinical translation. The figure is primarily divided into two directions: (A) Application in personalized precision medicine...</alt-text>
<graphic xlink:href="ol-32-02-15702-g03.tif"/>
</fig>
<fig id="f5-ol-32-2-15702" position="float">
<label>Figure 5.</label>
<caption><p>Spheroid culture methods. (A) Hanging-drop method. (B) Pellet culture. (C) Microfluidic chip method. (D) Three-dimensional bioprinting. (E) Rotating wall vessel method. (F) Liquid overlay method. (G) Spinner culture. (H) External force method.</p></caption>
<alt-text>Spheroid culture methods. (A) Hanging-drop method. (B) Pellet culture. (C) Microfluidic chip method. (D) Three-dimensional bioprinting. (E) Rotating wall vessel method. (F) Liquid overlay...</alt-text>
<graphic xlink:href="ol-32-02-15702-g04.tif"/>
</fig>
<table-wrap id="tI-ol-32-2-15702" position="float">
<label>Table I.</label>
<caption><p>Technical methods, principle, advantages and disadvantages of multicellular tumor spheroid construction methods.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="bottom">First author/s, year</th>
<th align="center" valign="bottom">Technical methods</th>
<th align="center" valign="bottom">Principle</th>
<th align="center" valign="bottom">Advantages</th>
<th align="center" valign="bottom">Disadvantages</th>
<th align="center" valign="bottom">(Refs.)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">Baral et al, 2026</td>
<td align="left" valign="top">Hanging-drop</td>
<td align="left" valign="top">Uses surface tension and gravitational force</td>
<td align="left" valign="top">Easy, convenient operation and low cost</td>
<td align="left" valign="top">Only suitable for short-term spherical culture, the medium is easy to evaporate, and the medium cannot be changed frequently</td>
<td align="center" valign="top">(<xref rid="b52-ol-32-2-15702" ref-type="bibr">52</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">Ryu <italic>et al</italic>, 2019</td>
<td align="left" valign="top">Pellet culture</td>
<td align="left" valign="top">Uses centrifugal force to concentrate cells</td>
<td align="left" valign="top">Generates uniformly sized and shaped spheres in a short period of time, enabling precise control of the cell culture environment</td>
<td align="left" valign="top">Unable to be mass-produced</td>
<td align="center" valign="top">(<xref rid="b53-ol-32-2-15702" ref-type="bibr">53</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">Pang <italic>et al</italic>, 2025</td>
<td align="left" valign="top">Microfluidic chip</td>
<td align="left" valign="top">Cell aggregation in microwells via microfluidic flow</td>
<td align="left" valign="top">Ability to rapidly form large, more homogeneous spheres of cells compared with conventional methods (e.g., the hanging-drop or liquid overlay method)</td>
<td align="left" valign="top">Higher costs</td>
<td align="center" valign="top">(<xref rid="b54-ol-32-2-15702" ref-type="bibr">54</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">Zhang <italic>et al</italic>, 2024</td>
<td align="left" valign="top">3D bioprinting</td>
<td align="left" valign="top">Building of cell spheres with 3D printers.</td>
<td align="left" valign="top">Ability to accurately control the size of the sphere.</td>
<td align="left" valign="top">Higher costs</td>
<td align="center" valign="top">(<xref rid="b55-ol-32-2-15702" ref-type="bibr">55</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">Moghe <italic>et al</italic>, 2026</td>
<td align="left" valign="top">Rotating wall vessel</td>
<td align="left" valign="top">Uses constant circular rotation of the vessel to create a low-shear, microgravity environment that promotes cell aggregation into spheroids</td>
<td align="left" valign="top">Ability to promote cell proliferation and differentiation, as well as mass production of cell spheres</td>
<td align="left" valign="top">Self-assembly of cell spheres cannot be observed in real time</td>
<td align="center" valign="top">(<xref rid="b56-ol-32-2-15702" ref-type="bibr">56</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">Depresle <italic>et al</italic>, 2025</td>
<td align="left" valign="top">Liquid overlay</td>
<td align="left" valign="top">Overlay uses non-adhesive materials to inhibit cell attachment</td>
<td align="left" valign="top">Automated production of spheres with uniform morphology and size, and easy dosing or medium change</td>
<td align="left" valign="top">Experimental instruments are costly and the culture plates (or the non-adherent coating) are not reusable, requiring a lot of labor and material resources</td>
<td align="center" valign="top">(<xref rid="b57-ol-32-2-15702" ref-type="bibr">57</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">Dauphin et al, 2025</td>
<td align="left" valign="top">Spinner culture</td>
<td align="left" valign="top">Use continuous stirring to keep cells in suspension and promote cell-cell aggregation</td>
<td align="left" valign="top">Mass production is possible</td>
<td align="left" valign="top">Shear stress-induced cell damage; unsuitable for shear-sensitive/anchorage-dependent cells</td>
<td align="center" valign="top">(<xref rid="b58-ol-32-2-15702" ref-type="bibr">58</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">Haisler et al, 2013</td>
<td align="left" valign="top">External force</td>
<td align="left" valign="top">Use of external forces to levitate cells</td>
<td align="left" valign="top">Suitable for long-term culture, high versatility, easy to operate, low cost, short incubation time</td>
<td align="left" valign="top">Susceptible to external electric fields</td>
<td align="center" valign="top">(<xref rid="b59-ol-32-2-15702" ref-type="bibr">59</xref>)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="tfn1-ol-32-2-15702"><p>3D, three-dimensional.</p></fn>
</table-wrap-foot>
</table-wrap>
</floats-group>
</article>
